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“The fortunate idea came to me to orient my crystals with reference to a plane perpendicular to the 
observer and then I noticed that the confused mass of crystals of paratartrate could be divided into two 
groups according to the orientation of their facets of symmetry. In one group, the facet of symmetry 
nearer my body was inclined to my right with reference to the plane of orientation which I just 
mentioned, whereas the facet of asymmetry was inclined to my left in the other. The paratartrate 
appeared as a mixture of two kinds of crystals, some asymmetric to the right, some asymmetric to the 
left.” [1, 2] 
(Louis Pasteur, 1982-1895) 
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Abstract 
Amino alcohols, and especially nor(pseudo)ephedrines, are compounds with various 
applications in organic synthesis and in the pharmaceutical industry. The strategies 
to these chiral molecules by classical chemical or chemo-enzymatical syntheses are 
challenging and therewith draw interest for industrial research efforts. In this thesis, 
the potential of enzyme cascades for the synthesis of chiral primary vicinal amino 
alcohols was demonstrated. In detail, the 2-step cascades combining thiamine 
diphosphate (ThDP)-dependent enzymes and ω-transaminases were investigated for 
the synthesis of nor(pseudo)ephedrines. This approach represents a completely new 
strategy for getting access to chiral amino alcohols. These valuable chemicals are 
now accessible in a highly atom- and step-efficient enzymatic process in only two 
reaction steps from inexpensive, achiral starting materials. 
 
Development of a novel screening assay for ω-transaminases 
In the developed synthetic enzyme cascade, amino alcohols are accessible via a 
carboligation of aldehydes and α-keto acids, followed by a subsequent reductive 
amination of the α-hydroxy ketone intermediate catalysed by ω-transaminases. For a 
fast and reliable screening of ω-transaminase activity in these reductive amination 
reactions, a novel screening assay was developed. This assay is meanwhile used by 
other working groups and companies to screen enzymatic reductive amination 
reactions. Using this assay, we identified valuable biocatalysts for the reductive 
amination of acetoin, 2-hydroxyacetophenone and phenylacetylcarbinol (PAC). The 
reductive amination of PAC was of special importance, since is the reaction 
intermediate in the 2-step cascade for the synthesis of nor(pseudo)ephedrines. 
 
1-Pot 2-step cascade combining ThDP-dependent enzymes and ω-transaminases 
The 2-step synthesis of (1R,2S)-norephedrine was investigated for the combination 
of the (R)-selective ThDP-dependent acetohydroxyacid synthase-I (AHAS-I) from 
Eschericia coli and the (S)-selective ω-transaminase from Chromobacterium 
violaceum. A major challenge was the low thermodynamic equilibrium constant for 
the reductive amination reaction. The equilibrium constant for the reductive amination 
of PAC with alanine as an amine donor was determined: Keq = 8.81·10-4. As a direct 
consequence, even with a 5-fold excess of alanine the conversion did not exceed 
5 %. This challenge in the second reaction step was overcome by removal of the co-
product (pyruvate) with the enzyme of the first reaction step (AHAS-I). This enzyme 
catalyses the carboligation of two pyruvate molecules to acetolactate. In process 
mode optimisations, best results were obtained for the 1-pot sequential cascade 
mode. Under optimised reaction conditions 78 % of the benzaldehyde (10 mM) was 
converted to (1R,2S)-norephedrine (ee >99 %, de >98 %). This is the first example 
where a reaction equilibrium shift was performed in cascade reactions without the 
addition for further enzymes, reactants or co-solvents. If this cascade is performed for 
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the combination of AHAS-I and the (R)-selective ω-transaminases from Aspergillus 
terreus (At-(R)TA) in the 1-pot 2-step sequential mode, product concentrations up to 
90 mM (= 90 % conversion) could be reached. The gained product (1R,2R)-nor-
pseudoephedrine again exhibits excellent stereoselectivity (ee >99 %, de >98 %). 
Moreover, not only a simple co-product removal was tested, but even a recycling of 
the pyruvate in the first cascade step was possible. In case of the 2-step recycling 
cascade with AHAS-I and At-(R)TA, 86 % (= 17.2 mM) of the benzaldehyde (20 mM) 
was converted to (1R,2R)-norpseudoephedrine (ee >99 %, de >98 %) while only 
10 mM pyruvate was initially present in the reaction setup. This novel ‘recycling 
cascade’ concept increases atom economy of reactions and can theoretically be 
applied in any cascade reactions where co-products from a later step can be 
recycled for a previous step. 
 
1-Pot 2-step cascade combining ω-transaminases and alcohol dehydrogenases 
For the synthesis of the pharmaceutical (1S,2S)-norpseudoephedrine, a highly (S)-
selective lyase is required in the first reaction step. However, such a lyase is currently 
not available. Therefore, an alternative strategy was investigated. Starting from 
1-phenylpropane-1,2-dione, the combination of (S)-selective transaminase from 
Chromobacterium violaceum with the alcohol dehydrogenase from Lactobacillus 
brevis resulted in the formation of (1S,2S)-norpseudoephedrine with excellent 
stereoselectivity (ee >98 %, de >99 %). This novel biocatalytic reaction cascade can 
be seen as a valuable alternative synthesis strategy to complement the amino 
alcohol platform. 
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Zusammenfassung 
Aminoalkohole, und insbesondere Nor(pseudo)ephedrine, sind Verbindungen mit 
vielseitigen Anwendungen in organischen Synthesen und in der pharmazeutischen 
Industrie. Die Herstellung dieser chiralen Moleküle ist durch klassische chemische 
Synthesewege häufig schwierig und daher Gegenstand aktueller Forschung. In 
dieser Arbeit wurde das Potential von Enzymkaskaden zur Synthese von chiralen 
primären vicinalen Aminoalkoholen demonstriert. Eine zweistufige Kaskade, 
bestehend aus Thiamindiphosphat (ThDP)-abhängigen Enzymen und 
ω-Transaminasen, wurden für die Synthese von Nor(pseudo)ephedrinen erforscht. 
Dieser Ansatz stellt eine neue Strategie zur Synthese von chiralen Aminoalkoholen 
dar. Die wertvollen Produkte können in einem Reaktionsgefäß mit zwei 
Reaktionsschritten ausgehend von preiswerten, achiralen Ausgangsmaterialien 
hergestellt werden. 
 
Entwicklung eines neuartigen Screening-Tests für ω-Transaminasen 
In der neu entwickelten synthetischen Enzymkaskade, sind Aminoalkohole über eine 
Carboligation von Aldehyden und α-Ketosäuren zugänglich. Anschließend erfolgt 
eine reduktive Aminierung des Zwischenprodukts (2-Hydroxyketon) durch 
ω-Transaminasen. Für ein schnelles und zuverlässiges Screening von 
ω-Transaminase-Aktivität wurde ein neuartiger Screening-Test entwickelt. Dieser 
wird mittlerweile von anderen Wissenschaftlern genutzt, um enzymatische reduktive 
Aminierungsreaktionen zu untersuchen. In unseren Arbeiten konnten 
Biokatalysatoren für den Umsatz von Acetoin, 2-Hydroxyacetophenon und Phenyl-
acetylcarbinol (PAC) identifiziert werden. Die reduktive Aminierung von PAC war 
dabei von besonderer Bedeutung, da PAC das Syntheseintermediat in der 2-Schritt-
Kaskade zur Gewinnung von Nor(pseudo)ephedrinen ist. 
 
2-Schritt-Kaskade: ThDP-abhängige Enzyme kombiniert mit ω-Transaminasen 
Die zweistufige Synthese von (1R,2S)-Norephedrin erfolgte durch Kombination des 
(R)-selektiven ThDP-abhängigen Enzyms Acetohydroxysäuresynthase-I (AHAS-I) 
aus Escherichia coli mit der (S)-selektiven ω-Transaminase aus Chromobacterium 
violaceum. Eine Herausforderung war die geringe thermodynamische Gleich-
gewichtskonstante der reduktiven Aminierung im zweiten Reaktionsschritt. Für die 
Reaktion von PAC mit Alanin als Amindonor (Keq = 8,81•10-4) ist selbst bei einem 
5-fachen Überschuss von Alanin nur ein maximaler Umsatz von 5 % erreichbar. 
Dieses Problem konnte durch Entfernung des Co-Produkts (Pyruvat) mit dem Enzym 
des ersten Reaktionsschrittes (AHAS-I) gelöst werden. Dabei wird Pyruvat zu 
Acetolactat umgesetzt. 
Nach Optimierung verschiedener Reaktions- und Prozessparameter konnte 
(1R,2S)-Norephedrin mit einem Umsatz von 78 % in der zweistufige Synthese 
generiert werden. Das Produkt hatte eine hohe optische Reinheit (ee >99 % und de 
>98 %). Diese Enzymkaskade ist das erste Beispiel, bei dem die Verschiebung eines 
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Reaktionsgleichgewichts ohne Zugabe weiterer Enzyme, Reaktanten oder Lösungs-
mittel durchgeführt werden konnte. Bei einer analogen Kaskade zur stereoselektiven 
Synthese von (1R,2R)-Norpseudoephedrin konnte durch Kombination der AHAS-I 
mit der (R)-selektiven ω-Transaminasen At-(R)TA aus Aspergillus terreus eine 
Produktkonzentration von 90 mM (ee >99 %, de >98 %) erreicht werden.  
 
Pyruvat, das Co-Produkt der ω-Transaminase-Reaktion, ist gleichzeitig auch ein 
Substrat, das von der AHAS-I bei der Synthese von PAC im ersten Kaskadenschritt 
benötigt wird. Führt man die Synthese in einem Reaktionsgefäß aus, kann so das 
Co-Produkt in den ersten Kaskadenschritt zurückgeführt werden. Bei dieser 
sogenannten Rezyklierungskaskade konnte in der Kombination aus AHAS-I und 
At-(R)TA 17,2 mM (1R,2R)-Norpseudoephedrin aus nur 10 mM Pyruvat erzeugt 
werden. Dieses Kaskadenkonzept stellt eine neue Art der Prozessführung dar und 
kann zur Erhöhung der Atomökonomie von Reaktionen beitragen. Theoretisch wäre 
es in allen Kaskadenreaktionen einsetzbar, bei der Nebenprodukte aus einem 
späteren Schritt als Substrate für vorherige Reaktionsschritte genutzt werden 
können. 
 
2-Schritt-Kaskade: ω-Transaminasen kombiniert mit Alkoholdehydrogenasen 
Für die Synthese des pharmazeutisch-aktiven Wirkstoffs (1S,2S)-Norpseudoephedrin 
wäre in der oben genannten Kaskade ein hoch (S)-selektives Enzym im ersten 
Reaktionsschritt erforderlich. Da ein solches Enzym derzeit nicht bekannt ist, wurde 
eine alternative Strategie erforscht. Ausgehend von 1-Phenyl-1,2-diketon, kann 
(1S,2S)-Norpseudoephedrin durch Kombination der (S)-selektiven -Transaminase 
mit einer (S)-selektiven Alkoholdehydrogenase in hohen optischen  Reinheiten 
(ee >98 %, de >99 %) erzeugt werden. Diese biokatalytische Reaktionskaskade 
ergänzt als wertvolle alternative Synthesestrategie die Plattform an zugänglichen 
Aminoalkoholen. 
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1 Introduction 
 
1.1 The impact of chirality in organic compounds 
Chiral organic compounds have found application way before chirality itself was 
discovered. The history of herbal remedies with chiral active drugs goes back 
approximately five millennia.[3] Among a large list, examples like februgine (reported 
2735 B.C. for the treatment of fever), quinine (used since the 16th century as an 
antimalarial agent) and cathinone or cathine (sympathomimetic action known since 
centuries[4, 5]) were reported.[3]  
As previously reviewed,[3, 6, 7] the basis for the discovery of chirality was the invention 
of circularly polarised light by Malus 1809. Only a few years later Arago and Biot 
observed left (levorotatory) or right (dextrorotatory) rotation of polarised light in 
different crystals and liquids. In 1848 Pasteur demonstrated that two different non-
superimposable mirror images of sodium ammonium tartrate crystals exist, which 
rotate polarised light differently after separation (see figure 1-1). Based on these 
studies, van’t Hoff and Le Bel presented independently the concepts of the 
asymmetric carbon atom in 1884. Only a few years later, first examples were 
reported demonstrating that one isolated isomer has a different physiological action 
in human body than its mirror image – as it is well known from cocaine (1894), 
atropine (1903) or epinephrine (1908).[3, 6, 7] 
 
 
 
Figure 1-1: Structure and hemihedral crystals of (+) and (−) sodium ammonium tartrate 
 (figure adapted with permission from reference [8]) 
 
Although these examples for biological impact of chirality in drugs were recognised 
early, an industrial guidance was released by the “US Food and Drug Administration” 
(FDA)[9] and the “European Committee for Proprietary Medicinal Products” only 
recently in 1992. Since that date, racemates were rated as a composition of single 
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isomers, associated with a determination of physiological agent profiles for each 
isomer.[6, 10, 11] Today, a large number of examples are known, where a discrepancy 
in effects of stereoisomers can be observed: (S)-bupivaccaine for instance has a 
vasoconstrictor effect, which is not observed for its enantiomer.[12] Dextromethorphan 
is widely used as a cough suppressant, while levomethorphan has opioid effects.[13] 
Racemic D,L-carnitine was described to cause symptoms like myasthenia or cardiac 
arrhythmias. However, the optically pure L-isomer prevents these negative effects 
and is used for multifunctional applications.[14] 
Plenty more examples for the relevance of chirality also in fields beyond the 
pharmaceutical industry (like in biochemicals, flavour or aroma chemicals, dyes, 
polymers, chemical catalysts…) are known, demonstrating the immense commercial 
potential of optically pure products.[10] 
 
 
1.2 Production of optically pure compounds 
In general, there are three ways to access to single optical isomers: chiral pool, 
resolution and asymmetric synthesis.[15-17] 
Chiral pool methods are based on available chiral resources in nature. Compounds 
generated by the complexity of biological metabolism can be extracted from their 
native source (plants, microorganisms or animals) and used directly as natural 
products or as chiral building blocks in organic synthesis. This strategy provides 
advantages for instance when a target with challenging synthetic strategies is 
available from inexpensive natural sources. However, the limited number of natural 
products on the one hand and the availability of natural resources on the other hand 
restricts the applicability of chiral pool methods for industrial processes.[15] 
Racemic mixtures are often much easier accessible than the pure enantiomers. 
Separation of single enantiomers from enantiomer mixtures is called resolution. 
Various techniques like preferential crystallisation, chromatographic methods or 
kinetic resolution have been developed to produce optically pure compounds.[10, 18-20] 
In all of these cases the yield is limited to 50 %, since often only one of both 
enantiomers is of interest. A smart solution, if applicable, is the dynamic kinetic 
resolution, where the undesired enantiomer is racemised in an additional reaction 
step, thus enabling 100 % conversion to the desired enantiomer. 
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Limitations of chiral pool methods and the lack of sustainability (caused by the low 
atom economy) of resolution techniques[21] can often be overcome by asymmetric 
synthesis.[17] Here, achiral substrates are converted via an asymmetric reaction to a 
chiral, non-racemic product. Many examples in all fields of organic synthesis indicate 
the relevance of asymmetric synthesis for industrial applications.[17]  
The efficiency of an asymmetric synthesis approach is depending on several criteria 
like high stereoselectivity, conversion rates, availability and separability of chiral 
catalysts or auxiliaries.[17] Here, biocatalysis offers an immense potential within this 
field of organic synthesis as summarised in chapter 1.3. 
 
 
1.3 Potential of industrial biotechnology 
The chemical industry is one of the main economic sectors in the world. Within this 
field, industrial biotechnology, synonymously named white biotechnology (in Europe), 
has become a valuable and continuously growing market in the last decades.[22-27] 
Although absolute numbers for global economy benefits differ a lot, general trends 
are obvious. In a recent statistic (figure 1-2 a), the market for chemical goods has 
been summed up to a volume of $ 1.2 trillion (USD) in 2001 with a growth of 25 % to 
$ 1.5 trillion (USD) in 2010. The value of biotechnological processes decupled in the 
same time period from $ 30 billion to $ 310 billion (USD). In 2010, this already 
corresponded to one-fifth of the total market for chemicals. Moreover, it is estimated 
that the impact of biobased chemicals in contrast to the petrochemical industry will 
continuously grow the next decades (figure 1-2 b).[25, 27] 
 
 
 
Figure 1-2: Trends in production of biobased chemicals in relation to petrochemicals 
(a) Global growth of biobased chemicals and polymers between 2001 and 2010. (b) US predictions for 
growth of the biobased industry until 2025. (adapted with permission from reference [27]) 
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1.3.1 Enzymes in asymmetric synthesis 
Biocatalysis, as part of the biotechnology platform, is nowadays used as a powerful 
tool for the synthesis of chemical compounds also in industrial scale 
applications.[28, 29] Applications of biocatalysts in the field of organic synthesis are 
known for all enzyme classes (EC)[30]: oxidoreductases (EC 1), transferases (EC 2), 
hydrolases (EC 3), lyases (EC 4), isomerases (EC 5) and ligases (EC 6). However, 
only ligases are still of low relevance in technical-scale syntheses.[23, 29, 31] 
Advantages of enzymatic catalysis, especially in terms of asymmetric synthesis, are 
well known and pointed out in many reviews.[29, 31-33] Commonly, high regio-, chemo- 
and stereoselectivities are mentioned. This often enables a selective synthesis of 
target molecules, which are otherwise only accessible in multistep chemical reactions 
with several protection and deprotection steps. Furthermore, enzymes are often 
active under mild reaction conditions, such as ambient temperature, atmospheric 
pressure, water as reaction media or physiological pH. These points and the fact that 
the catalyst itself is biodegradable are often referred to an environmentally friendly, 
“green” chemical process. In addition to that, enzymatic reaction rates can be 
108-1010 or in some cases even 1017 fold faster than the non-catalysed reaction, 
which is typically order of magnitudes better than known rates for chemical 
catalysts.[34] In theory, almost each organic reactions can be carried out by 
enzymes[22, 32] and the nowadays >4,000 identified different enzymes[31] enable 
already almost all of these reaction types.[32] 
Although there is a large list of reasons for application of enzymes in organic 
syntheses, examples of biocatalytic or chemo-enzymatic processes in industry are 
still below expectation.[23] A major drawback is that the amount of ‘Candida antarctica 
lipase B type enzymes’ that is available for the hydrolases, is still limited within other 
enzyme classes. Ideally, enzymes and the processes they are used in need to fulfil 
the following requisites for industry (adapted from [29]): 
 
- atom economy and sustainability of the process 
- availability and costs of the required substrates 
- optical purity of the isolated product (ee, de >99 %) 
- availability and characterisation data for the catalyst 
- activity (>1 U mg-1), stability and recyclability of the catalyst 
- conversions (>95 %) and substrate concentrations (>100 g L-1 ) 
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According to a recently published review which summarises the “use of enzymes in 
organic synthesis and life sciences”,[23] manufacturing processes with lipases, 
proteases and alcohol dehydrogenases are generally feasible for large scale 
applications. Although, the number of processes with amidases, nitrilases, 
hydroxynitrilases and transaminases has increased in the last years, there is still a 
great potential also for oxygenase and C-C bond forming enzymes (decarboxylases, 
aldolases, enoate/ene reductases). Here, an agreement between chemists and 
biologists as well as between industry and academia is suggested by the authors to 
fulfil the achievements for a broader range of biocatalytic large scale applications. 
Challenging tasks and requirements are (adapted from reference [23]): 
 
- identification of novel robust biocatalysts especially for large scale 
applications 
- screening kits of ready to use and stable enzymes for all EC classes 
have to be set up and/or need to be enlarged 
- increase of functional characterisation data like optimal reaction 
conditions and substrate scope 
- (R)- and (S)-selective catalysts are required to ensure the enantio-
complementarity of synthesis route 
- increase of catalytic activity is required for many enzymes 
 
 
 
1.4 ‘Green’ reductive amination – an “aspirational reaction” [35] 
The vast majority of medical drugs and drug candidates contain amine groups or 
functional groups derived from amines.[35, 36] These groups often introduce chirality 
into a molecule, indicating the increasing interest for the development respective 
synthesis strategies. A large number of physiologically active compounds with a 
chiral amine motif can be synthesised from primary amines.[37] Selected examples for 
drugs with diverse applications derived from different building blocks are highlighted 
in scheme 1-1. 
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Scheme 1-1:  Selected examples of the large platform of chiral amines used as synthons for the 
synthesis of physiological active compounds 
(adapted with permission from reference [37]) 
 
 
1.4.1 Chemical synthesis of chiral amines 
Various methods for the chemical synthesis of chiral amines are described in 
literature and were recently reviewed:[36] 
Nucleophilic addition of carbanions to imines - radical addition to imines - Brønsted 
acid catalysed - reduction of imines by chiral Lewis bases - vinylogous Mannich 
reactions - metal-mediated hydrogenation - asymmetric reductive amination - 
hydrogenation of enamines - enamide reduction - reduction of nitrogen-based 
heteroaromatic compounds - asymmetric hydroamination - C-H amination - 
asymmetric Aza-Morita–Baylis–Hillman reaction.  
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For the synthesis of -chiral primary amines, asymmetric addition of carbanions and 
asymmetric hydrogenation are frequently considered methods (scheme 1-2).[37] 
Starting from commercially available ketones or aldehydes, the substitution of the 
oxygen atom by a nitrogen atom results either in an aldimine or a ketimine. An 
additional reduction followed by a deprotection gives access to the desired amine. In 
both synthesis strategies, enantioselectivity is introduced either by using chiral 
auxiliaries[38-40] or by chiral ligands coordinated to metal complexes.[41, 42] 
 
 
Scheme 1-2:  Two frequently used chemical synthesis strategies for α-chiral amines are 
asymmetric hydrogenation and asymmetric addition. 
(adapted with permission from reference [37]) 
 
 
Although a large number of methods exists, examples with high stereoselectivities 
(ee, de >99 %) are still rare. In addition, often expensive starting materials and/or 
multi-step reactions are required, so that further innovations in the field of amine 
synthesis will be necessary in future to solve future challenges.[36] 
In 2005, the American Chemical Society (ACS), the Green Chemistry Institute (GCI) 
and various global pharmaceutical companies founded the “ACS GCI Pharmaceutical 
Roundtable”. The overall aim was to bring “key medicines to the patients with a 
minimal impact on the environment”.[35] This should be achieved by integration of 
more sustainable, ‘greener’ chemistry in pharmaceutical production processes.[35] 
The 2nd highest vote number by the Roundtable on “future priority research areas” 
got the chiral amines synthesis were especially the green reductive amination was 
highlighted as an “aspirational reaction” for future research activities.[35] Here, 
biocatalytic approaches offer a great potential to meet the above mentioned 
challenges.[37] 
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1.4.2 Biocatalytic synthesis of chiral amines 
As an alternative to chemical synthesis strategies, several biocatalytic routes based 
on hydrolases, oxidoreductases, lyases and transferases have been developed to 
overcome the remaining challenges in chiral amine production (scheme 1-3).[37, 43]  
 
Scheme 1-3:  Biocatalytic routes to optically active α-chiral primary amines 
(adapted with permission from reference [37]) 
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Each route provides advantages and drawbacks for specific parameters like 
substrate range, stereoselectivity, starting material, cofactor recycling and theoretical 
reaction yield (see scheme 1-3).[37]  
Both, kinetic resolution with lipases or other hydrolases[44-48] and deracemisation with 
monoamine oxidases[49-52] offer valuable opportunities for the synthesis of optically 
pure amines. Especially the application of hydrolases is a frequently used technique 
in industry.[47, 53] However, only 50 % theoretical yield can be achieved, if a dynamic 
kinetic resolution cannot be applied. Moreover, achievement of high optical purity 
(>98 %) is challenging and often requires additional purification effort.[47, 53] Amine 
dehydrogenases are valuable catalysts, since an inexpensive amine donor can be 
used and enzymes with broad substrate ranges are known. Here, the most important 
requirement is the improvement of enantioselectivity for future applications. [54-56] 
Moreover, as for the imine reductases[57-60], an additional cofactor recycling is 
obligatory which increases reaction costs. Imine reductases and ammonia lyases[61-
63] expand the biocatalytic platform but have limited substrate range and are thereby 
restricted to special applications. 
ω-Transaminases can be used for kinetic resolution as well as for the asymmetric 
synthesis of chiral amines. The latter is often preferred, since on the one hand the 
theoretical yield is 2-fold higher[64] and on the other hand achiral precursors are 
usually less expensive than racemic mixtures.[65] Although challenges like low 
reaction equilibria and substrate/product inhibition need to be overcome, the broad 
substrate ranges, high enantioselectivities, fast reaction rates and the independency 
of cofactor recycling steps demonstrate the high potential of ω-transaminases.[64, 66-68] 
The application of these enzymes for the asymmetric synthesis of optically pure 
amines is discussed in the following chapter.  
 
 
1.4.3 ω-Transaminases for the asymmetric synthesis of chiral amines 
Transaminases, also known as aminotransferases, are pyridoxal-5’-phosphate (PLP)-
dependent enzymes and catalyse the transfer of amino groups. These enzymes are 
ubiquitous in nature and crucial enzymes in the nitrogen metabolism within all kind of 
cells.[69] 
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1.4.3.1 Taxonomy of transaminases 
According to the Enzyme Commission (EC) classification transaminases belong to 
the main class of transferases (EC 2).[30] Enzymes transferring an amine group are 
summarised in group EC 2.6.1, which is currently further divided in 101 subgroups[70] 
(EC 2.6.1.X) regarding their substrate specificities (like EC 2.6.1.1: aspartate 
transaminases, EC 2.6.1.2: alanine transaminases…). For a detailed classification, 
transaminases are sorted concerning fold types, sequence similarities, regio- and 
stereospecificities in different groups and classes.[71-73] 
Transaminases require the cofactor pyridoxal-5’-phosphate (PLP). In general, PLP-
dependent enzymes are grouped by their three-dimensional structure similarities in 
seven folding types (I–VII). However, transaminases can only be found in fold type I 
(“aspartate transaminase fold”) and fold type IV (“D-alanine transaminase fold”).[74, 75] 
 
Table 1-1: Selected examples for classification of transaminases (TA) and their main amine 
donor/acceptor pairs[71-73] 
fold type: classification based on three-dimensional structure 
TA class: sorted by structure similarities  
 
fold 
type 
TA 
class 
region 
specificity enzyme EC name main donor main acceptor 
I I/II 
α aspartate TA L-aspartate oxaloacetic acid 
α alanine TA L-alanine pyruvate 
α aromatic TA L-aromatic amino acids α-keto glutarate 
I III 
α ornithine TA ornithine α-keto glutarate 
β β-aminocarboxylic acid TA 
β-aminocarboxylic 
acid pyruvate 
γ γ-aminobutyrate TA γ-aminobutyrate α-keto glutarate 
ω (S)-selective ω-TA or amine TA 
(S)-α-methyl-
benzylamine pyruvate 
IV IV 
α D-amino acid transaminases D-amino acid α-keto glutarate 
α branched-chain amino acid TA 
L-valine, 
L-(iso)leucine α-keto glutarate 
ω (R)-selective ω-TA or amine TA 
(S)-α-methyl-
benzylamine pyruvate 
I V α (phospho)serine TA L-(phospho)serine pyruvate 
I VI  sugar amino TA amino sugars α-keto glutarate 
 
Beside the three-dimensional structure, transaminases are divided by primary 
structure similarities into six classes (I-VI).[71] Often, sequence similarities correlate 
well with substrate specificities. Enzymes in classes I, II and V catalyse the transfer 
of an amino acid to a keto acid and are to a great extend involved in the amino acid 
metabolic pathway. In class III, transaminases are listed which accept substrates 
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with no acid group in α-position to the respective keto- or amino function. To this 
class belong non-α-amino acid transaminases such as the ornithine- or the γ-
aminobutyrate transaminase and ω-transaminases (also called amine transferases). 
Class IV contains enzymes which accept substrates in different configurations. While 
branched-chain amino acid transaminases only accept L-amino acids like L-leucine, 
D-amino acid transaminases (such as D-alanine transaminase) and (R)-selective 
amine transferases (like the (R)-amine pyruvate transaminase from Arthrobacter 
sp.[76]) have also been described. Enzymes transferring amino groups from amino 
sugars are summarised in class VI.[71, 73] 
A more general way for the classification of transaminases is the division in α-, β-, γ- 
and ω-transaminases concerning their regiospecificity.[72, 73, 77] α-Transaminases only 
accept substrates with an amino group in α-position to a carbonyl group, whereas β- 
and γ-transaminases prefer substrates with amines in β- or γ-position, respectively. 
In contrast, ω-transaminases catalyse the transfer of amine groups to aldehydes and 
ketones. However, often only α- and ω-transaminases are distinguished and other 
enzymes than α- are referred to as ω-transaminases.[66, 71, 72] 
Moreover, transaminases can be distinguished regarding their stereoselectivity in D- 
or L-selective amino acid transaminases and (S)- or (R)-selective ω-transaminases, 
respectively.[66, 71, 72] 
 
 
1.4.3.2 Reaction mechanism and stereoselectivity 
The reaction mechanism of all PLP-dependent enzymes can be divided in two half 
reactions. In general PLP-dependent oxidoreductases, transferases, hydrolases, 
lyases and isomerases share a common initial deprotonation step, followed by 
different subsequent reaction steps.[69] 
For transaminases, the first half reaction comprises three major steps (see scheme 
1-4). First, an internal Schiff base (internal aldimine) between the PLP and the 
ε-amino group of a lysine is replaced by the reaction of an amine donor and the PLP 
(external aldimine). In the second step, the α-proton is abstracted from the aldimine 
by the lysine to form a quinoide intermediate, which is then reprotonated to a 
ketimine. In the final step of the first half reaction hydrolysis of the ketimine releases 
the keto co-product and the aminated pyridoxamine-5’-phosphate (PMP). 
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Scheme 1-4: Reaction mechanism of transaminases[71, 78-80] 
 
 
The steps of the second half reaction take place in reverse order relative to the first 
half reaction. The amine group of PMP is transferred to an amine acceptor, which 
finally results in the release of the corresponding amino product and regenerated 
PLP in its internal aldimine form. The mechanistic model of transaminases is called 
ping-pong bi-bi mechanism.[71, 78-80] 
ω-transaminases are only active as homodimers or higher-ordered oligomers since 
the active site is located at the interface of two monomers.[66] The stereoselectivity of 
transaminases is determined by the relative orientation of the residues attached to 
the external aldimine (see R1 and R2 in scheme 1-4). This orientation is a 
consequence of the active site structure, which determines the transition states’ 
stabilities. Most of the known crystal structures of transaminases show two binding 
pockets with different capacities (“large” L and “small” S binding pocket) for the 
stabilisation of these residues in the active site (see scheme 1-5). In (R)- and (S)-
selective ω-transaminases, the orientation of these binding sides are inverted. 
Therewith, the resulting amine is either formed in the (R)- or (S)-configuration, 
respectively (see scheme 1-5).[69, 71, 72, 81] 
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Scheme 1-5: Stereoselectivity of (S)- and (R)-selective ω-transaminases 
 
 
 
1.4.3.3 Screening for ω-transaminase activity 
When ω-transaminases became a hot-topic in industrial and academic research, the 
development of screening assays for a fast identification and characterisation of 
enzymes with novel properties was required. Meanwhile, various screening assays, 
each specific for different applications, are available.[66, 82] 
Screening assays specific for α-transaminases, like the glutamate-/malate 
dehydrogenase assay (scheme 1-6-a)[83], are often based on the conversion of one 
amino acid or keto acid, respectively. If ω-transaminases accept these substrates, a 
screening with ketones/amines as co-substrates is feasible. Most of the known 
assays are based on this principle. The first screening assay for ω-transaminase was 
developed by Kim and co-workers. When a α-keto acid (such as pyruvate) is used as 
an amine acceptor, the resulting amino acid can be quantified by a coloured 
copper/amino acid complex (scheme 1-6-b).[84] Bornscheuer and co-workers 
published a conductivity screening assay based on the production of amino acids 
from α-keto acids (scheme 1-6-c).[85] In another assay, the accumulated amino acid is 
oxidised to the corresponding imine by an amino acid oxidase (scheme 1-6-d). The 
co-product, H2O2, can be detected colourimetrically when pyrogallol and horseradish 
peroxidase are added.[86] Moreover, the production of alanine from pyruvate can be 
used as a growth selection assay when alanine is used as a single nitrogen source 
(scheme 1-6-e).[87] This assay was used for a high-throughput screening of 85.000 
PCR derived variants of the ω-transaminase from Vibrio fluvialis.[87] 
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Scheme 1-6: Screening assays for ω-transaminases known from literature 
α-KG: α-keto glutarate, Asp: aspartic acid, Glu: glutamic acid, MDH: malate dehydrogenase, GlDH: 
glutamate dehydrogenase, AAO: amino acid oxidase, TA: transaminase, GDH glucose dehydrogenase, 
LDH: lactate dehydrogenase 
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Vice versa, when alanine is used as an amine donor, the corresponding pyruvate is 
measured in a coupled enzymatic reaction combining a lactate dehydrogenase and a 
glucose dehydrogenase (scheme 1-6-f). Gluconic acid, produced in the cofactor 
regeneration step, causes a pH shift in the reaction medium which can be detected 
by a pH indicator.[88] In addition to these amino acid and keto acid based screening 
assays, Bornscheuer and co-workers developed an assay based on activities 
towards α-methylbenzylamine (scheme 1-6-g). The corresponding co-product, 
acetophenone, is detected photometrically at 245 nm.[89] Moreover, a screening 
assay based on degradation of amino tetralone (scheme 1-6-h) was used for the 
identification of more active and thermostable variants of the ω-transaminase from 
Arthrobacter citreus.[90] 
By development of these screening assays the identification and partial 
characterisation of different wild type ω-transaminases was supported. Thus, high 
throughput screening of variant libraries for new enzyme properties was enabled. 
However, it is obvious that all assays are limited to specific applications. Besides 
their specific advantageous and drawbacks, they are based either on a specific set of 
amine donors or amine acceptors. Moreover, only two of the α-methylbenzylamine 
based assays and the amino tetralone assay do not presuppose enzymatic activity 
towards keto acids or amino acids, respectively. The development of novel screening 
assays with properties like high reliability, screening for enantioselectivity, 
independent substrate sets and high throughput compatibility is mandatory for future 
investigations and improvements of ω-transaminases.[82] 
 
1.4.3.4 History, availability and substrate range of ω-transaminases 
The very first application of ω-transaminases in chiral amines synthesis was 
published 1990 by the American company Celgene.[91] This example prompted 
research in academia to focus on the potential of these biocatalysts. Pioneering work 
was done by Shin and Kim in the late 1990s.[64, 92-94] They discovered 
ω-transaminases activity in microorganisms from soil samples, such as Bacillus 
thuringiensis and Klebsiella pneumonia.[93] In 1999, asymmetric synthesis with the 
(S)-selective ω-transaminase from Vibrio fluvialis was demonstrated.[64] This enzyme 
was purified and characterised in 2003 and crystallised in 2010.[95, 96] Meanwhile the 
potential for biotechnological applications has been broadly demonstrated[87, 97-100] 
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and pilot-plant scale applications in a packed-bed reactor[101] and a membrane 
reactor[102] were shown. Ward and co-worker performed a BLAST-based sequence 
homology search based on the protein sequence of the V. fluvialis ω-transaminase. 
Among a number of different novel wild type enzymes, the (S)-selective 
ω-transaminase CV2025 (or Cv-(S)TA) from Chromobacterium violaceum enlarged 
the application platform of ω-transaminase enormously due to its broad substrate 
range.[103] 
More than 30 (S)-selective ω-transaminase are nowadays described in literature,[67] 
whereas the number of non-public available enzymes (especially in industry) is 
possibly much higher.[68] The gap of missing (R)-selective enzymes was initially 
closed by the identification of the ω-transaminase from Arthrobacter sp. KNK168.[76] 
This very potent wild type enzyme was engineered by Saville et al. for the 
asymmetric synthesis of the bulky-bulky substrate sitagliptin.[104] Moreover, 17 novel 
(R)-selective ω-transaminase have been identified by Höhne and Bornscheuer in 
2010 via sequence alignment.[81] This discovery represents a significant contribution 
to the (R)-selective catalyst toolbox. 
Nowadays, a broad substrate spectrum is covered by commercially available and 
literature-known ω-transaminases. Selected examples from a large list of compounds 
(recently published in several reviews[66, 68, 71]) are presented in scheme 1-7. 
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Scheme 1-7:  Selected examples for the large substrate platform of chiral amines accepted by 
ω-transaminases (adapted with permission from reference [66, 68, 71]) 
Numbers 1-21 belong to selected ω-transaminases - (R) or (S) represents the 
stereoselectivities: 
1: Alcaligens denitrificans (S); 2: ArRmut11* (R); 3: Arthrobacter sp. (R); 4: 
Arthrobacter citreus (S); 5: Aspergillus fumigatus (R); 6: Aspergillus oryzae (R); 7: 
Aspergillus terreus (R); 8: ATA-103** (S); 9: ATA-113** (S); 10: ATA-114** (S); 11: 
Bacillus megaterium (S); 12: Chromobacterium violaceum (S); 13: Gibrella zeae (R); 
14: Hyphomonas neptunium (R); 15: Mycobacterium vanbaalenii (R); 16: Neosartoya 
fischeri (R); 17: Penicilium crysogenum (R); 18: Pseudomonas fluorescens (S); 19: 
Vibrio fluvialis (S); 20: other Celene, Codexis ATAs (see ref [66]); 21: ATA-117** (R) 
* ArRmut11: 11-fold mutant of the Codexis transaminase ATA-117* (see ref. [104]) 
** ATA-XX: -transaminase nomenclature by Codexis (ATA: amine transaminases) 
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1.4.3.5 Reaction equilibrium – a challenge for ω-transaminases reactions 
As mentioned above, transaminase catalysed reactions follow a ping-pong bi-bi 
mechanism consisting of two half reactions.[71, 78-80] Both half reactions have 
independent half reaction equilibrium constants (K1 and K2). The reaction equilibrium 
constant of the overall reductive amination step (Keq) is given by the product of both 
half reaction constants (equation 1-1). 
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Equation 1-1: Two independent reaction equilibrium constants of the first and the second half 
reaction (K1 and K2) contribute to the overall thermodynamic reaction 
equilibrium of the transaminase reaction (Keq) 
 
A well-known problem for the application of ω-transaminases in processes is the low 
equilibrium constant of the overall reaction.[66, 68, 105] As a first example, Shin and Kim 
calculated the reaction thermodynamics for the syntheses of α-methylbenzylamine 
and pyruvate from acetophenone and alanine (scheme 1-8). The reaction equilibrium 
constant lies towards the substrate side (Keq = 8.81·10-4).[94] An easy and reliable 
experimental method to determine the equilibrium constant of ω-transaminase 
catalysed reactions was published by Woodley and co-workers in 2012.[105] As was 
known before, their studies demonstrate that the choice of the amine donor 
significantly influences the theoretical maximal conversion of the overall reaction due 
to the independent half reaction thermodynamics. E.g. for the same amine acceptor, 
a much higher conversion is achieved if α-methylbenzylamine is used instead of 
alanine. To shift the reaction equilibrium, an excess of the amine donor can be used 
if no substrate inhibition occurs and if the amine donor is inexpensive. This concept is 
often applied when isopropylamine can be used.[67] 
 
Scheme 1-8:  Example of an equilibrium limitation in chiral amine synthesis.[94] 
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Moreover, the reaction can be shifted to completion when the product (either the 
amine or the keto co-product) is removed. Since this is a general issue, different 
chemical, enzymatic and reaction engineering approaches have been developed. 
These techniques have been summarised in several reviews.[66, 68, 105, 106] 
The amine product can be removed e.g. by addition of an ion exchange resin to the 
reaction solution, which removed the amine reversibly from the reaction by binding it 
to the resin (scheme 1-9).[107] Moreover, a spontaneous follow-up reaction of the 
amine product (e.g. like an intra-molecular cyclisation[107, 108]) or another 
simultaneous chemical/enzymatical reaction can shift the reaction, if these additional 
reactions are feasible and/or desired. 
 
 
 
Scheme 1-9:  Possibilities to shift the reaction equilibrium for ω-transaminase catalysed 
reductive amination reactions – (adapted with permission from reference [66]). 
ADH: alcohol dehydrogenase, ALS: acetolactate synthase, AHAS: acetohydroxyacid 
synthases, PDC: pyruvate decarboxylase, LDH: lactate dehydrogenase, AADH: amino 
acid dehydrogenase 
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Often more generally applicable is a removal of the keto co-product. If small aliphatic 
amine donors (like isopropylamine[109] or butylamine[110]) can be used, it is possible to 
remove the corresponding ketones by evaporation under reduced pressure.[66, 109, 110] 
Moreover, reduction of the co-product acetophenone by alcohol dehydrogenases 
(ADH) shifts the reaction equilibrium e.g. when α-methylbenzylamine is used.[111] 
However, in this setup additional cofactor regeneration is required. A very well 
characterised and frequently applied method is enzyme-catalysed pyruvate removal 
using alanine as amine donor (see scheme 1-9).[66, 82] The equilibrium can be shifted 
by the addition of lactate dehydrogenases (LDH), pyruvate decarboxylases (PDC), 
acetolactate synthases (ALS) or acetohydroxyacid synthases (AHAS) and amino acid 
dehydrogenases (AADH), respectively. In general, enzyme-catalysed co-product 
removal is a suitable alternative to prevent high co-substrate concentrations. 
However, in all the described enzyme-based equilibrium shift reactions the addition 
of at least one further enzyme (or two, if additional cofactor regeneration is required) 
increases system complexity and reaction costs.  
 
 
 
1.5 Chiral vicinal amino alcohols – valuable products from 
inexpensive starting materials 
1.5.1 Synthetic strategies for valuable vicinal alcohols 
The motif of vicinal (often also referred to as 1,2-) amino alcohols can be found in a 
variety of natural products, biologically active compounds and ligands and auxiliaries 
used in organic synthesis.[112-115] Since such compounds can contain two vicinal 
stereogenic centres, chirality plays an important role for amino alcohols used in 
asymmetric synthesis (such as Evans’ chiral auxiliaries[115-117], oxaborolidines[118] or 
ephedrine derivatives[119-122]) as well as for those with pharmaceutical properties. 
Selected examples are highlighted in scheme 1-10. 
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Scheme 1-10:  Selected examples of pharmaceutically active compounds with vicinal amino 
alcohol motifs – (adapted with permission from reference [123]) 
  References: Ref. 1: [124]; Ref. 2: [125]; Ref. 3: [126]; Ref. 4: [127]; Ref. 5:[113] 
 
 
 
1.5.2 Synthetic routes towards chiral vicinal amino alcohols - chemical 
and enzymatic methods 
Numerous chemical methods for the synthesis of chiral vicinal amino alcohols have 
been described in literature (see scheme 1-11).[112, 113, 128] Frequently used methods 
are based on functional group manipulation of molecules with two heteroatoms (such 
as addition of nucleophiles to α-hydroxy imines or α-amino aldehydes, reductive 
amination of α-hydroxy ketones and reduction of α-amino ketones). Moreover, 
oxygen/nitrogen heteroatom addition, Sharpless or Davies aminohydroxylation of 
olefins, ring opening of epoxides and acylaziridines or coupling reactions were 
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described.[113, 128] Especially in case of primary vicinal amino alcohols, the number of 
pure chemical syntheses reported with high yields, high optical purities and high 
regioselectivities is still rare or require multistep strategies.[112, 114]  
 
 
Scheme 1-11:  Chemical synthesis of primary vicinal amino alcohols (adapted references [113, 128]) 
 
Various enzymatic or chemo-enzymatic synthesis routes have been published to 
access vicinal amino alcohols (scheme 1-12). A well-known example is the two-step 
synthesis of L-ephedrine patented by Hildebrandt and Hirsch from 1930,[129] which is 
still utilised to produce 120 t a-1.[130] In the first step (R)-phenylacetylcarbinol is 
generated via fermentation with baker’s yeast in the presence of benzaldehyde. 
Here, a pyruvate decarboxylase catalyses carboligation of pyruvate with 
benzaldehyde yielding (R)-phenylacetylcarbinol (scheme 1-12; strategy 1). 
Subsequently, L-ephedrine is formed by a chemical diastereoselective reductive 
amination with methylamine. Moreover, a chemo-enzymatic three-step synthesis of 
enantiomerically pure (1R,2R)-1-amino-2-indanol (ee, de >98 %) via chemical 
acetoxylation, lipase catalysed ester hydrolysis and reductive amination by 
ω-transaminases was published in 2006 (scheme 1-12 - strategy 2).[131] Another 
outstanding example is the combination of transketolases and ω-transaminases for 
the synthesis of 2-amino-1,3-diols (scheme 1-12 - strategy 3)[132, 133] such as (2S,3S)-
2-aminopentane-1,3-diol[134] (26 % yield, ee >98 %, de 61 %) or (2S,3S)-2-amino-
1,3,4-butanetriol[135] (26 % yield, single isomer). 
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Scheme 1-12:  Selected examples for the enzymatic and chemo-enzymatic synthesis of primary 
vicinal amino alcohols[129-135] 
 
 
1.5.3 Nor(pseudo)ephedrines – interesting compounds with challenging 
synthetic strategies 
Valuable chiral vicinal amino alcohols with challenging synthesis strategies are the 
four phenylpropanolamine (PPA) isomers: (1S,2S)-norpseudoephedrine, (1R,2R)-
norpseudoephedrine (NPE), (1S,2R)-norephedrine and (1R,2S)-norephedrine (NE). 
These compounds belong to the amphetamine family of ephedra alkaloids and are 
found in plants like khat (Catha edulis)[136, 137] or in Ephedra species[138]. In the human 
body they are known to have sympathomimetic function[124] by acting as non-
selective adrenergic receptor agonists[139] and norepinephrine re-uptake inhibitors[139]. 
As pharmaceuticals, PPA were used in the beginning of the 20th century for induction 
of mydriasis (dilation of pupils), to stabilise the blood pressure or as nasal 
decongestion.[140, 141] In early studies it turned out that PPA exhibits anorectic action 
therefore it was sold later on as an appetite suppressant[142]. Moreover it has been 
widely used in cold and flu medications.[143] However in 2000, the “Food and Drug 
Administration” (FDA) recommended that PPA should no longer be available for 
over-the-counter use[144], since permanent uptake increases the risk of haemorrhagic 
stroke[145-147]. Therefore, PPA was removed as an over-the-counter drug in most 
countries, but is still available on prescription.[148] On the German market, Cathine 
((1S,2S)-norpseudoephedrine) is currently sold as the main drug in ALVALIN® 
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provided by the RIEMSER Pharma GmbH, which is sold as an appetite suppressant 
for short-term use.[149-151] 
Beside the pharmacological interest, the four phenylpropanolamine stereoisomers 
are used as valuable synthons, ligands and chiral auxiliaries in various organic 
syntheses.[126, 127] A SciFinder® search (with unspecified stereochemistry in both 
stereogenic centres) resulted in 5071 different reactions where nor(pseudo)-
ephedrines are used as reactants.[152] Selected examples from the large list of 
applications with optical pure N(P)E are the synthesis of a neurokinin-3 receptor 
antagonist (treatment of mental disorder)125 and a phosphodiesterase inhibitor (anti-
inflammatory, anti-allergic)126 (scheme 1-10). Many more products derived from 
N(P)E can be found in literature. 
 
As already specified in chapter 1.5.2, the enantiomerically and diastereomerically 
pure synthesis of primary vicinal amino alcohols is often challenging and the 
nor(pseudo)ephedrines do not represent an exception. Only optically pure (1S,2S)-
NPE is currently sold as natural product isolated from khat shrub (Arabia, 
Ethiopia)[153]. For all four stereoisomers currently 355 different synthesis strategies 
with N(P)E as final products were described in SciFinder®.[152] However, only few of 
these strategies result in N(P)Es with good optical purities (ee, de >98 %). The 
number of routes decreases significantly when asymmetric synthesis is the method of 
choice. Some prominent methods have recently been reviewed[154] (scheme 1-13): 
(1S,2S)-NPE can be synthesised in eight steps from an chloramphenicol synthesis 
intermediate with excellent ee and de (>99 %)[155] in three steps with a de of 82 %[156]; 
(1R,2R)-NPE is accessible in five steps to with 82 % ee[157] or as a by-product in the 
Sharpless aminohydroxylation with an ee of 74 %[158, 159]; (1S,2R)-NE was 
synthesised in two chemical steps with an ee of 86 %[160], in a chemo-enzymatic 
reaction from benzaldehyde and nitroethane using a hydroxynitrile lyase (from Hevea 
brasiliensis) and H2 reduction to give an ee ~95 % and a dr of 9:1[161] or by baker’s 
yeast and LiAlH4 reduction in ee ~95 % and a of dr of 9:1[162]; or (1R,2S)-NE in one 
step with a moderate ee of 76 %[163]. 
The methods reported for asymmetric syntheses of nor(pseudo)ephedrines, require 
either multi-step preparative routes, are based on relatively expensive reagents, or in 
particular lack high enantio- and diastereomeric puritiy. 
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Scheme 1-13:  Selected examples for the synthesis of nor(pseudo)ephedrines 
Ref. 1 [155], Ref. 2 [156], Ref. 3 [157], Ref. 4 [160], Ref. 5 [163], Ref. 6 [154], Ref. 7 
[155], Ref. 8 [161], Ref. 9 [162] 
 
In 2012, a novel and highly stereoselective method was described for the synthesis 
of all four phenylpropanolamine isomers in high optical purities (ee, de >99 %).[154] 
Norephedrine isomers were accessible in four steps (40 % yield) and norpseudo-
ephedrine in seven steps (35 % overall yield) starting from 2-phenyl-2-trimethyl-
silyloxyacetonitrile (scheme 1-14). However, a multi-step reaction protocol with 
several isolation and protection/deprotection steps is required. 
 
 
Scheme 1-14:  Chemical synthesis strategy for all four nor(pseudo)ephedrine isomers in 
excellent optical purities of ee, de >99 % (here, (1R,2R)-NPE is shown)[154] 
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1.5.4 Nor(pseudo)ephedrine synthesis – what we can learn from nature 
As mentioned in chapter 1.5.3, phenylpropanolamines can be found in plants. In 
2011, the biochemical pathway (see scheme 1-15) of these and other phenyl-
propylamino alkaloids was published for khat (Catha edulis)[136] and in 2012 for some 
plants of Ephedra species[138]. 
In both types of plants, the suggested synthetic pathway contain benzaldehyde as an 
intermediate, which is derived from L-phenylalanine via non-oxidative deamination by 
a phenylalanine ammonia lyase and subsequent aldol cleavage by a benzaldehyde 
carboxyligase. In khat, a dehydrogenase catalyses the oxidation of benzaldehyde to 
benzoic acid and a thiamine diphosphate (ThDP)-dependent enzyme catalyses the 
carboligation with pyruvate to 1-phenylpropane-1,2-dione. In Ephedra species a 
reverse order of oxidation and carboligation was suggested. Here, hydroxypropio-
phenone and/or phenylacetylcarbinol (PAC) is synthesised from benzaldehyde first 
and a dehydrogenase catalyses the oxidation to 1-phenylpropane-1,2-dione. In both 
cases, this intermediate is transformed into (S)-cathinone by an (S)-selective 
ω-transaminase. In the last step of the (1S,2S)-norpseudoephedrine and (1S,2R)-
norephedrine biosynthesis, either an (S)- or (R)-selective dehydrogenase reduces 
the keto group to an (S)- or (R)-configured alcohol (see scheme 1-15). 
 
 
 
Scheme 1-15:  Biochemical synthesis pathway of phenylpropanolamines. 
Presented is the biosynthesis pathway of (1S,2S)-norpseudoephedrine and (1S,2R)-
norephedrine in the plant khat135 (synthesis via benzoic acid - blue arrows) and in 
Ephedra species[138] (synthesis via hydroxypropiophenone and phenylacetylcarbinol - 
green arrows). The synthesis of N(P)E from phenylacetylcarbinol in Ephedra species 
(dashed arrow) was so far not postulated.[138] 
  
PAL: phenylalanine ammonia lyase, BCL: benzaldehyde carboxyligase, ThDP: thiamine 
diphosphate 
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The two biosynthetic intermediates 1-phenylpropane-1,2-dione (cheapest catalogue 
price: 0.73 € g-1)[164] and benzaldehyde (cheapest catalogue price: 0.006 € g-1)[165] are 
commercially available and moreover relatively inexpensive. Looking at the “trick” 
from nature, two independent asymmetric synthesis strategies for the production of 
phenylpropanolamines from these intermediates are conceivable (scheme 1-16). 
The first strategy encompasses the reductive amination of 1-phenylpropane-1,2-
dione by an ω-transaminase. The subsequent reduction of cathinone by a 
dehydrogenase gives access to nor(pseudo)ephedrine (scheme 1-16-A). Starting 
from benzaldehyde in the second strategy, a carboligation with (decarboxylated) 
pyruvate in the first reaction step generates phenylacetylcarbinol. As suggested by 
the biosynthetic pathway hypothesis, in the next step the already introduced 
stereochemistry might be removed by oxidation and two subsequent steps would be 
required to introduce stereochemistry again (see scheme 1-15). In contrast to this 
postulated biosynthetic pathway, a direct reductive amination of phenylacetylcarbinol 
could lead in only one step to the final products (scheme 1-16-B). As described in 
chapter 1.4.3, ω-transaminases are valuable catalysts for a ‘green reductive 
amination’ in this step. However, this has never been described in literature. 
 
 
 
Scheme 1-16:  Two novel strategies for the asymmetric synthesis of phenylpropanolamines  
 A: reductive amination by an ω-transaminase and subsequent reduction by a 
dehydrogenase opens access to nor(pseudo)ephedrines. B: the carboligation of 
benzaldehyde with (decarboxylated) pyruvate generates phenylacetylcarbinol and in 
contrast to the postulated biosynthetic pathway (scheme 1-15) an ω-transaminase 
could catalyse the reductive amination to the desired amino alcohol. With highly 
selective enzymes in all steps, theoretically all four nor(pseudo)ephedrine isomers 
should be accessible in high purities. 
 
Both synthesis strategies could theoretically give access to all four nor(pseudo)-
ephedrine isomers. If highly selective enzymes are used in all steps, high optical 
purities of all compounds might be achievable. However, these novel synthesis 
strategies are described within this thesis for the first time.  
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1.5.5 Availability of enzymes for biocatalytic synthesis of nor(pseudo)-
ephedrines 
As mentioned above (see chapter 1.5.4), the combination of three different 
biocatalysts (ω-transaminases, dehydrogenases and ThDP-dependent enzymes) can 
open up the biocatalytic access for the production of nor(pseudo)ephedrines through 
respective enzyme cascades. 
 
1.5.5.1 ThDP-dependent enzymes 
ThDP-dependent enzymes are involved in many biosynthetic pathways and catalyse 
the formation and/or breakdown of C–C, C–S, C–N, C–O and C–P bonds.[166] For the 
formation of nor(pseudo)ephedrine (scheme 1-16-B), enzymes catalysing the highly 
stereoselective C-C bond formation (also called carboligation) are required. One 
focus was the access of all possible stereo- and regioisomers products for the 
ligation of an aromatic and an aliphatic aldehyde (or the corresponding α-keto acids, 
respectively) with high selectivities (scheme 1-17).  
 
Scheme 1-17: Examples of the ThDP-dependent enzyme toolbox for the asymmetric synthesis 
of α-hydroxy ketones. More details can be found in reviews.[123, 167, 168]  
 
BAL: benzaldehyde lyase (Pseudomonas fluorescens), PDC: pyruvate decarboxylase (Acetobacter pasteurianus: ApPDC), 
BFD: benzoylformate decarboxylase (Pseudomonas putida), SucA (E1 subunit of the α-keto glutarate dehydrogenase complex 
in Escherichia coli), CDH: cyclohexane-1,2-dione hydrolase (Azoarcus sp.), AHAS: acetohydroxyacid synthases (Escherichia 
coli), MenD: 2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexene-1-carboxylate synthase (Escherichia coli). 
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This subclass of ThDP-dependent enzymes was intensively studied within the last 
decades. Due to this, various wild type enzymes and variants are available for the 
asymmetric synthesis of α-hydroxy ketones (scheme 1-17).[167-172] The toolbox 
created in the working group “Biocatalysis and Biosensors” of Prof. Martina Pohl and 
Dr. Dörte Rother (IBG-1, Forschungszentrum Jülich GmbH, Germany) currently 
contains 20 wild type enzymes and more than 150 active variants. Three of those 
ThDP-dependent enzymes have been used in this thesis. 
 
ApPDC-E469G (pyruvate decarboxylase variant from Acetobacter pasteurianus) 
As its natural function, the wild type ApPDC (EC 4.1.1.1) catalyses the cleavage of 
pyruvate to acetaldehyde and CO2 in the oxidative metabolism of Acetobacter 
pasteurianus.[173] In organic syntheses, the enzyme has been used for various 
carboligation reactions.[168, 169, 174] The carboligation can be performed with aldehydes 
as well as α-keto acids as donors and benzaldehyde derivatives as acceptors. Since 
the enzyme is highly (R)-selective, an (S)-selective variant was generated by a point 
mutation in the active site of wild type ApPDC, where a glutamate in position 469 was 
replaced by glycine. This mutation opened up a region in the active site, the so called 
(S)-pocket, allowing for the synthesis of (S)-phenylacetylcarbinol (PAC) and 
derivatives thereof.[174] Compared to the wild type enzyme (ee(R)-PAC = 97 %), the 
variant ApPDC-E469G catalyses the synthesis of (S)-PAC with an ee of 61 % in 
buffer in the presence of 20 % (v/v) DMSO[174] and with an ee of 89 % in the absence 
of organic solvents[175]. 
 
AHAS-I (acetohydroxyacid synthases from Escherichia coli) 
Acetohydroxyacid synthases (AHAS, EC 2.2.1.6) are found in plants, bacteria, algae 
and fungi, where they are involved in the biosynthesis of branched-chain amino acids 
(valine, leucine, isoleucine) and other biosynthetic precursors (like pantothenate and 
coenzyme A).[176, 177] Besides, the acetohydroxyacid synthase I from Escherichia coli 
(AHAS-I) is known to catalyse also the carboligation of benzaldehyde and 
(decarboxylated) pyruvate to (R)-PAC with high enantioselectivity (ee >98 %).[178, 179] 
Mechanistic studies revealed that first pyruvate is bound to the ThDP cofactor in the 
active site. After decarboxylation, CO2 is released from the active site while the 
hydroxyl-ethyl group remains covalently attached to the C2-atom of the thiazolium-
ring in ThDP (hydroxyl-ethyl-ThDP).[179] This acyl group can be ligated with a second 
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pyruvate molecule acting as acyl-acceptor yielding acetolactate. In contrast to this, 
(R)-PAC is formed if the hydroxyl-ethyl group is transferred to benzaldehyde. The 
reaction rates for the carboligation towards acetolactate and PAC, respectively, in 
presence of pyruvate and benzaldehyde (at equal concentrations) indicate that 
acetolactate is the kinetically favoured product (fast ligation of two pyruvate 
molecules), while PAC is the thermodynamically favoured product (concentration of 
acetolactate decreases over the time while PAC is the major product under steady-
state conditions).[179] For the carboligation of benzaldehyde and pyruvate the optimal 
pH-range was found between pH 6.5-8.0.[180]  
 
PfBAL (benzaldehyde lyase from Pseudomonas fluorescens) 
Due to a benzaldehyde lyase (BAL, EC 4.1.2.38), the gram-negative bacteria 
Pseudomonas fluorescens is able to grow on carbon sources like anisoin or 
benzoin.[181] Until now, there is no other enzyme known that catalyses the cleavage 
of benzoins into the respective benzaldehyde derivatives. In terms of carboligation, 
BAL shows outstanding high activity, a broad substrate range and high (R)-
selectivities for a broad range of products.[182] One example is the synthesis (R)-HPP 
with an ee >99 % and >300 U mg-1.[182] These properties have been used for 
(S)-benzoin production in kinetic resolution mode from racemic benzoin.[183] The 
concept was further investigated within the PhD thesis of Álvaro Gómez Baraibar, 
who developed the so called “chiral polishing” of (S)-PAC. Starting from moderate 
optical purity (ee(S)-PAC ~70 %), (S)-PAC is enriched to >97 % ee by a PfBAL 
catalysed kinetic resolution (scheme 1-18).[184] 
 
 
 
Scheme 1-18:  “Chiral polishing” of (S)-PAC. 
(S)-PAC with a low optical purity generated by catalysis of a lyase (e.g. by ApPDC-
E469G) is converted to highly pure (S)-PAC with an ee >97 % by PfBAL (highly (R)-
selective) catalysed kinetic resolution. 
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1.5.5.2 Alcohol dehydrogenases 
For a substrate similar to cathinone, Kihumbu et al. showed that the synthesis of 1-
phenylpropane-1,2-diol by enzymatic reduction of 1-hydroxy-1-phenylpropan-1-one 
(HPP) is feasible.[185] This concept was further investigated in the PhD thesis of 
Justyna Kulig.[186] Beside others, the properties of different wild type alcohol 
dehydrogenases and a carbonyl reductase were compared concerning the reduction 
of HPP. Highest activity and excellent (S)-stereoselectivity for the reduction of bulky 
substrates like PAC was found for the alcohol dehydrogenase from Ralstonia sp. 
(RADH). An (R)-selective enzyme with valuable properties is the LbADH from 
Lactobacillus brevis.[186, 187]  
 
 
LbADH (alcohol dehydrogenase from Lactobacillus brevis) 
The Lactobacillus brevis alcohol dehydrogenase (LbADH, EC 1.1.1.2) is a versatile 
catalyst with a broad substrate scope, including linear and branched aliphatic as well 
as aromatic and aromatic-aliphatic aldehydes ketones and diketones.[187, 188] The 
enzyme has a pH-optimum for the reduction at pH 6.5-8.5 and for oxidation at 
pH 7-10.[189] The (R)-selective enzyme was used as well in industrial processes such 
as for the production of (R)-ethyl-3-hydroxybutanoate.[28, 190] Moreover, the production 
of (1S,2S)- and (1S,2R)-1-phenylpropane-1,2-diol from (R)- or (S)-HPP was already 
shown to be feasible in gram-scale with excellent stereoselectivity (ee >99 %, de 
>98 %) and good reaction yields (>85 %).[185] In this example, the cofactor NADPH 
was recycled by a commercially available formate dehydrogenase (FDH, EC 1.2.1.2) 
in presence of sodium formate in excess.[185] 
 
 
RADH (alcohol dehydrogenase from Ralstonia sp.) 
The alcohol dehydrogenase from Ralstonia sp. (RADH) is a useful enzyme for the 
reduction of bulky-bulky and bulky-small ketones.[186, 187, 191] RADH has a broad pH-
optimum at pH 6–9.5 for the reduction reaction and a sharp optimum at pH 10–11.5 
for the oxidation reactions. Highest stability was found between pH 5.5–8 at 8–15 °C 
only in the presence of CaCl2. For the reduction of HPP to 1-phenylpropane-1,2-diol, 
the enzyme is highly (S)-selective (ee >99 %) with activities of 362 U mg-1 and 
17 U mg-1 for the reduction of (R)-HPP and (S)-HPP, respectively.[186] 
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1.5.5.3 Toolboxes of (R)- and (S)-selective ω-transaminases 
As summarised in chapter 1.4.3.4, nowadays various (S)- and (R)-selective 
ω-transaminases are available for reductive amination of ketones and aldehydes to 
the respective amines. One toolbox of (S)-selective ω-transaminases was developed 
by Ward, Hailes and co-workers.[103] In the last years, the missing gap of (R)-
selective enzymes was filled by the work of Bornscheuer, Höhne and co-workers.[81] 
These (R)-selective ω-transaminases are now sold by the company Enzymicals AG. 
In a cooperation with the working groups of Prof. John M. Ward and Prof. Helen C. 
Hailes from the University College London and later on as well with the Enzymicals 
AG, we got access to 20 (S)-selective and seven (R)-selective wild type 
ω-transaminases. 
 
 
(S)-selective ω-transaminases toolbox 
In order to identify enzymes with new properties, Ward and co-worker performed a 
BLAST-based sequence homology search using the ω-transaminase (TA) from 
Vibrio fluvialis as a template. As a result, further (S)-selective ω-TA from different 
organisms were identified (see appendix II): 
Saccharopolyspora erythraea (SeTA), Streptomyces avermilitis (SaTA), Strepto-
myces coelicolor (ScTA), Thermobifida fusca (TfTA), Pseudomonas putida (PpTA), 
Pseudomonas aeruginosa (PaTA), Chromobacterium violaceum (CvTA, also referred 
to as CV2025), Klebsiella pneumoniae (KpTA), Escherichia coli (EcTA). 
Only two of these ω-TA have been described in literature. The enzyme from 
Pseudomonas aeruginosa was used in a 2-step synthesis together with a 
transketolase to produce a single isomer of 2-amino-1,3,4-butanetriol with overall 
yields of 21 %.[135] The best characterised and widely applied enzyme is the CV2025 
(EC 2.6.1.18). Its broad substrate range (chapter 1.4.3.4) and the application for 1,3-
amino alcohol syntheses (chapter 1.5.2) have been discussed previously. The 
enzyme has a pH optimum at pH 8-10 and shows a ~10-fold higher activity in HEPES 
buffer compared to phosphate buffer at the same pH.[103] For a wide range of 
substrates (especially for bulky-aliphatic ketones/amines), this ω-transaminase is 
highly (S)-selective (e.g. synthesis of (S)-α-methylbenzylamine with an ee >99 %).[103] 
Since 2012, crystal structures of the enzyme (two of the apo form, one of the holo 
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form, one in an intermediate state (without substrate/inhibitor) and one with an 
inhibitor) are available.[192, 193] Using this structural knowledge, active site variants like 
CV2025-F88A/A231F with inverted small and large pockets sizes were generated 
(see chapter 1.4.3.2). This variant shows in general decreased (S)-selectivity for 
most substrates compared to the wild type enzyme and is moreover (R)-selective for 
a limited range of cyclic amines.[194] 
 
 
(R)-selective ω-transaminases toolbox 
In 2010, 17 novel (R)-selective ω-transaminases from different origins were 
discovered by an in silico approach. Based on structural information and protein 
sequences of (S)-selective ω-transaminase, protein databases were screened for 
enzymes with complementary enantiopreference.[81, 195] Nowadays, seven of these 
(R)-selective ω-transaminases are commercially available by Enzymicals AG[196] and 
were provided within a cooperation with this company as lyophilised crude cell 
extracts:  
Aspergillus fumigatus (AfTA), Gibberella zeae (GzTA), Neosartorya fischeri (NfTA), 
Aspergillus oryzae (AoTA), Aspergillus terreus (AtTA), Penicillium chrysogenum, 
(PcTA), Mycobacterium vanbaalenii (MvTA) 
All enzymes are known to catalyse the reductive amination reactions of bulky-
aliphatic substrates with excellent stereoselectivities (e.g. synthesis of (R)-α-methyl-
benzylamine from acetophenone with an ee >99 %).[81] Moreover, these enzymes 
have been broadly used for various applications (see chapter 1.4.3.4). 
 
 
 
1.6 Enzymatic cascade reactions – advantages and challenges 
As described in chapter 1.5 for the specific example of amino alcohols, the synthesis 
of compounds with more than one chiral centre usually requires more than one 
catalytic step. The combination of two or more catalysed reactions is defined as a 
reaction cascade.[197-204] In general, these multi-step reactions can be subdivided in 
two types of cascades: 
Chapter 1 
 
- 34 - 
Introduction
A)  “domino” reaction cascade: 
An unstable product of a reaction step undergoes a spontaneous reaction to 
form a stable product. Examples for spontaneous (chemical) reactions are 
Diels-Alder reactions, rearrangement, fragmentation and cyclisation.[199] 
 
B)  “tandem” reaction cascade: 
The combination of several catalysed reactions which could in principle be 
performed separately (one after another) is called “tandem” cascade. Here, 
the reaction intermediates need to be stable.[197, 201]  
 
 
In addition to this, cascades are defined as biocatalytic cascades when at least one 
biocatalytic step is involved. This includes multi-enzymatic, chemo-enzymatic and 
enzyme-initiated spontaneous (domino) reactions.[197] For the synthesis of amino 
alcohols, such as nor(pseudo)ephedrines two different 2-step enzymatic (tandem) 
cascades were investigated in this thesis (see chapters 1.5.4 and 1.5.5).  
 
 
1.6.1 Enzyme (tandem) cascades: cascade designs and reaction modes  
Four different general designs of enzymatic cascade reactions were known (scheme 
1-19 A-D).[197] The most simple cascade is the ‘linear cascade’, where a product is 
synthesised via one (or more) intermediates (scheme 1-19 A). ‘Orthogonal cascades’ 
are more complex. Here, the product formation is coupled to a cofactor/co-substrate 
regeneration step or co-product removal reactions (scheme 1-19 B). In 
‘cyclic cascades’ one substrate of the reaction mixture is enriched by removal of the 
other, which is then subsequently converted back into the starting material (scheme 
1-19 C). A typical example is the dynamic kinetic resolution of racemic compounds. 
Similar to orthogonal cascades, in ‘parallel cascades’ product formation is coupled to 
the synthesis of a co-product (scheme 1-19 D). Here, the co-product is not removed 
and is optimally a valuable second product.  
In addition to different reaction designs, a cascade can be performed in different 
reaction modes: The classical reaction mode is a multi-step reaction performed in 
several reaction vessels (pots). Here, isolation of reaction intermediates after each 
reaction step is required: “X-step X-pot reaction”. Moreover, cascades can be 
performed in 1-pot without isolation of the reaction intermediates. If these reactions 
are performed one after another, such systems are referred to as “1-pot X-step 
sequential cascade” In a “1-pot X-step simultaneous cascade” all catalysts are added 
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in one reaction vessel at the same time. For a “1-pot 2-steps linear cascades” these 
different reaction modes are itemised in scheme 1-19 (A-1 to A-3). 
 
 
 
Scheme 1-19:  Different cascade designs and reaction modes for a 2-step enzymatic cascade 
(modified from references: [197, 203]) 
 Enzymatic cascade designs: A) linear cascade, B) orthogonal cascade, C) cyclic 
cascade, D) parallel cascade[197] and different reactions modes of a 2-step linear 
cascade[203]: A-1) 2-steps 2-pots, A-2) 1-pot 2-step sequential cascade (the 2nd step is 
performed after the 1st reaction), A-3) 1-pot 2-step simultaneous cascade (both 
reactions are performed simultaneously). 
 
A cascade where all reactions can be performed in one pot, reduces not only the 
number of intermediate isolation steps, it thereby decreases amount of chemicals 
(reagents, solvents and/or absorbents), lowers energy consumption and reduces 
waste production. Each point does not only contribute to a more efficient process in 
terms of production costs, but simultaneously to a more environmentally friendly 
reaction process.[201-203, 205-208] In general, the most time-efficient way to perform such 
a cascade is the simultaneous mode, where all catalysts act at the same time. 
Moreover, the complexity of the reaction procedure is reduced when all components 
of a multi-step reaction can be added at once. In contrast to this, the complexity of 
the system is significantly increased. If side reactions occur (e.g. caused by substrate 
competition with an enzyme of another reaction step), the benefit of an easier 
simultaneous mode needs to be compared with lower purification effort and most 
likely higher reaction yield in a sequential mode.[197, 200, 201, 208] Especially in 
simultaneous cascades, an optimal interplay of all catalysts is required. Optimal 
cascade parameters (such as pH, temperature, substrate concentrations and the 
S I PA)
S I
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I P
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S
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reaction time t1 reaction time t2
reaction time t1 reaction time t2
+S1 S2 +I S2
Chapter 1 
 
- 36 - 
Introduction
relative ratio of enzymes) have to be found. Since reaction engineering of multi-
parameter systems can be rather challenging, implementation of mathematical 
modelling (see chapter 1.6.2) can help to increase reaction yields by finding optimal 
operation windows.[197, 200] 
 
 
1.6.2 Easy and efficient multi-parameter optimisation 
Multi-parameter optimisation, often required for classical reaction engineering, is time 
consuming and due to the number of experiments as well cost intensive. One main 
challenge is the intersection between statistical relevance/significance of data and 
their interpolations on the one hand and the number of experiments on the other. 
Here, design of experiments (DOE) offers a mathematical way to minimise the 
number of necessary experiments by building a relationship between independent 
variable factors and the outcomes of an experiment.[209-211] This relationship can for 
example be visualised in a 3-D plot (see scheme 1-20) where two variables (x1 and 
x2 – e.g. pH, temperature, substrate concentrations and enzyme ratio) are plotted 
against one outcome factor (y, e.g. reaction yield or optical purity).  
 
 
 
Scheme 1-20:  Basis steps for reaction engineering supported by mathematical modelling[200] 
e.g. via the Kriging method and 3-D visualisation (see 3-D plot).  
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Various methods for mathematically supported reaction engineering are described in 
literature.[197, 200] One approach is the so called “Kriging method”. In this statistical 
method the values of an interpolating function are determined by a weighted sum of 
all measurement data. These weights are locally computed, such that the expectation 
value of the interpolating function matches the true value with minimised deviation 
but highest statistical significance. Thus, the Kriging method allows an optimal 
interpretation of experimental datasets. Further mathematical details on the Kriging 
method can be found in the literature.[212, 213] 
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2 Aim of the work 
 
One focus of the working group “Biocatalysis and Biosensors” (IBG-1, Forschungs-
zentrum Jülich GmbH, Germany), headed by Prof. Martina Pohl and Dr. Dörte 
Rother, is to offer biocatalytic solutions for challenging synthesis strategies. Amino 
alcohols are valuable compounds for the pharmaceutical as well as for the chemical 
industry. An example from this large list of valuable molecules are the four 
stereoisomers of nor(pseudo)ephedrine. To enable the biocatalytic access to these 
compounds was of special interest for this thesis. Known chemical synthesis routes 
and chemo-enzymatic reaction cascades towards these products often require 
multiple steps or lack high stereo- and regioselectivities. 
As summarised in chapter 1.5.4, 2-hydroxy ketones are intermediates in natural 
biosynthetic pathways of amino alcohols. Synthetically, 2-hydroxy ketones can be 
synthesised from aldehydes or respective 2-keto acids by using ThDP-dependent 
enzymes. An enzyme toolbox consisting of 20 wild type enzymes and more than 150 
active variants was developed in the working group of Prof. Pohl and Dr. Rother to 
generate a platform of various 2-hydroxy ketones with high selectivities. Among this 
platform, specifically (R)- and (S)-phenylacetylcarbinol (PAC) represented a perfect 
starting point to access all four nor(pseudo)ephedrines by reductive amination of the 
prochiral carbonyl group. A goal of this thesis was to identify appropriate biocatalysts 
for the reductive amination of these 2-hydroxy ketones. Respective catalytic activity 
was assumed for ω-transaminases (see chapter 1.5.4). A toolbox for the screening of 
18 (S)- and eight (R)-selective ω-transaminases was available from cooperation 
partners (chapter 1.5.5.3).  
 
Development of an efficient screening assay for ω-transaminases 
To analyse the potential of these ω-transaminases for the reductive amination of 
2-hydroxy ketones in general, and for PAC specifically, an efficient screening assay 
had to be developed. This assay should allow a rapid analysis of the substrate range 
independent of the amine donor (co-substrate) spectrum.  
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Strategies for the biocatalytic synthesis of nor(pseudo)ephedrine 
ω-Transaminases with promising properties for the reductive amination of PAC 
should be tested in combination with ThDP-dependent enzymes for the 2-step 
synthesis of nor(pseudo)ephedrines (scheme 2-1).  
 
 
Scheme 2-1:  Synthesis of nor(pseudo)ephedrines combining ThDP-dependent enzymes and 
ω-transaminases 
 
 
As an alternative to this synthetic route, a second strategy for the synthesis of 
synthesis of nor(pseudo)ephedrines is deduced from the natural biosynthesis 
pathways (chapter 1.5.5.3). Starting from 1-phenylpropane-1,2-dione, the 
combination of an ω-transaminase in the first step with subsequent alcohol 
dehydrogenase catalysed reduction could be evaluated according to scheme 2-2.  
 
 
 
Scheme 2-2:  Synthesis of nor(pseudo)ephedrines combining ω-transaminases and 
dehydrogenase 
 
A special challenge of both approaches is to identify reaction conditions, under which 
both enzymes are active in a cascade reaction with optimal productivity and for that 
high stereoselectivity and low by-products are feasible.  
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3 Publications 
 
 
3.1  TTC-based screening assay for ω-transaminases: a rapid 
method to detect reduction of 2-hydroxy ketones 
 Journal of Biotechnology (2012) 
 159(3):188-94. doi: 10.1016/j.jbiotec.2011.12.023. Epub 2012 Jan 2. 
 Reproduced with permission of Elsevier B.V. 
 
 
 
3.2  Two steps in one pot: Enzyme cascade for the synthesis of 
nor(pseudo)ephedrine from inexpensive starting materials 
 Angewandte Chemie International Edition (2013) 
 52(26):6772-5. doi: 10.1002/anie.201300718. Epub 2013 May 9. 
 Reproduced with permission of WILEY-VCH Verlag GmbH & Co. KGaA 
 
 
 
3.3  Efficient 2-step biocatalytic strategies for the synthesis of all 
nor(pseudo)ephedrine isomers 
Green Chemistry (2014), in press, doi:10.1039/C4GC00100A. 
Reproduced with permission of WILEY-VCH Verlag GmbH & Co. KGaA 
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4 Discussion 
Context of publications and invention disclosures 
The combination of ThDP-dependent enzymes, alcohol dehydrogenases and 
ω-transaminases can constitute two different routes towards chiral vicinal amino 
alcohols (chapter 1.5.4). A main focus of this thesis was set on the identification and 
characterisation of ω-transaminases for the 2-step syntheses of vicinal amino 
alcohols. For a fast and reliable screening of ω-transaminases (chapter 1.5.5), a 
novel screening assay was developed. Enzymes with most promising properties were 
investigated in combination with ThDP-dependent enzymes or alcohol 
dehydrogenases in different 2-step cascade modes for the synthesis of optically pure 
nor(pseudo)ephedrines. 
 
Publication I describes the functionality and reliability of the established screening 
assay for ω-transaminases. Results for the reductive amination of nine 2-hydroxy 
ketones in combination with three amine donors were shown for four selected 
enzymes. The complete screening set and the possibility to expand the assay’s 
application are discussed in the following. 
 
Publication II reports the results for the synthesis of (1R,2R)-norpseudoephedrine 
and (1R,2S)-norephedrine in two reaction steps by combining highly (R)-selective 
ThDP-dependent enzymes with ω-transaminases. The reaction equilibrium constant 
for the reductive amination step was determined. A solution for a required reaction 
equilibrium shift without addition of further reactants or catalysts is presented. For the 
2-step cascade a parameter optimisation (pH, temperature, enzyme concentrations 
and amine donor/PAC ratio) was performed. 
 
Publication III describes and compares the synthesis routes to all nor(pseudo)-
ephedrine stereoisomers either by a combination of ThDP-dependent enzymes with 
ω-transaminases in the one strategy or ω-transaminases and dehydrogenases in the 
other. In both strategies the application of (S)- and (R)-selective enzymes is 
investigated. Moreover, reactions with lyophilised whole cells, crude cell extracts and 
purified enzymes were compared. 
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Invention disclosures I and II [214, 215] demonstrates the specifically the access to 
(1S,2S)-norpseudoephedrine (trivial name: Cathine) in the two different synthesis 
routs presented in publication III. This compound is sold e.g. on the German market 
as the main drug as an appetite suppressant for short-term use.[149-151] Invention 
disclosure I reports access to (1S,2S)-norpseudoephedrine by combination of the 
pyruvate decarboxylase variant ApPDC-E469G from Acetobacter pasteurianus with 
the -transaminase CV2025 from Chromobacterium violaceum.[214] Moreover, the 
concept of chiral enrichment (also referred to as “chiral polishing”) of the intermediate 
(S)-phenylacetylcarbinol to gain high optical purities (ee >97 %) is shown. In 
invention disclosure II the access to (1S,2S)-norpseudoephedrine in high optical 
purities is shown by using the -transaminase CV2025 in the first step and the 
alcohol dehydrogenase LbADH from Lactobacillus brevis in the second step.[215]  
 
 
4.1 A novel screening assay for ω-transaminases 
In the beginning of this work a toolbox of 18 putatively (S)-selective ω-transaminases 
(chapter 1.5.5.3) and later on eight (R)-selective enzymes were accessible. Without 
detailed knowledge about their amine acceptor range and amine donor preference at 
hand, the combination of these catalysts with 10 synthesised or available 2-hydroxy 
ketones and 12 selected amine donors would have resulted in an enormous number 
of single reactions to analyse. In order to achieve a quick and reliable analysis of 
these reactions, an ω-transaminase screening assay had to be established first. 
The few existing screening assays were limited to a specific set of amine donors or 
amine acceptors (chapter 1.4.3.3). Since one intention of this work was the 
identification of enzymes for reductive amination of 2-hydroxy ketones, we would 
have been restricted to a screening with either alanine or α-methylbenzylamine as 
amine donors. On the basis of work from Breuer et al.,[216] an assay which had been 
developed for the detection of 2-hydroxy ketones in carboligation reaction, was used. 
In this assay, the colourless reagent 2,3,4-triphenyltetrazolium chloride (TTC) is 
reduced at basic conditions to a red-coloured 1,3,5-triphenylformazan, whereby the 
2-hydroxy ketone is oxidised to the corresponding diketone. In this thesis, this 
concept was used to analyse the ω-transaminase catalysed reductive amination of 
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2-hydroxy ketones, by analysing the concentration of remaining 2-hydroxy ketones 
(scheme 4-1). The conversion can be quantified relative to a calibration curve with 
known 2-hydroxy ketone concentration (publication I, chapter 3.1). 
 
 
 
Scheme 4-1:  TTC-based screening assay for ω-transaminases activity. 
The TTC-reagent oxidises very specifically 2-hydroxy ketones to the corresponding 
diketones and is thereby reduced to red-coloured formazan. Therewith conversion of 
2-hydroxy ketones by ω-transaminases can be quantified photometrically at 510 nm 
and is related to the amount of remaining substrate after a certain reaction time. 
Further details are described in publication I (chapter 3.1). 
 
 
4.1.1 Characterisation of the TTC-based screening assay 
For a precise quantification of 2-hydroxy ketones with this TTC-assay, the linear 
measuring range for each substrate needed to be determined (publication I and 
chapter 3.1). An important factor is the compound specific factors colouration rate, 
which is given by the reactivity of the 2-hydroxy ketones with the TTC-reagent. 
The colouration rate for acetoin is for instance one order of magnitude higher than for 
propioin. Similar trends were observed for the substrate pairs 2-hydroxyaceto-
phenone (2-HAP) and 2-hydroxypropiophenone (HPP) or for phenylacetylcarbinol 
(PAC) and phenylpropionylcarbinol (PPC), which differ only in one methyl/methylene 
group, respectively, like acetoin and propioin (see table 4-1). 
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Table 4-1: Amine donors and amine acceptors used in the TTC-assay 
Given is the compound specific colouration rate after TTC-addition and the 
recommended steps for the TTC-colouration reaction (A). All tested amine donors did 
not cause any background reaction (B) 
 
A: amine acceptors 
structure name 
colouration rate  
 
[mAU/(mM*min)] 
recommended steps 
dilution of the reaction 
solution before TTC 
addition 
incubation after TTC 
addition 
 
acetoin 0.034 - 2 min 
 
propioin 0.004 - 10 min 
 
2-HAP 1.096 1:10 1 min 
 
HPP 0.022 - 4 min 
 
PAC 0.329 1:10 2 min 
 
PPC 0.090 - 1 min 
 
oBr-HMBP 0.012 - 10 min 
 
pBr-HMBP 0.013 - 10 min 
 
pBr-HCPPP 0.005 - 30 min 
 
 B: amine donors  
 
isopropylamine 
 
(S)-sec-butylamine
 
(R)-sec-butylamine 
   
hexane-1,6-diamine 
 
benzylamine 
 
(S)-α-MBA 
 
(S)-tetrahydronaphthalen-1-amine 
(THNA) 
 
(S)-1-(naphthalen-1-yl)-
ethanamine (NEA) 
 
 
L-alanine 
 
 
 
β-alanine  D- and L-asparagine  D- and L-phenylalanine 
  O
OH
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As the assay is specifically sensitive for PAC (0.33 mAU mM-1 min-1) and 2-HAP 
(1.10 mAU mM-1 min-1), a pre-dilution of the reaction solution is recommended before 
the TTC-reagent is added to initiate the colour reaction. Bulky-bulky 2-hydroxy 
ketones like ortho- and para-bromo-2-hydroxy-3-methyl-butylpropiophenone (o/p-Br-
HMBP) or para-bromo-2-hydroxy-3-cyclopropyl-propiophenone (p-Br-HCPPP) can 
also be quantified but require a longer incubation time after TTC addition. Only 
benzoin could not be used since precise quantification within the low solubility range 
of benzoin (~1 mM) was not possible. Moreover, 2-hydroxy ketones with a tertiary 
alcohol group cannot be oxidised to the corresponding diketone and thus cannot be 
used in this assay. 
Compared to the high sensitivity for 2-hydroxy ketones, none of the 12 different 
amine donors used in the screenings showed significant background colouration 
(chapter 3.1). The same holds for the buffer (100 mM HEPES), the cofactor (200 µM 
PLP), the crude cell lysates and the corresponding amino alcohols (publication I, 
chapter 3.1). 
 
4.1.2 Reliability of the TTC-based screening assay 
The general reliability of the TTC-assay was evaluated by a comparison of positive 
TTC-screening results with instrumental analyses data for selected reactions 
(publication I, chapter 3.1). Gas chromatography (GC) and high performance liquid-
chromatography (HPLC) analyses data for TTC-reactions with acetoin, 2-HAP, PAC 
with (S)-α-methylbenzylamine (MBA) and four different ω-transaminases showed in 
almost all cases only 5 % to maximal 10 % deviation in conversion values compared 
to the TTC-screening assay results. 
As a single exception, positive TTC-screening results with HPP as amine acceptor 
did not fit to data determined by instrumental analysis. More detailed investigation of 
this divergence, which would have contradicted the general reliability of TTC-based 
screening results, indicated that a chemical instability of the substrate under the 
applied reaction conditions was responsible for these false positive screening hits. 
When 10 mM HPP is incubated for 16 h at 27 °C in 100 mM HEPES (pH 7.5, 
containing 200 µM PLP and 10 mM (S)-α-MBA) in the presence of 1 mg mL-1 crude 
cell extract of BL21(DE3), HPLC analyses indicated that ~5 % of initially pure HPP 
was isomerised to the regioisomer PAC. As mentioned above, PAC shows a ~15-fold 
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higher colouration rate in the TTC-assay than HPP (table 4-1). Therefore, already 
5 % PAC in a HPP solution account for ~50 % of the colour intensity, resulting in a 
false positive signal. Theoretically, such problems can occur with all instable 
2-hydroxy ketones for which the respective regioisomer has a higher colouration rate. 
However, in case of HPP a significant lower PAC concentration was observed when 
purified enzymes were used instead of crude cell extracts (<1 % PAC detected by 
HPLC). This indicates that the isomerisation of HPP was caused by the E. coli crude 
cell extract and thus can be overcome by the use of purified enzyme. 
 
4.1.3 Results of the TTC-based screening assay for (S)-selective 
ω-transaminases 
After the general reliability was validated, the TTC-based screening assay was used 
to identify and moreover quantify conversion of nine different 2-hydroxy ketones (see 
table 4-1). First all substrates were tested in combination with the 18 
ω-transaminases of the (S)-selective toolbox and with at least three different amine 
donors: (S)-α-methylbenzylamine, benzylamine and L-alanine. 
Only for three of the nine tested substrates conversion was detected: acetoin, 
2-hydroxyacetophenone (2-HAP) and phenylacetylcarbinol (PAC). These substrates 
are all small-bulky substrates with respect to the carbonyl group, carrying either a 
methyl group (acetoin, PAC) or a hydroxymethyl group (2-HAP) as the small 
substituent. All substrates with larger substituents were not accepted, indicating that 
none of the enzymes has a “small pocket” in the active site (see chapter 1.4.3.2) 
where residues larger than hydroxymethyl groups fit in. Due to the random error of 
the TTC-assay (standard deviation of the negative control: +10 %), values for a 
substrate depletion lower than 10 % are not significantly detectable. However, low 
activities and conversion values might be an interesting starting point for further 
enzyme engineering. In order to overcome these limitations, we developed a refined 
protocol for these purposes (see chapter 4.1.4). 
As mentioned above, significant conversions of acetoin, 2-HAP and PAC with some 
of these enzymes were detected using this assay. One advantage of this assay is 
that it is independent of the selected amine donors, which was not possible with any 
of the already published screening assays (chapter 1.4.3.3). This allowed to test 
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another 12 amine donors (table 4-1-B) as co-substrates for the (S)-selective 
transaminases toolbox. Outstanding conversion values for the reductive amination of 
acetoin and PAC (see table 4-2-A and table 4-2-C) were detected for the enzymes 
CV2025 (from Chromobacterium violaceum), PP5182, PP2799 and PP0596 (all from 
Pseudomonas putida) and PA0221 (from Pseudomonas aeruginosa). Here, a 
general trend could be deduced from different amine donors combination (highest 
conversion values listed first): (S)-α-methylbenzylamine ~ isopropylamine ~ (S)-/(R)-
sec-butylamine > (S)-NEA > (S)-THNA ~ benzylamine ~ L-alanine (table 4-2). Only 
with few enzymes very low conversions were found also with hexane-1,6-diamine 
and β-alanine. However, these low conversion values should be validated with 
instrumental analysis in case its application would become of interest in the future. 
No significant conversations were detected for D- and L-asparagine or D- and L-
phenylalanine as amine donors. Although exceptions are known, ω-transaminases 
generally don’t accept α-amino acids as amine donors (see chapter 1.4.3.4). In 
contrast to the high conversions found for acetoin and PAC, reductive amination of 
2-HAP was detected only with CV2025 and different amine donors and with PP5182 
in the presence of (S)-α-methylbenzylamine (table 4-2-B). Although higher chemical 
reactivity can be expected for 2-HAP compared to PAC, the terminal hydroxymethyl 
group in 2-HAP might already cause steric hindrance, which might explain the lower 
conversions observed with 2-HAP. 
 
For the reductive amination of PAC, which is the intermediate in the desired 2-step 
synthesis of nor(pseudo)ephedrine (chapter 1.5), highest conversions in the TTC-
assay were detected with CV2025, which catalysed the conversion of >95 % PAC 
using (S)-α-methylbenzylamine as amine donor. Further suitable amine donors for 
this enzyme under the tested conditions were isopropylamine (~90 % conv.), (S)-sec-
butylamine (~90 % conv.) and (R)-sec-butylamine (~80 % conv.); even (S)-NEA 
(~70 % conv.) might be suitable alternative amine donor. Besides, (S)-THNA, 
benzylamine and L-alanine (each ~20 % conv.) are also accepted, but their 
application would require further reaction optimisation to improve the overall 
conversions.
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Table 4-2: Screening results for the conversion of acetoin, 2-hydroxyacetophenone (2-HAP) and phenylacetylcarbinol (PAC) with 18 (S)-
selective ω-transaminase measured using the TTC-assay 
reaction conditions:  10 mM acetoin and 10 mM amine donor (isopropylamine and (S)-/(R)-sec-butylamine: 200 mM) in HEPES buffer (100 mM, pH 7.5), containing 200 µM PLP, 1 mg mL-1 crude 
cell extract, incubated in 96-well plate at 27 °C, 100 rpm, 16 h. Conversions (given in % of 2-hydroxy ketone consumption) were determined relative to an internal calibration 
curve at 510 nm after colouration with TTC (see publication I and chapter 3.1) 
“-”:  no significant conversion (cut-off: 10 %) detectable 
negative control: 1 mg mL-1 clarified crude cell extract of E. coli BL21(DE3) cells transformed with an empty plasmid (pET-29a) 
 
A) reductive amination of acetoin 
 
Chapter 4 
 
- 103 - 
 Discussion
Table 4-2 – continued from page 96. 
 
 
B) reductive amination of 2-hydroxyacetophenone (2-HAP) 
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Table 4-2 – continued from page 96. 
 
 
C) reductive amination of phenylacetylcarbinol (PAC) 
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4.1.4  “Reverse” TTC-based screening assay 
With a slight modification of the setup for the TTC-based screening assay compared 
to the published procedure (see publication I, chapter 3.1) the application of the 
assay could be expanded. Using chiral 2-hydroxy ketones as substrates this assay 
allows also a screening for stereoselectivity on the one hand and on the other hand a 
reliable screening with instable substrates (like HPP, see chapter 4.1.2) was feasible. 
The reductive amination catalysed by transaminases is in general a reversible 
reaction. As a consequence, it is possible to screen not only for the forward but also 
for the reverse reaction. In contrast to the typical setup where an 2-amino alcohol is 
produced from a 2-hydroxy ketone, the amino alcohols are used as substrates in the 
“reverse TTC-assay” (scheme 4-2). Therewith the conversion refers to deamination 
of the 2-amino alcohol. The corresponding 2-hydroxy ketones can be detected 
analogously (chapter 3.1). As a consequence an amine acceptor is required for the 
reaction. For ω-transaminase reaction with alanine as an amine donor (yielding 
pyruvate) the thermodynamic equilibrium is known to be on the substrate (alanine) 
side (chapter 1.4.3.5). By using pyruvate as an amine acceptor in the reverse 
reaction, this disadvantage was turned into an advantage. Therefore, pyruvate is 
recommended as a suitable amine acceptor in the “reverse” TTC-assay setup. 
 
 
 
Scheme 4-2:  Classical and “reverse” TTC-based screening assay for ω-transaminases. 
In contrast to the typical TTC-assay (A), in the “reverse” setup (B) amino alcohols are 
used as substrates for the reaction. With an amine acceptor (e.g. pyruvate) the 
corresponding 2-hydroxy ketone is produced in the reductive amination reaction. 
Using the same colouration parameters as for the typical setup (publication I, chapter 
3.1), the 2-hydroxy ketone can be quantified. 
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4.1.4.1 Application of the “reverse” TTC-assay to screen for enzyme 
stereoselectivity 
Later in the project, we got access to seven (R)-selective ω-transaminases provided 
by the company Enzymicals AG (Greifswald, Germany) and to the putatively 
(R)-selective double variant CV2025-F88A/A231F (see chapter 1.5.5.3) by Prof. Per 
Berglund (KTH Stockholm, Sweden). The “reverse” setup of the TTC-assay was 
applied to determine enzyme stereoselectivity for the nor(pseudo)ephedrine 
synthesis. Here, (1R,2R)-norpseudoephedrine and (1R,2S)-norephedrine were used 
in independent reaction setups as substrates for the oxidative deamination in 
combination with the amine acceptor pyruvate. Conversion of the deamination of 
nor(pseudo)ephedrine was detected by following the formation of PAC using the 
TTC-assay. The idea behind was that a highly (R)-selective enzyme would only 
accept (1R,2R)-norpseudoephedrine. In contrast, conversion with a highly (S)-
selective transaminase would only be detectable with (1R,2S)-norephedrine as a 
substrate. Thus, a comparison of the conversion values for one or the other substrate 
stereoisomer allowed estimation of the enzyme stereoselectivity (scheme 4-3). 
 
 
Scheme 4-3:  “Reverse” TTC-assay for screening of -transaminase stereoselectivities with 
(R)- and (S)-configured amine groups of nor(pseudo)ephedrine. 
reaction condition: 10 mM (1R,2R)-norpseudoephedrine or (1R,2S)-norephedrine were incubated with 10 mM pyruvate in 
100 mM HEPES buffer (pH 7.5, containing 200 µM PLP) and 1 mg mL-1 crude cell extract in closed 96-well 
plate at 27 °C and 100 rpm for 16 h. Conversion values (given as % of 2-hydroxy ketone formation) were 
determined relative to an internal calibration curve at 510 nm after colouration with TTC-colouration 
(publication I, chapter 3.1). Information on enzymes can be found in chapter 1.5.5.3. 
negative control: 1 mg mL-1 clarified crude cell extract of E. coli BL21(DE3) transformed with an empty plasmid (pET-29a) 
“theoretical” de: calculated from conversion values of both stereoisomers in the reverse synthesis direction. 
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The results for this “reverse” TTC-assay indicate that all enzymes of the toolbox 
provided by Enzymicals AG are highly (R)-selective for nor(pseudo)ephedrines 
(scheme 4-3). Here, the concentration of PAC, generated from (1R,2S)-nor-
ephedrine, is in all cases lower than 2 % (which is at the detection limit of this assay 
setup). In contrast to this, conversion values higher than 90 % were obtained with 
(1R,2R)-norpseudoephedrine. This can be taken as a hint for a high stereoselectivity 
of these enzymes, which was additionally confirmed by instrumental analysis. 
Calculated “theoretical” de values for the reverse (synthesis) direction were >97 %. 
The respective results for the CV2025 variant F88A/A231F indicated that the enzyme 
is more (S)- than (R)-selective for the tested substrates. As a control for this reverse 
TTC-assay, the ω-transaminase CV2025 was used, since the enzyme is known to be 
highly (S)-selective. The results point out that a very high selectivity for the synthesis 
of (1R,2S)-norephedrine can be expected with CV2025 (“theoretical” de >96 %). This 
fits well to respective GC data, demonstrating a selectivity >99 % for the (S)-selective 
reductive amination of PAC catalysed by CV2025 (see chapter 3.2). 
In general these data underline that the “reverse” TTC-assay mode is a useful tool for 
the screening of ω-transaminase libraries not only towards activities, but as well 
towards stereoselectivities. 
 
 
 
 
4.1.4.2 Application of the “reverse” TTC-assay for instable 2-hydroxy ketones 
As mentioned above (see chapter 4.1.2), substrate instability can disturb the general 
reliability of the screening assay. An isomerisation of HPP to its regioisomer PAC 
caused false-positive signals due to a higher colouration rate of PAC compared to 
HPP. Also this problem could be overcome by “reverse” TTC-assay. The respective 
product from the reductive amination of HPP is 1-amino-1-phenylpropane-2-ol (APP). 
This 2-amino alcohol was stable under the tested conditions and was therefore used 
as substrate in the “reverse” TTC-assay setup (scheme 4-4).  
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Scheme 4-4:  “Reverse” TTC screening assay for instable 2-hydroxy ketones (here HPP). 
reaction condition: 10 mM (1R,2R)-1-amino-1-phenylpropane-2-ol (ee ~80 %) were incubated with 10 mM pyruvate in 100 mM 
HEPES buffer (pH 7.5, containing 200 µM PLP) and 1 mg mL-1 crude cell extract (here CV2025) in closed 
96-well plate at 27 °C and 100 rpm for 16 h. Conversion values (given as % of 2-hydroxy ketone synthesis) 
were determined relative to an internal calibration curve at 510 nm after TTC-colouration would be possible 
(here only uses as a yes-no answer). Colouration procedure see publication I (chapter 3.1) 
negative control: 1 mg mL-1 clarified crude cell extract of E. coli BL21(DE3) transformed with an empty plasmid (pET-29a) 
 
 
Since APP was not commercially available, (1R,2R)-APP was chemically synthesised 
with an ee ~80 % (detail information for the synthesis procedure see appendix). As a 
consequence of the low optical purity, this APP-batch could be used to screen for 
both, (S)- and (R)-selective ω-transaminases. The product of this oxidative amination 
reaction is HPP, which can be detected by the TTC-assay. Due to the chemical 
isomerisation of HPP to the regioisomer PAC, a precise determination of conversion 
values is not recommended, but the application as a yes-no answer is compared to 
the normal assay mode reliable in this setup. 
So far, this assay setup was tested as a first proof of principle only with the (S)-
selective ω-transaminase CV2025. Here, the colouration after TTC-addition was 
below the significant conversion detection limit of <2 %. These results were validated 
by GC for the synthesis of APP from HPP (see chapter 4.1.3), indicating that neither 
HPP nor APP are accepted by CV2025 substrates. However, this reaction setup 
provides a highly reliable, rapid and easy to handle screening assay, which is now 
available for the screening of large variant libraries for future applications. 
 
 
4.1.5 Summary TTC-based screening assay for ω-transaminases 
The TTC-based screening assay is a novel tool to expand the ω-transaminase 
toolbox. It can be applied for all 2-hydroxy ketones which react with the TTC-reagent 
to give a quantifiable colour response. The assay is fast, highly reliable and can be 
used to measure conversion curves. Moreover, it was demonstrated in this thesis, 
that the whole assay procedure could be fully automated (reaction setup, incubation, 
TTC-colouration and photometrical readout) can be performed with a Tecan Infinite 
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M1000 robotic system. By a modification of the assay setup (“reverse” TTC-assay), it 
was possible to use the assay to screen for stereoselectivity. With the same setup, 
the limitation caused by instable 2-hydroxy ketone substrates was overcome. One of 
the major advantages compared to all other published screening assay (see chapter 
1.4.3.3) is that the amine donor may be varied. So far, none of the amine donors 
tested influenced the assay properties significantly.  
 
Table 4-3: Advantages and limitations of the TTC-based screening assay for the detection 
of reductive amination by ω-transaminases 
advantages Limitation 
+    absolute conversion values 
      (not only initial rate activities) 
+    inexpensive and rapid method 
+    suitable for 96-well plates 
+    reproducible within an error range of 5-10 % 
  +    time-depended conversion curves 
  +    different donor-acceptor/hydroxy ketone ratios 
 ++   crude cell extracts & pure enzyme 
 ++  fully automatable 
+++  independent of the amine donor 
+++  screening for stereoselectivity possible 
+++  reverse mode for instable 2-hydroxy ketones 
 -   “TTC-active” compound required 
 -  error range makes cut-off for significant 
conversion values necessary in the 
“normal” mode 
 -  substrate instability might cause false 
positive screening hits 
      => validation of screening results  
      => “reverse” mode can overcome 
  these limitations 
 
 
 
Using this assay, we were able to identify enzymes catalysing the reductive 
amination of 2-hydroxy ketones like PAC, 2-HAP and acetoin. Moreover, the 
substrate range of amine donors was investigated. 
It should be noted that the assay has also been considered as useful by other groups 
as could be deduced from recent presentations of the ACIB GmbH (Graz, Austria; 
talk on 1st ω-transaminases conference 2013, Stockholm, Sweden) and Prof. Per 
Berglund and co-workers (talk on the conference BioTrans 2013, Manchester, GB). 
With the help of this assay, the ACIB GmbH could e.g. identify a novel 
ω-transaminases which accepts bulky-bulky residues. This application highlights the 
high potential of this assay to enlarge the toolbox of ω-transaminase as versatile 
industrial biocatalysts in the future. 
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4.2 Combining lyases and ω-transaminases for the synthesis of 
nor(pseudo)ephedrines in two steps (strategy 1) 
Another major tasks of this thesis was the investigation of the 2-step reaction for 
nor(pseudo)ephedrines combining ThDP-dependent lyases and ω-transaminases 
(see chapter 1.5.4). Theoretically all stereoisomers are accessible in four different 
combination of (S)- and (R)-selective enzymes in both reaction steps (scheme 4-5, 
strategy 1 A-D). 
 
Scheme 4-5:  2-Step cascades for the synthesis of nor(pseudo)ephedrines combining ThDP-
dependent enzymes and ω-transaminases. In the first reaction step (carboligation) 
either an (R)- (AHAS-I) or (S)-selective (ApPDC-E469G) results in the formation of 
(R)- or (S)-PAC, respectively. In the second (reductive amination) step, nor(pseudo)-
ephedrines are accessible in different configuration by either an (R)- (At-(R)TA) or (S)-
selective (CV2925) ω-transaminases. Theoretically all isomers are accessible via four 
different routes (strategy 1 A-D). 
 
 
As mentioned above, PAC is an intermediate of the first reaction step from which a 
reductive amination will lead to the desired products. As was deduced from results 
obtained with the TTC-assay, the enzyme CV2025 showed most promising 
properties for the synthesis of nor(pseudo)ephedrine among the toolbox of available 
(S)-selective ω-transaminases (chapter 1.5.5.3). Using this enzyme, conversions of 
PAC >95 % were detected using (S)-α-methylbenzylamine as an amine donor. In 
contrast to this, all enzymes of the (R)-selective toolbox from the Enzymicals AG 
showed similarly high conversion values and excellent stereoselectivities 
(publication II, chapter 3.2). As a consequence, all of these enzymes were further 
investigated concerning their properties in the 2-step synthesis. 
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4.2.1 2-Step synthesis of (1R,2S)-norephedrine with α-methylbenzyl-
amine as amine donor (strategy 1-A) 
The synthesis of (1R,2S)-norephedrine can be performed in two biocatalytic steps by 
combining the (R)-selective acetohydroxyacid synthase I (AHAS-I, chapter 1.5.5.1) 
for the carboligation step and the (S)-selective ω-transaminase CV2025 (also 
referred to as Cv-(S)TA, chapter 1.5.5.3) for the reductive amination reaction 
(scheme 4-5, strategy 1-A). 
 
Finding a compromise for reaction parameters in 1-pot cascade reactions: 
If two reactions are performed in one reaction pot, a compromise in terms of reaction 
parameter needs to be found for an optimal reaction process. The carboligation 
reaction was known to be highly enantioselective (ee(R)-PAC >98 %) and relatively fast 
(>3 U mg1purified enzyme) if benzaldehyde and pyruvate are used as substrates.[179] The 
initial rate activity for the reductive amination of (R)-PAC with (S)-α-methyl-
benzylamine catalysed by CV2025 was determined as ~0.06 U mg-1 (100 mM 
HEPES pH 7.5, 200 µM PLP, 30 °C - publication II, chapter 3.2). The differences in 
reaction velocities suggested that the transaminase rather than the AHAS-I-catalysed 
reaction would be rate limiting in a 2-step reaction cascade. Therefore, the cascade 
was performed under optimal reaction parameters for the reductive amination 
reaction as known from literature for the enzyme CV2025 (see chapter 1.5.5.3). 
Under analogous reaction conditions (100 mM HEPES pH 7.5, 200 µM PLP, 100 µM 
ThDP, 50 µM FAD, 5 mM MgSO4, 30 °C), the carboligase activity of AHAS-I was still 
>1.5 U mg-1purified enzyme, using 10 mM benzaldehyde and 10 mM pyruvate as 
substrates (publication II, chapter 3.2). 
 
2-step cascade combining of AHAS-I and CV2025 as purified enzyme: 
As mentioned in chapter 1.6.1, there are different options to perform 2-step reaction 
cascades. In a 2-pot 2-step reaction (scheme 4-6-A), the intermediate (R)-PAC was 
isolated and purified after the first reaction step by flash chromatography. Although 
high conversion was observed in the carboligation step (>95 %) as well as in the 
reductive amination step (~97 %), the isolation of the intermediate reduced the 
overall conversion to ~85 %. 
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In a 1-pot 2-step simultaneous cascade (scheme 4-6-B), both enzymes were added 
at the same time. Here, an isolation of the reaction intermediate was not necessary. 
However, the overall conversion towards (1R,2S)-norephedrine was with 7 % 
significantly lower. In this setup, not the targeted norephedrine but benzylamine was 
detected as the main product (>90 %). These results suggested that benzylamine is 
produced in a competitive side reaction (reductive amination of benzaldehyde) by the 
ω-transaminase CV2025. Further investigation pointed out (publication II, 
chapter 3.2) that the adverse product/by-product ratio is caused by a difference in 
reaction velocities for PAC (~0.06 U mg-1) and benzaldehyde (~1 U mg-1) of the 
ω-transaminase CV2025. 
 
 
    
 
cascade reaction parameter: 
 
  
Scheme 4-6:  Different reaction modes (A-C) for the 2-step cascades towards (1R,2S)-nor-
ephedrine combining the acetohydroxyacid synthase I and the ω-transaminases 
CV2025 with (S)-α-methylbenzylamine (MBA) as amine donor. 
2-pot 2-step cascade (A): Carboligation was performed in 100 mM HEPES (pH 7.5) with 100 µM ThDP, 50 µM FAD and 
5 mM MgSO4 at 30 °C in 10 mL reaction volume with stirrer mixing (100 rpm) for 12 h (t1). (R)-
PAC (ee>98 %) was isolated (extracted three times with ethyl acetate; dried over MgSO4; 
solvent evaporated under reduced pressure) and purified (flash chromatography with 
ethylacetate:petrol ether = 85:15). The yield of this step was 85 %. Reductive amination was 
performed in 100 mM HEPES (pH 7.5) and 200 µM PLP in a volume of 2 mL at 27 °C and 
200 rpm shaking in 2.5 mL glass vials for 16 h (t2).  
1-pot 2-step cascades (B, C): were performed in 100 mM HEPES (pH 7.5) with 200 µM PLP, 100 µM ThDP, 50 µM FAD and 
5 mM MgSO4 at 30 °C in 2 mL reaction volume in 2.5 mL closed glass vials. Reaction times for 
the sequential mode (B) was: t1 = 2 h, t2 = 12 h and for the simultaneous mode: t1 = 16 h. 
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By performing the 1-pot 2-step reaction as a sequential cascade (scheme 4-6-C), the 
by-product formation was overcome by adding the ω-transaminase after the 
carboligation step (conversion: >95 %), when benzaldehyde was already almost 
completely converted to PAC. As a result the benzylamine formation was reduced 
to <5 % and ~93 % of the benzaldehyde were finally converted to (1R,2S)-
norephedrine. In all cascade modes the product (1R,2S)-norephedrine was obtained 
in high optical purity of >99 % ee and >98 % de (scheme 4-6). 
 
 
2-step cascade combining AHAS-I and CV2025 lyophilised whole cells: 
Since the cascade was demonstrated successfully with purified lyophilised enzymes, 
the application of lyophilised whole cells (LWC) for both reaction steps was 
subsequently investigated (publication II, chapter 3.3). Whole cells offer the potential 
to reduce catalyst production costs by a factor of 10 compared to purified 
enzymes.[217] The specific activity of AHAS-I for the formation of (R)-PAC from 
benzaldehyde and pyruvate is ~1.5 U mg–1purified enzyme. 1 mg purified AHAS-I equals 
to 5 mg mL–1 lyophilised recombinant E. coli cells. In both cases a complete 
conversion of 10 mM benzaldehyde was reached within 1 h reaction time 
(publication III, chapter 3.3). A similar trend was observed for the reductive amination 
of (R)-PAC. Reactions with 1 mg mL–1 purified CV2025 showed an analogous 
conversion curve as reactions with 5 mg mL–1 lyophilised whole cells (publication III, 
chapter 3.3). Within 3 h a conversion of ~85 % (1R,2S)-norephedrine was reached 
with whole cells, corresponding to a space-time yield of ~10 g L-1 d-1. In general, this 
clearly demonstrates that whole cells can be a valuable alternative for a cost and 
time efficient production of (1R,2S)-norephedrine. 
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4.2.2 2-Step synthesis of nor(pseudo)ephedrines with alanine as amine 
donor 
In the previous chapter the enzymatic synthesis of (1R,2S)-norephedrine in two 
reaction steps from inexpensive achiral starting was demonstrated. Although the 
product was obtained with good conversion and high stereoselectivity (>99 % ee and 
>98 % de), the major drawback of this cascade setup was the necessity to separate 
the co-product and especially the residual amine donor from the desired product. 
Due to the structural similarity of (S)-α-methylbenzylamine and (1R,2S)-
norephedrine, a chromatographic separation with MeOH/CHCl3 = 1:1 was necessary. 
 
4.2.2.1 The challenge of alanine as an amine donor 
As was identified by the TTC-assay, other amine donors can be used for the 
reductive amination of PAC which might in general provide an easier downstream 
processing (chapter 4.1.2, table 4-2). In contrast to α-methylbenzylamine, which is 
known to be an amine donor with product favouring thermodynamics, other amine 
donors often show lower reaction equilibrium constants.[66, 68, 105] One example of a 
frequently used amine donor with benefits in terms of low product/substrate inhibition, 
but poor reaction thermodynamics is alanine. In order to make alanine as amine 
donor in ω-transaminase reactions applicable, several methods have been 
developed to shift the reaction equilibrium towards the product (pyruvate) side.[66, 67] 
The TTC-assay results showed that L-alanine is accepted by the enzyme CV2025 for 
the reductive amination of PAC (table 4-2; publication I). Conversions of ~20 % were 
observed with equimolar concentrations of both substrates (table 4-2; publication I). 
In contrast to this, only 5 % conversion was detected with purified CV2025 instead of 
crude cell extract (publication II, chapter 3.2). As known from literature, E. coli 
housekeeping proteins (e.g. alcohol dehydrogenase, lactate dehydrogenases, 
pyruvate dehydrogenases) can shift the reaction equilibrium in whole cells.[66]  
 
Thermodynamic equilibrium constant for the reductive amination of PAC with alanine: 
To investigate whether the reaction is limited by thermodynamics, the equilibrium 
constant for the reductive amination of (R)-PAC with L-alanine as an amine donor 
was determined according to the method of Tufvesson et al.[105] (scheme 4-7-A). A 
value of Keq = 2.3110-3 (scheme 4-7-A, publication II) clearly shows that the reaction 
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thermodynamic is on the substrate side of the reaction. As a consequence of the low 
equilibrium constant, a theoretical conversion of maximal ~5 % is possible with 
equimolar concentrations of PAC and alanine (scheme 4-7-B). A 5.000-fold excess of 
alanine would be required to achieve >90 % conversion (scheme 4-7-B). As 
summarised in chapter 1.4.3.5, chemical engineering, enzyme engineering and 
reaction engineering approaches are known to shift the reaction equilibrium towards 
the product side. Among these, enzyme-catalysed pyruvate removal is a frequently 
used method.[66, 82] Here, lactate dehydrogenases (LDH), pyruvate decarboxylases 
(PDC), acetolactate synthase (ALS), acetohydroxyacid synthase (AHAS) or amino 
acid dehydrogenases (AADH) can be added to remove the co-product pyruvate 
(chapter 1.4.3.5) and thus shift the reaction equilibrium to the product side. Although 
high conversions can be reached, the major drawback of this cascade setup is that at 
least one additional enzyme is needed (two in case of an additional cofactor 
regeneration step). Compared to reactions without an equilibrium shift, this increases 
the system complexity and moreover the process costs. 
 
 
 
 
 
             A: determination of the equilibrium constant Keq              B) maximal conversion without equilibrium shift 
             
Scheme 4-7:  Determination of the thermodynamic equilibrium for the reaction of (R)-PAC to 
(1R,2S)-norephedrine with alanine as an amine donor (A, left) and theoretical 
maximal conversion for this reaction without equilibrium shift (B, right). 
Reaction details and calculations can be found in the supporting information of 
publication II (chapter 3.2) 
 
++
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As described above, the 1-pot 2-step synthesis of (1R,2S)-norephedrine could be 
performed by the combination of an acetohydroxyacid synthase and an 
-transaminase. As known from literature, the AHAS-I from E. coli is not only able to 
catalyse the carboligation of (decarboxylated) pyruvate and benzaldehyde to PAC, 
but also the carboligation of two pyruvate molecules to acetolactate.[178, 179] If alanine 
is used as an amine donor in the reductive amination step, AHAS-I can catalyse the 
required reaction equilibrium shift for the transaminase step intrinsically as soon as 
pyruvate is produced. In the 1-pot 2-step cascade, the AHAS-I is already present in 
the reaction solution from the first reaction step. Thus, the equilibrium shift needed 
for the transaminase reaction in the second step of the cascade should be possible 
without addition of further enzymes, co-substrates or reagents.  
To test this hypothesis, the system complexity was reduced in a first approach and 
the AHAS-I coupled equilibrium shift was studied only for the reductive amination 
step. As a first proof of principle, the reductive amination of 10 mM (R)-PAC was 
performed with CV2025 and 30 mM L-alanine in presence of AHAS-I (both enzymes: 
0.5 mg mL-1 purified protein). Compared to a reaction without AHAS-I where only 5 % 
conversion could be achieved, the combination with AHAS-I increased the 
conversion to ~48 % (scheme 4-8), which clearly indicates a successful equilibrium 
shift (publication II, chapter 3.2). 
 
 
 
Scheme 4-8:  AHAS-I coupled equilibrium shift for the CV2025-catalysed reductive amination 
of (R)-PAC with alanine as amine donor. 
Reaction conditions: The reductive amination was performed with 10 mM (R)-PAC (ee 84 %) and 30 mM L-alanine 100 mM 
HEPES (pH 7.5) with 100 µM ThDP, 50 µM FAD and 5 mM MgSO4 in a volume of 2 mL in 2.5 mL 
closed glass vials. 0.5 mg mL-1 CV2025 was added as purified enzyme without (A) or with 0.5 mg mL-1 
AHAS-I (B). The reactions were incubated at 27 °C for 24 h. 
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4.2.2.2 Reaction parameter optimisation for AHAS-I coupled equilibrium shift 
of -transaminase reactions 
To further improve the conversion of the reductive amination step via AHAS-I 
coupled equilibrium shift (see chapter 4.2.2.1, scheme 4-8), the reaction parameters 
like enzyme concentrations and amine donor/PAC ratio (scheme 4-9) or pH and 
temperature (scheme 4-10) were optimised. 
Highest conversions for the reductive amination of (R)-PAC with alanine as amine 
donor and AHAS-I coupled equilibrium shift were achieved at pH 7.5, 25 °C with 
1 mg mL-1 CV2025, 0.5 mg mL-1 AHAS-I and a 5-fold excess of L-alanine relative to 
the hydroxy ketone. Under these optimised cascade conditions 80 % of (R)-PAC was 
converted to (1R,2S)-norephedrine (publication II, chapter 3.2).  
 
 
   
varied reaction parameter: AHAS-I concentration and PAC/alanine ratio 
 
Scheme 4-9:  Examples of the reaction parameter optimisation for the CV2025-catalysed 
reductive amination of (R)-PAC with AHAS-I coupled equilibrium shift (part 1). 
Reaction conditions:  constant parameters: 1 mg mL-1 CV2025, pH 7.5, 25 °C – varied parameter: AHAS-I concentration and 
PAC/alanine ratio. All reactions were performed in 100 mM HEPES containing 200 µM PLP, 50 µM 
FAD, 100 µM ThDP and 5 mM MgCl2 and incubated for 20 h at different temperatures in 2.5 mL glass 
vials. For statistical data analysis and interpolation (pink dots) the ‘kriging algorithm’ (see publication II, 
chapter 3.2) was used. 
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varied reaction parameter: pH and temperature 
 
Scheme 4-10:  Examples of the reaction parameter optimisation for the CV2025-catalysed 
reductive amination of (R)-PAC with AHAS-I coupled equilibrium shift (part 2). 
Reaction conditions:  constant parameters: 1 mg mL-1 CV2025, 0.5 mg mL-1 AHAS-I, 10 mM PAC, 50 mM L-alanine – varied 
parameters: pH and reaction temperature. All reactions were performed in 100 mM HEPES containing 
200 µM PLP, 50 µM FAD, 100 µM ThDP and 5 mM MgCl2 and incubated for 20 h at different 
temperatures in 2.5 mL glass vials. For statistical data analysis and interpolation (pink dots) the ‘kriging 
algorithm’ (see publication II, chapter 3.2) was used. 
 
 
 
 
4.2.2.3 1-Pot 2-step cascade for the synthesis of (1R,2S)-norephedrine under 
optimised reaction conditions with alanine as amine donor 
(strategy 1-A) 
With optimised reaction parameters for the reductive amination step (chapter 
4.2.2.2), the 1-pot 2-step cascade for the synthesis of (1R,2S)-norephedrine was 
performed in the sequential and the simultaneous cascade mode (publication II, 
chapter 3.2). In the simultaneous reaction mode, where AHAS-I and CV2025 were 
added at once, only 2 % of the initial benzaldehyde was converted to the 2-amino 
alcohol (scheme 4-11-A). Similar to the cascade with (S)-α-methylbenzylamine 
(chapter 4.2.1) the major product was benzylamine, which was caused by fast 
reductive amination of benzaldehyde in a competitive side reaction. As pointed out 
earlier (chapter 2.2), this problem could be overcome by performing the cascade in a 
1-pot 2-step sequential reaction mode (scheme 4-11-B), yielding an overall 
conversion of 78 % to the desired product (1R,2S)-norephedrine with a de >98 % and 
an ee >99 % (publication II, chapter 3.2).  
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cascade reaction parameter: 
  
Scheme 4-11:  1-Pot 2-step cascade for the synthesis of (1R,2S)-norephedrine with alanine as 
amine donor. The 1-pot 2-step cascade combining the AHAS-I with the (S)-selective 
-transaminases CV2025 can be run in different cascade modes (see chapter 1.6.1): 
simultaneously (A) or sequentially (B). Further reaction details can be found in 
publication II (chapter 3.2). 
 
 
4.2.2.4 1-Pot 2-step cascade for the synthesis of (1R,2R)-norpseudoephedrine 
under optimised reaction conditions with alanine as amine donor 
(strategy 1-B) 
In contrast to the 2-step synthesis of (1R,2S)-norephedrine, the 1-pot 2-step cascade 
for the production of (1R,2R)-norpseudoephedrine requires a highly (R)-selective 
-transaminase (scheme 4-5, strategy 1-B). Since all enzymes of the (R)-selective 
toolbox (supplied by Enzymicals AG as lyophilised crude cell extracts, see 
chapter 1.5.5.3) showed very high conversions for the reductive amination of PAC in 
the TTC-assay (chapter 4.1.4.1), all -transaminase were investigated for the 
application in the 2-step cascade. 
As a conclusion from the cascade results for the combination AHAS-I/CV2025 
(chapter 4.2.1 and 4.2.2.3), the most challenging but still in general most efficient 
cascade mode (see chapter 1.6.1) is the 1-pot 2-step simultaneous cascade. 
Therefore, the application of all (R)-selective -transaminases was investigated in 
this simultaneous cascade mode (scheme 4-12) using the reaction parameters 
previously optimised for the combination of AHAS-I and CV2025 (chapter 4.2.2.2). 
Under these conditions, all (R)-selective -transaminases showed a significant 
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higher conversion in the simultaneous cascade mode than CV2025. Such high 
conversions resulted from a significantly lower benzylamine by-product formation 
(scheme 4-12). Surprisingly, without further reaction optimisation, conversions >85 % 
were detected for the combinations of AHAS-I with the transaminases Pc-(R)TA or 
At-(R)TA. Although the cascade was performed in a simultaneous mode, less than 
10 % benzylamine was produced. To investigate this further, the initial rate activity for 
the reductive amination of PAC and benzaldehyde was measured independently for 
At-(R)TA. Compared to the initial reaction rates of CV2025, which was significantly 
higher for benzaldehyde compared to PAC), At-(R)TA showed an almost similar initial 
rate activity (~0.08-0.09 U mg-1) for both amine acceptors (see publication II, chapter 
3.2). These activity differences in combination with the high carboligase activity of 
AHAS-I (>1.5 U mg-1) enables an efficient simultaneous 1-pot 2-step cascade with 
minimised by-product formation. 
 
 
Scheme 4-12:  1-Pot 2-step simultaneous cascade for the synthesis of (1R,2R)-norpseudo-
ephedrine combining AHAS-I and seven (R)-selective ω-transaminases. 
Reaction conditions:  For the 1-pot 2-step reaction 10 mM benzaldehyde, 10 mM pyruvate and 50 mM D- or L-alanine in 
100 mM HEPES (pH 7.5 with 200 µM PLP, 50 µM FAD, 100 µM ThDP, 5 mM MgCl2) were added 
simultaneously to both enzymes (AHAS-I: 0.5 mg mL-1 and -TA 1 mg mL-1). Further reaction details 
can be found in publication II (chapter 3.2). The (S)-selective transaminase CV2025 was used as a 
control. 
 
Based on these promising results, At-(R)TA was tested in combination with AHAS-I in 
the 1-pot 2-step sequential cascade mode. As a result 96 % of the initially added 
benzaldehyde were converted to (1R,2R)-norpseudoephedrine. The product was 
obtained with an excellent stereoselectivity (>98 % de and >99 % ee, scheme 4-13). 
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Scheme 4-13:  1-Pot 2-step cascade for the synthesis of (1R,2R)-norpseudoephedrine with 
alanine as amine donor. The 1-pot 2-step cascade combining the AHAS-I with the 
(R)-selective At-(R)TA can be run in different cascade modes (see chapter 1.6.1): 
simultaneously (A) or sequentially (B). Further reaction details can be found in 
publication II (chapter 3.2). 
 
 
To increase the cascade efficiency further, the minimal amount of required enzyme 
for this 1-pot 2-step sequential cascade was determined. 0.5 mg mL-1 AHAS-I and 
0.4 mg mL-1 At-(R)TA were sufficient to reach 95 % conversion of 20 mM 
benzaldehyde, 20 mM pyruvate with 100 mM D-alanine within 13.5 h (scheme 4-12). 
Compared to the non-optimised data, this corresponds to a reduction in catalyst load 
of 50 % for AHAS-I and of 80 % for the At-(R)TA.  
 
   
Scheme 4-14:  Determination of minimal catalyst load for the 1-pot 2-step sequential cascade 
for the synthesis of (1R,2R)-norpseudoephedrine with of AHAS-I and At-(R)TA. 
Reaction parameter:  20 mM benzaldehyde, 20 mM pyruvate and 100 mM D-alanine in 100 mM HEPES (pH 7.5 with 200 µM 
PLP, 50 µM FAD, 100 µM ThDP, 5 mM MgCl2). In accordance to the initial reaction rates of AHAS-I 
(~1.5 U mg-1, see chapter 4.2.1), At-(R)TA was added in 90 min after AHAS-I without isolation of the 
reaction intermediate (R)-PAC. The complete reaction was analysed after another 12 h as an endpoint 
determination (pink dots). Further reaction details can be found in publication III (chapter 3.3). 
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However, due to the low substrate concentrations the space-time-yields were with 
5 g L–1 d–1 relatively low. To further increase the space-time-yield, the equimolar 
substrate concentration (benzaldehyde and pyruvate) wre increased to 25, 50, 75 
and 100 mM. Under the optimised catalyst/substrate ratios (per mM benzaldehyde: 
0.025 mg mL-1 AHAS-I, 0.02 mg mL-1 At-(R)TA, 2.5 mM D-alanine - scheme 4-15), 
more than 90 % conversion was detected even for substrate concentrations of up to 
100 mM. Interestingly, even emulsion systems (>50 mM benzaldehyde) did not 
significantly reduce the reaction performance. Thereby ~90 mM of the product 
(1R,2R)-norpseudoephedrine were obtained within 13.5 h, corresponding to a 5-fold 
increased space-time-yield of ~26 g L–1 d–1 (publication III, chapter 3.3). 
 
 
 
Scheme 4-15:  1-Pot 2-step sequential cascade for the synthesis of (1R,2R)-norpseudo-
ephedrine with high substrate concentrations. 
Reaction parameter: 1-Pot 2-step sequential cascade for the synthesis of (1R,2R)-NPE with 25, 50, 75 or 100 mM 
benzaldehyde (BA) and equimolar concentrations of pyruvate. In accordance to the optimisation date 
(scheme 4-14), per mM benzaldehyde 0.025 mg mL-1 AHAS-I were used and after 90 min reaction time 
0.02 mg mL-1 At-(R)TA and 2.5 mM D-alanine was added per mM initial benzaldehyde concentration. 
The solution was analysed after another 12 h reaction time. Reaction parameter: 100 mM HEPES pH 
7.5, 200 µM PLP, 50 µM FAD, 100 µM ThDP, 5 mM MgCl2, 25 °C. 
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4.2.2.5 1-Pot 2-step recycling cascade for the synthesis of (1R,2R)-norpseudo-
ephedrine and (1R,2S)-norephedrine with alanine as amine donor 
In the 1-pot 2-step cascade with alanine as amine donor we demonstrated that a co-
product removal (here: pyruvate) was possible without the addition of any further 
catalysts or reactants (chapter 4.2.2.3 and 4.2.2.4). However, acetolactate is 
accumulated as waste in the reaction mixture, which reduced the atom efficiency of 
the process. 
To further increase the atom efficiency, a co-product recycling rather than a simple 
removal was investigated. Pyruvate, which accumulates in the second reaction step, 
is a substrate of the carboligation reaction in the first carboligation step. In general, 
there are two possible ways of pyruvate recycling for this cascade. One is a direct 
consumption of pyruvate by the AHAS-I, the other is a recycling via AHAS-I catalysed 
acetolactate cleavage. More precisely, in the acetolactate cleavage reaction one 
pyruvate molecule is released from the active site while the second one remains 
bound to the ThDP-cofactor as hydroxy-ethyl group and is thus directly available for 
the carboligation with benzaldehyde to PAC (see scheme 4-16). 
 
cascade reaction parameter: 
 
Scheme 4-16:  1-Pot 2-step recycling cascade for the synthesis of (1R,2S)-norephedrine and 
(1R,2R)-norpseudoephedrine with alanine as amine donor. 
The cascade combines AHAS-I in the first step and either an (S)-selective (CV2025) 
or (R)-selective (At-(R)TA) -transaminases in the second step. Pyruvate, generated 
in the reductive amination step as a co-product, is used as substrate in the first 
reaction step and is recycled directly or via reversible acetolactate formation. The 1-
pot 2-step cascade can be run in different cascade modes (see chapter 1.6.1): 
simultaneously (A) or sequentially (B). Further details can be found in publication II 
(chapter 3.2). 
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Also this novel recycling cascade could be performed in two different cascade 
modes. In the simultaneous mode (scheme 4-16-A) all catalysts and reactants were 
added at once, while in the sequential cascade mode (scheme 4-16-B) the 
transaminase was added after the carboligation step. Addition of additional 
benzaldehyde (but no further pyruvate) started the carboligation again. It was 
expected that with an excess of benzaldehyde (20 mM) relative to the initial pyruvate 
concentration (10 mM) conversions >10 mM could only be achieved in both cascade 
modes, if the pyruvate (generated as the co-product in the reductive amination step) 
is successfully recycled. 
In line with the experimental data from the 1-pot 2-step cascade described in chapter 
4.2.2.3, the combination AHAS-I/CV2025 in the simultaneous recycling cascade 
mode resulted in a low overall conversion of 3 % (scheme 4-16). As expected, most 
of the benzaldehyde (>95 %) was converted to benzylamine. In the sequential 
recycling cascade mode the by-product formation could significantly be reduced and 
64 % (=12.8 mM) of the benzaldehyde was converted to (1R,2S)-norephedrine with 
high optical purity of >99 % ee and >98 % de.  
By contrast, the combination AHAS-I/At-(R)TA resulted in both cascade modes in 
significantly higher conversions compared to the cascade with CV2025. As discussed 
previously (chapter 4.2.2.4) this is a consequence of the different reaction rates for 
reductive amination of benzaldehyde and pyruvate, which is equally fast for both 
substrates with At-(R)TA but much faster for benzaldehyde in case of CV2025. As a 
result, in the 1-pot 2-step simultaneous recycling cascade an overall conversion of 
71 % (=14.2 mM) was obtained. However, the highest concentration was achieved in 
the sequential mode. Here 86 % (=17.2 mM) of the benzaldehyde was converted to 
(1R,2R)-norpseudoephedrine. The product was obtained as well in high optical purity 
of >99 % ee and >98 % de.  
 
Compared to the already efficient method of co-product removal in the 1-pot 2-step 
sequential cascade, the ‘recycling cascade’ might help to increase the reaction 
efficiency in terms of atom economy and sustainability further. In the presented 
setup, the amount of pyruvate required for the 2-step synthesis could be reduced by 
50 % compared to the simple 2-step sequential cascade (chapter 4.2.2.3 and 
4.2.2.4). From the process point of view, the most valuable approach would be the 
simultaneous recycling cascade mode. However, highly selective catalysts with a low 
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by-product formation rate in all cascade steps are required. If such an enzyme is not 
available, the sequential (recycling) cascade mode offers a valuable alternative to 
reduce the amount of by-products. In general, this recycling approach is not limited to 
applications with -transaminases. The removal of co-products with a catalyst of 
another reaction step can be applied for any multi-reaction cascade where a smart 
combination of enzymes (or even chemical catalysts) is possible. 
 
 
4.2.3 2-Step synthesis of (1S,2S)-norpseudoephedrine and (1S,2R)-
norephedrine (strategy 1-C and 1-D) 
For the synthesis of the two missing N(P)E stereoisomers, (1S,2S)-norpseudo-
ephedrine and (1S,2R)-norephedrine, a highly (S)-selective lyase is required for the 
first reaction step (see scheme 4-5; strategy 1-C and 1-D). However, such a lyase is 
currently not available. The ApPDC-E469G from Acetobacter pasteurianus is the 
enzyme with the highest selectivity for the synthesis of (S)-PAC.[175] Here, a whole 
cell biotransformation (40 mM benzaldehyde, 400 mM pyruvate, 2.5 mM MgSO4, 
100 mM potassium phosphate, 100 µM ThDP) resulted in formation of (S)-PAC with 
a good isolated yield of 95 % but an optical purity of only ~70 % ee.[184] Still, since it 
is the best variant, this enzyme was studied for the synthesis of (1S,2S)-norpseudo-
ephedrine and (1S,2R)-norephedrine by combining it with either the (R)-selective At-
(R)TA or the (S)-selective CV2025.  
 
Scheme 4-17:  2-Pot 2-step synthesis of (1S,2S)-norpseudoephedrine and (1S,2R)-nor-
ephedrine combining an (S)-selective lyase (ApPDC-E469G) in the first step with 
either an (S)-selective (CV2025) or (R)-selective (At-(R)TA) -transaminase in the 
second step. Further reaction details can be found in publication III (chapter 3.3). 
Carboligation: 40 mM benzaldehyde, 400 mM pyruvate, 2.5 mM MgSO4, 100 mM potassium phosphate, 
100 µM ThDP. Incubated for 48 h in glass vials with 100 rpm magnetic stirring. The product was isolated 
by extraction (3x with ethyl acetate), dried over MgSO4 and purified via flash chromatography (petrol 
ether : ethyl acetate = 90 : 10).[184] 
Reductive amination: 10 mM (S)-PAC (ee 70 %) were incubated with 10 mM (R)- or (S)-α-methylbenzylamine in 100 mM 
HEPES (pH 7.5) with 200 µM PLP and 1 mg mL-1 CV2025 purified enzyme or 1 mg mL-1 At-(R)TA in 
closed glass vials for 24 h. 
Chapter 4 
 
- 126 - 
 Discussion
Since in this reaction a high pyruvate concentration (400 mM) was used for the 
carboligation step, the cascade was not performed in a 1-pot mode. Here, a by-
product, caused in the reaction of pyruvate to alanine, was avoided by a 2-pot 2-step 
mode (see chapter 1.6.1). As a consequence, the advantage of an internal co-
product removal is not possible. Thus, methylbenzylamine and was used as an 
amine donor instead of alanine. The reductive amination of isolated (S)-PAC with 
(R)- or (S)-α-methylbenzylamine, respectively, resulted in both cascades in the 
desired products (1S,2R)-norephedrine (with At-(R)TA) and (1S,2S)-
norpseudoephedrine (with CV2025) with conversions >95 %. Due to the high 
stereoselectivity of both transaminases both products were obtained with high ee 
(>99 %). However, due to the initially low optical purity of the (S)-PAC the resulting 
diastereomeric excess was only ~70 %. It can be concluded that (S)-PAC is accepted 
by the transaminases, but higher purity of this intermediate is needed in order to 
obtain the amino alcohols in high optical purities.  
As a consequence, a protocol for the synthesis of (S)-PAC in high enantiomeric 
excess will be target of future investigations. Here, further enzyme engineering of the 
Acetobacter pasteurianus PDC may improve stereoselectivity. If this is not suitable, 
chiral enrichment technologies like chiral chromatographic methods or kinetic 
resolution can be used. As a proof of principle, the so called “chiral polishing” of 
(S)-PAC (scheme 4-18) with the (R)-selective benzaldehyde lyase (BAL) from 
Pseudomonas fluorescens was described in the thesis of A.G. Baraibar[184] and in the 
invention disclosure I [214]. Here, (S)-PAC could be enriched to an ee >97 %. 
However, this “chiral polishing” reaction was only performed on analytical scale. 
 
 
Scheme 4-18:  The concept for “chiral polishing” of (S)-PAC to gain high optical purities. 
(S)-PAC with a low optical purity generated by catalysis of a lyase (e.g. by ApPDC-
E469G) can be converted to highly pure (S)-PAC with an ee >97 % by the highly (R)-
selective PfBAL.[184, 214] 
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4.3 Combining ω-transaminases and alcohol dehydrogenases for 
the synthesis of nor(pseudo)ephedrines in two steps 
(strategy 2) 
To overcome the required chiral purification effort in the syntheses of (1S,2S)-nor-
pseudoephedrine (NPE) and (1S,2R)-norephedrine (NE), an alternative synthetic 
strategy was investigated (see chapter 1.5.4). Starting from 1-phenylpropane-1,2-
dione (PPDO), the combination of a highly selective biotransformation with an 
-transaminases (TA, chapter 1.5.5.3) in the first reaction step and alcohol 
dehydrogenases (ADH, chapter 1.5.5.2) in the second step was expected to give 
access to all nor(pseudo)ephedrine isomers. Combination of the (S)-selective 
-transaminase CV2025 with the (S)-selective LbADH (from Lactobacillus brevis) 
should result in (1S,2S)-NPE (scheme 4-19; strategy 2-A), while the combination with 
the (R)-selective RADH (from Ralstonia sp.) would give access to (1R,2S)-NE 
(scheme 4-19; strategy 2-B). Further, the (R)-selective At-(R)TA in combination with 
the same set of alcohol dehydrogenases would lead to (1S,2R)-NE and (1R,2R)-NPE 
(scheme 4-19; strategy 2-C and 2-D). 
 
 
Scheme 4-19:  Overview of the 1-pot 2-step reaction for the synthesis all nor(pseudo)-
ephedrines combining an (S)-selective (CV2025) or an (R)-selective (At-(R)TA) 
-transaminase in the first step with either an (R)-selective (RADH) or (S)-
selective (LbADH) alcohol dehydrogenase (ADH) in the second step. 
Theoretically all isomers are accessible via four different routes (strategy 2 A-D). 
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Diol by-product formation in the 1-pot 2-step sequential cascade (strategy 2-A): 
Based on the optimised reaction parameters for the transaminase step for the 
enzyme CV2025 (1.5 fold excess of (S)-α-methylbenzylamine relative to PPDO), it 
was tested whether the subsequent ADH reaction could be performed in the same 
reaction vessel without isolation of the reaction intermediate 1-amino-1-phenyl-
propane-2-one (APPO). For both ADH reactions, the cofactor NADPH was 
regenerated by using the formate dehydrogenase (FDH) from Pseudomonas sp. and 
sodium formate as co-substrate.[185] 
The combination of the (S)-selective CV2025 with LbADH was expected to give 
(1S,2S)-norpseudoephedrine (scheme 4-19; strategy 2-A). The reaction was 
performed with isolated enzymes in both steps as a 1-pot 2-step sequential cascade. 
For the first reaction step (reductive amination of 10 mM PPDO) an initial reaction 
rate of ~0.008 U mg-1 was measured (detail information see publication III in chapter 
3.3). Compared to the reductive amination of PAC in the nor(pseudo)ephedrine 
synthesis strategy 1-A (~0.06 U mg-1; see chapter 4.2), the reaction rate is about one 
order of magnitude lower. However, still a complete conversion of 10 mM PPDO was 
reached within 48 h. In the second reaction step, the amino alcohol product 
accumulated in the beginning of the ADH reaction (over ~4 h reaction time to ~40 % 
product), but within the next 2 h product formation stopped completely. Further HPLC 
investigations indicated that 1-phenylpropane-1,2-diol was formed as a by-product. 
However, the diol can only be formed, in case of a reversible -transaminase 
PPDO<=>APPO reductive amination reaction (publication III, chapter 3.3). 
 
Suppression of the diol by-product formation: 
In order to suppress this undesired by-product formation, an inactivation of the 
-transaminase by a pH shift or by a removal of the biocatalyst (ultrafiltration) was 
investigated after the reductive amination step (publication III, chapter 3.3). For these 
cascade reactions purified enzymes were used in order to avoid further side 
reactions by further enzymes in E. coli crude cell extracts. 
Using the pH shift inactivation of the enzyme CV2025 before the LbADH was added, 
an overall conversion of 80 % was reached in 52 h reaction time. The product, 
(1S,2S)-NPE, was obtained in excellent optical purity of >99 % de and >98 % ee 
(table 4-4, entry #4) and did not degrade in the course of the reaction. Compared to 
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the pH shift method, a removal of the CV2025 by ultrafiltration before LbADH addition 
resulted in a slightly lower conversion of 57 % in 60 h (table 4-4, entry #2). 
The same trend was found for the combination of CV2025 with RADH (scheme 4-19; 
strategy 2-B). Using the pH shift method (table 4-4, entry #5), 82 % of the substrate 
PPDO was converted in the 1-pot 2-step sequential cascade to (1R,2S)-NE, again 
with high optical purity (>99 % de, >97 % ee). Compared to this, in the ultrafiltration 
method a slightly lower optical purity (>99 % de, >97 % ee) and a significantly lower 
conversion (57 % compared to 80 %) was measured. This difference in conversion 
and ee was not further investigated, since the easier and less expensive pH shift 
method resulted in higher values than the ultrafiltration.  
 
 
Table 4-4: Reaction overview for the synthesis strategy: “transaminase-ADH” 
 TA reactiona ADH reactionc overall conversion 
&  
total reaction 
timed 
product ratio [in %] and  
optical purity of major isomer (bold) 
 
Entry catalyst type terminationb catalyst type (1S,2S)-NPE 
(1R,2R)-
NPE 
(1S,2R)- 
NE 
(1R,2S)- 
NE 
optical purity 
ee de or dr 
#1 CV2025 purif. - LbADH purif.     0 % 48 h - - - - - - 
#2 CV2025 purif. filtration LbADH purif.   57 % 60 h 99.3 0.7 - - >98 % de >99 %#3 filtration RADH purif.   55 % 60 h - 2.4 - 97.6 >99 % de ~95 %
#4 CV2025 purif. pH shift LbADH purif.   80 % 52 h 99.4 0.6 - - >98 % de >99 %#5 pH shift RADH purif.   82 % 40 h - 1.5 - 98.5 >99 % de 97 % 
#6 At-(R)TA CCE pH shift LbADH purif.   40 % 36 h 79.9 - 20.1 - >99 % de ~60 %#7 pH shift RADH purif. >95 %   8 h - 77.4 - 22.6 >99 % de ~55 %
#8 CV2025 LWC pH shift LbADH LWC   62 % 36 h 92.0 3.0 5.0 - ~92 % de ~90 %#9 pH shift RADH LWC   67 % 27 h 2.1 17.6 - 80.3 >99 % dr ~8:2 
#10 At-(R)TA CCE pH shift LbADH LWC   77 % 30 h 77.3 2.0 20.7 - ~95 % de ~80 %#11 pH shift RADH LWC   93 % 11 h - 75.2 0.9 23.9 >99 % dr ~7.5:2.5
 TA: transaminase, ADH: alcohol dehydrogenase, purif.: purified, CCE: crude cell extract, LWC: lyophilised whole cells, NE: 
norephedrine, NPE: norpseudoephedrine - time dependent reaction curves and reaction analytics can be found in the Supp. 
Information of publication III (chapter 3.3). 
a reaction conditions for reductive amination was carried out as indicated with purified enzyme (1 mgprotein mL-1), CCE 
(1 mgprotein mL-1) or LWC (10 mgLWC mL-1) of the respective transaminases (At-(R)TA or CV2025) in 100 mM HEPES (pH 7.5), 
200 µM PLP, with ~10 mM 1,2-PPDO (see Supp. Information) and 15 mM (R)- or respectively (S)-α-MBA at 27 °C. As 
indicated (by joined columns in the TA step), the reaction solutions were spit for the subsequent reductive hydrogenation step. 
b reactions were terminated either by ultrafiltration (membrane cut-off: 10 kDa), pH shift (titrated with 20 % (v/v) HCl to pH 2, 
then re-titrated with 10 M NaOH to pH 7.5) or not terminated. 
c reaction conditions for reductive hydrogenation: 0.5 mM NADP+, 150 mM sodium formate, 10 µL mL-1 FDH. Either purified 
enzyme (1 mgprotein mL-1), or lyophilised whole cells (10 mgLWC/mL) of the respective alcohol dehydrogenases (LbADH or 
RADH) were added to the corresponding solution and incubated at 27 °C. 
d overall conversion (sum of N(P)E related to the initial substrate concentration) and the total reaction time is given for the 
complete 2-step reaction.  
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Comparison of purified enzymes, crude cell extracts and lyophilised whole cells: 
The results of the 1-pot 2-step cascade for the synthesis of N(P)E with the 
combination of lyases and -transaminases (chapter 4.2) suggested that lyophilised 
whole cells might be used in this cascade setup as well. Therefore, we compared the 
application of purified enzymes with lyophilised whole cells (LWC) in both cascade 
steps. As an exception, the At-(R)TA was only available as crude cell extract, which 
has to be considered for reactions with this enzyme. All cascades were performed as 
1-pot 2-step sequential reactions with pH shift inactivation of the transaminase before 
the ADH was added. 
 
With lyophilised whole cells, the combination CV2025/LbADH (scheme 4-19; strategy 
2-A) gave (1S,2S)-NPE (ee >89 %, de 87 %) (table 4-4, entry #8). Under analogous 
reaction conditions, reactions with purified enzymes led to significant higher optical 
purities than reactions with lyophilised whole cells. According to these data the 2-step 
cascade with lyophilised whole cells of CV2025 and RADH (strategy 2-B) resulted in 
the formation of (1S,2R)-NE with an optical purity of >99 % ee but a diastereomeric 
ratio (dr) of ~8:2 (table 4-4, entry #5). A possible reason might be a background 
reactions mediated by E. coli cellular enzymes or the instability of the APPO 
intermediate (e.g. amine-imine tautomerisation). Both could decrease the optical 
purity of the N(P)E products although the cascade enzymes (ADH and 
-transaminase) are highly selective. 
In contrast to the CV2025, the At-(R)TA was only available as crude cell extract (see 
chapter 1.5.5.3). In combination with the RADH (strategy 2-D) as purified enzyme or 
as LWC conversions >90 % were detected (table 4-4, entry #7 and #11). Compared 
to the reactions with CV2025, the diastereomeric excess of the product (1R,2R)-NPE 
was with ~55 % de rather low even when purified ADH was used for the second 
reaction step (table 4-4, entry #7). Moreover, the cascade with At-(R)TA and LbADH 
(strategy 2-C) did not produce (1S,2R)-NE, but (1S,2S)-NPE as the major isomer. If 
LbADH was used as lyophilised whole cells, the undesired product (1S,2R)-NE had 
an optical purity of >95 % ee, >80 % de (table 4-4, entry #10), while application of 
LbADH as purified enzyme resulted in >92 % ee and >90 % de for (1S,2S)-NPE 
(table 4-4, entry #6). As mentioned above, an isomerisation of APPO could result in a 
decrease of the diastereomeric excess although the At-(R)TA is highly selective for 
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this compound. However, we were not able to measure the ee of the intermediate 
APPO to investigate the reason for the reduced optical purity obtained with crude cell 
extracts or whole cells. In case the synthesis of (1R,2R)-NPE and/or (1S,2R)-NE in 
this 2-step strategy is of interest in the future, the application of purified enzymes in 
both reaction steps is currently the method of choice to achieve high optical purities 
as demonstrated for the combination CV2025/LbADH or CV2025/RADH. 
 
 
Alternative 2-step cascade combining -transaminases and alcohol dehydrogenases 
for the synthesis of (1S,2S)-norpseudoephedrine: 
(1S,2S)-norpseudoephedrine is a compound with challenging synthetic strategy and 
is e.g. sold as a natural isolate from the plant khat. Since resources are limited, effort 
to develop respective synthesis strategies of this pharmaceutical is worthwhile. As 
mentioned above, a highly (S)-selective lyase for the synthesis of (S)-PAC as an 
intermediate is currently not available (see chapter 4.2.3). Therefore, an alternative 
novel synthesis strategy combing a -transaminases with an alcohol dehydrogenase 
was developed. A 2-step strategy combining the (S)-selective CV2025 with the 
(S)-selective LbADH results in the formation of (1S,2S)-NPE with excellent optical 
purity (ee >98 %, de >99 %) when purified enzymes were used. Although the space-
time-yields are still relatively low (~0.5 g L-1 d-1), this cascade can be performed in 
one reaction pot without isolation of the intermediate product, if the transaminase is 
inactivated via a pH shift prior to addition of the LbADH. According to our results, 
lyophilised whole cells should not be used in this process since the optical purities 
were significantly higher with purified proteins in both reaction steps. Beside (1S,2S)-
norpseudoephedrine, (1R,2S)-norephedrine could also be synthesised using this 
strategy in high optical purity of ee >97 % and a de >99 %.  
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5 Conclusion and future perspectives 
Chiral primary vicinal amino alcohols are valuable compounds for the pharmaceutical 
industry and find as well various applications e.g. as synthons or chiral ligands in 
organic chemistry. These chiral compounds are hardly accessible with classical 
chemical synthesis strategies. In this thesis, the general access to such compounds 
in only two reaction steps and with high stereoselectivities was demonstrated. The 
biocatalytic cascade reaction, combining ThDP-dependent enzymes in the first 
reaction step followed by subsequent reductive amination catalysed by 
-transaminases in the second step, offers great potential for the production of 
vicinal amino alcohols. 
The synthesis of nor(pseudo)ephedrines was investigated in more detail. It was 
possible to perform the reaction in one reaction vessel without isolation of the 
respective reaction intermediate. One pot reactions in general lower process costs by 
reducing downstream processing effort. For the 1-pot 2-step cascade towards 
(1R,2S)-norephedrine and (1R,2R)-norpseudoephedrine in the sequential mode, high 
conversion values and excellent stereoselectivities were obtained. The simultaneous 
cascade, where both enzymes are active at the same time, would be the most 
process-efficient approach for cascades reactions, which is especially true in terms of 
reaction times and simplicity. However, the simultaneous strategy is as well the most 
challenging one since highly selective catalysts in all cascade steps are required to 
avoid the formation of undesired by-products. In our 2-step cascade we observed an 
undesired benzylamine formation, resulting from a reductive amination of 
benzaldehyde by the -transaminases. The by-product/product ratio could 
successfully be reduced by application of -transaminases with decreased affinity 
towards benzaldehyde relative to the 2-hydroxy ketone.  
A further increase of transaminase affinity for mixed aromatic-aliphatic 2-hydroxy 
ketones relative to aromatic aldehydes by structure- and mechanism-guided enzyme 
engineering would be a promising project for the future. However, the sequential 
recycling cascade mode offers a valuable alternative to the simultaneous cascade 
mode. Here as well, high efficiency and sustainability by novel process designs are 
feasible. Reactions in preparative scales as well as efficient downstream processing 
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protocols must be developed to demonstrate the benefit of the 2-step cascade in 
larger scales. Here, analyses of process costs and sustainability would be useful to 
evaluate the different strategies and process designs, which were studied in this 
thesis for larger scale applications. To decrease overall process costs, it could 
already be demonstrated that whole cell biocatalysis can be used in some cascades 
as an alternative to purified enzymes or crude cell extracts. Furthermore, the 
‘recycling cascade’ offers the potential to increase the atom economy by reducing 
waste production. To perform this cascade type even more efficiently, highly 
selective biocatalysts are required to avoid by-product formation as far as possible. 
As an alternative to these approaches, the 2-step synthesis of amino alcohols 
combing -transaminases and alcohol dehydrogenases was developed to 
complement the amino alcohol platform. By using purified enzymes in both reaction 
steps, (1S,2S)-norpseudoephedrine was produced for the first time in high optical 
purity (>98 % and ee >99 %) by a 2-step cascade. In addition, (1R,2S)-norephedrine 
can be obtained with similar high purities (table 5-1). 
 
 
Table 5-1: Optical purity of nor(pseudo)ephedrines obtained via the two different 2-step 
synthesis strategies developed in this thesis 
 
 
 
 
  
 (1R,2S)-nor 
ephedrine 
 
(1R,2R)-nor 
pseudoephedrine
(1S,2S)-nor 
pseudoephedrine 
(1S,2R)-nor 
ephedrine 
Strategy 1:     combining ThDP-dependent enzymes and -transaminases 
strategy 1-A 1-B 1-C 1-D 
enzyme 
combination 
AHAS-I 
with CV2025 
AHAS-I 
with At-(R)TA 
ApPDC-E469G 
with CV2025 
ApPDC-E469G 
with At-(R)TA 
optical purity de >98 %, ee >99 % 
de >98 %, 
ee >99 % 
de >98 %, 
ee >70 % 
de >98 %, 
ee >70 % 
space-time-
yield 2.1 g L
–1 d–1 26 g L–1 d–1 2-pot reaction 2-pot reaction 
Strategy 2:     combining -transaminases and dehydrogenases 
strategy 2-B 2-D 2-A 2-C 
enzyme 
combination 
CV2025 
with RADH 
At-(R)-TA 
with RADH 
CV2025 
with LbADH 
CV2025 
with LbADH 
optical purity de >97 %, ee >99 % 
de >55 %, 
ee >99 % 
de >99 %, 
ee >98 % 
only as minor 
isomer 
space-time-
yield 0.75 g L
-1 d-1 4.3 g L-1 d-1 ~0.5 g L-1 d-1 - 
(R)
(S)
NH2
OH
(S)
(R)
NH2
OH
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For future perspectives, the application of these cascade concepts to other valuable 
amino alcohols will be of interest. As long-term goal, a platform of various substituted 
amino alcohols to otherwise hardly accessible chiral compounds can be generated. 
Two independent factors limit the access to a broad product platform using ThDP-
dependent enzymes and -transaminases strategy.  
On the one hand, the substrate scope of -transaminases is still restricted by 
residues fitting into the “small pocket” of the active site. The number of examples in 
literature of accepted substrates with residues larger than ethyl groups is still rare. 
Variants generated by directed evolution or rational design can be screened with the 
developed TTC-based screening assay. On the one hand, highly (S)-selective ThDP-
dependent enzymes will be required for the synthesis of (S)-PAC and derivatives 
thereof. Here, on-going enzyme engineering might help to complement the already 
existing enzyme toolbox. Another method would be the chiral enrichment of (S)-PAC 
(“chiral polishing”), which has already been demonstrated as a proof-of-concept. 
Using an (R)-selective lyase, which cleaves (R)-PAC into benzaldehyde and 
acetaldehyde, the optical purity of (S)-PAC could be increased to an ee ~97 %. The 
implementation of this approach at preparative scale will be a target for future 
research. 
 
In general, the amino alcohol platform itself offers a great potential as synthons for 
subsequent chemical or enzymatic steps, such as imine-formation, ether- or 
esterification and addition or elimination reactions. 
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Appendix 
 
I.)  Syntheses of reference substances 
 
The syntheses of (1R,2R)-1-amino-1-phenylpropane-2-ol (APP) was performed in 
two reaction steps according to the literature. In the first reaction step, Sharpless 
asymmetric aminohydroxylation[1], (4R,5R)-5-methyl-4-phenyloxazolidin-2-one is 
synthesised. The subsequent oxazolidinone hydrolysis[2] results in the formation of 
(1R,2R)-APP with an ee of ~80 %. 
 
 
I.a) Sharpless asymmetric aminohydroxylation[1] 
 
 
 
 
NaOH (26 mmol, 1045 mg) were dissolved in 47 mL distilled water in a 250 mL 
round-bottom flask. Potassium-osmate-(VI)-oxide-hydrate (0.2 mmol 72.0 mg) was 
solved in 2 mL of the 0.5 M NaOH solution. 1-propanol (23.4 mL), urethane 
(26 mmol, 2.40 g) and 1,3-dichloro-5,5-dimethylhydantoin (13 mmol, 2.61 g) were 
added to the remaining NaOH solution. (E)-prop-1-en-1-ylbenzene (8.45 mmol, 998.6 
mg) and DHQD2(PHAL) (0.2 mmol, 152 mg) was taken up in 1-propanol (7 mL). The 
solution was added to the 0.5 M NaOH solution and then potassium osmate solution 
added. The solution was stirred for 4 hours at room temperature and then NaOH (26 
mmol, 1045 mg) was added. After 30 min of stirring, 25 mL H2O was added. The 
solution was extracted three times with ethyl acetate (50 mL). The organic layers 
were combined and dried over magnesium sulphate. The crude product was purified 
via chromatography (silica, 70 : 30, cyclohexane : ethyl acetate) to separate the 
regioisomers. (4R,5R)-5-methyl-4-phenyloxazolidin-2-one was obtained in a yield of 
53.4 % (4.52 mmol, 803 mg). 
 
 
(4R,5R)-5-methyl-4-phenyloxazolidin-2-one:  
1H-NMR (600 MHz, CDCl3): 1.50 (d, 3J1,2 = 5.7 Hz, 3 H, 1-H), 4.44 (m, 2 H, 2-H, 3-H), 
5.54 (s, 1 H, N-H), 7.24-7.45 (m, 5 H, arom.-H). The NMR data are in accordance to 
the literature data.[1] 
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I.b) Oxazolidinone hydrolysis[2] 
 
 
 
(4R,5R)-5-methyl-4-phenyloxazolidin-2-one (2.1 mmol, 365 mg) of the Sharpless 
asymmetric aminohydroxylation product was dissolved in 36 mL ethanol and 15 mL 
distilled water. Lithium hydroxide (61.8 mmol, 1.48 g) was added. The reaction was 
heated up to 90 °C and heated under reflux for 12 h. The organic solvent was 
evaporated under reduced pressure and then three times extracted with 30 mL ethyl 
acetate. The organic layers were combined, dried over magnesium sulphate and then 
concentrated under reduced pressure. The product was purified via chromatography 
(silica, 50 : 50 = methanol : chloroform). (1R,2R)-1-amino-1-phenylpropane-2-ol was 
obtained in a yield of 93 % (1.95 mmol, 295 mg). 
 
(1R,2R)-1-amino-1-phenylpropane-2-ol: 
1H-NMR (600 MHz, CDCl3): 1.04 (d, 3J1,2 = 6.0 Hz, 3 H, 1-H), 2.22 (brs, 3 H, NH2, 
OH), 3.55 (d, 3J3,2 = 7.9 Hz, 3-H), 3.75 (dq, 3J2,1 = 6.0 Hz, 3J2,3 = 7.9 Hz, 2-H), 7.25-
7.36 (m, 5 H, arom.-H). Spectroscopic data are in agreement with those published 
previously.[2] The optical purity was determined by chiral HPLC: ee = 79.3 % (Daicel 
CROWNPAK® CR(+) Analytical Column, eluent: H2O/H3PO4 pH 2, 0.4 mL min-1. 
(1R,2R)-APP: 20.8 min, (1S,2S)-APP: 19.5 min)  
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the one-pot preparation of chiral oxazolidin-2-ones. Org. Lett., 2000, 2, 2821-2824. 
2. S. J. Katz and S. C. Bergmeier, Convenient methods for the hydrolysis of oxazolidinones to 
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II.)  Cloning strategy, gene- and protein sequences of unpublished 
enzymes 
 
II.a) ω-transaminase Sery1824 
Cloning strategy  
The coding region of the transaminases Sery1824 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103]  
 
 
Gene sequence: 
ATGTCGGCATCGGCCAGTCCGGACACGACCAGCACCCGGCTGTGGCACCCGTTCGCGAACATGGCGGACGTGAAGAACCAGGCCTTCCTGGTGG
ACCGCGCCGAGGGGGTGTGGGTCTACGACCAGGACGGGCGGCAGTACCTGGACGCCACCGCGAGCCTCTGGTACGTCAACATCGGACACGGCAG
GCGCGAGATCGCCGACGCCGTCGCCGCCCAGATGAGCAGGCTCGACGCGTTCAACGTCTTCAACGACTACACCAACCGGCCCGCCGAGGAGCTG
GCCGCCCGCCTGGCCGCGCTGGCGCCGATGGACGACGCGCGGGTGTTCTTCACCTCCGGCGGCGCCGACTCCATCGAGACCGCCGCGAAGCTGG
CCCGGTTGTACTGGGTCAACCGCGGGCAGCCGCAGCGCACCCACCTGCTCAGCCGCGGGCAGGCCTACCACGGCACCCACGGCGTGGGCACGAG
CATCGCGGGCATCCAGGCCAACCGGGACGGCTTCGGCGAGATGATCGCCGACACCACGCGGGTCTCCAACGAGGACCCCGAGGACCTGCGGGAC
GCGATCGAGCGGCTCGGCGCCGACCGGGTCGCCGCCTTCTTCGCCGAACCGGTGATCGGCGCGGGCGGGCTCATCCCGCCCAAGCCGGGATACC
TGGAGGCGGTCGCCAAGATCTGCCGCGAGTACGACGTGCTGTTCGTGGCCGACGAGGTCATCTGCGGTTTCGGCCGCCTCGGGCACTGGTTCGG
CTCGCAGCGCTTCGACCTGCGCCCGGACCTGATCACCTTCGCCAAGGGCGTCACCAGCGGCTACCTCCCACTCGGCGGGGTCATCGCGGCGGGC
TCGGTCGCCGAGCCGTTCTGGACCGACGGCGGCAGGCCGTTCCGGCACGGCCCCACCTACTCCGGGCACCCGACGGTGGCCGCCGCGGCGCTGG
CGAACCTCGACATCCTGGAACGGGAGGACCTGCTGGGCCGCTCCCGCGAGCTTGAGCAACCGCTGTTCGACGTGCTGCGGTCGCTCACCGACCA
CCCCGCCGTCAGCGAGGCCCGCGGCGGTGTGGGCCTGCTGGGCGCGGTGGAGCTCGACGCCGCACTGCTGGCCGAGGAACCCGGGCTGGTTCTG
CGCGCGCACCAGGCGATCCGCGCCGCCGGTGTCATCACCCGCCCGCTGGGCAGCGCACTGGCGGTCTCCCCGCCGCTGACGATCACGACGGAGC
AGGTCGACCTCATCGGCCAGGGCATCCGCGCCGGGCTGGACGCGACGCTGTCCTGA 
 
Protein sequence: 
MSASASPDTTSTRLWHPFANMADVKNQAFLVDRAEGVWVYDQDGRQYLDATASLWYVNIGHGRREIADAVAAQMSRLDAFNVFNDYTNRPAEEL
AARLAALAPMDDARVFFTSGGADSIETAAKLARLYWVNRGQPQRTHLLSRGQAYHGTHGVGTSIAGIQANRDGFGEMIADTTRVSNEDPEDLRD
AIERLGADRVAAFFAEPVIGAGGLIPPKPGYLEAVAKICREYDVLFVADEVICGFGRLGHWFGSQRFDLRPDLITFAKGVTSGYLPLGGVIAAG
SVAEPFWTDGGRPFRHGPTYSGHPTVAAAALANLDILEREDLLGRSRELEQPLFDVLRSLTDHPAVSEARGGVGLLGAVELDAALLAEEPGLVL
RAHQAIRAAGVITRPLGSALAVSPPLTITTEQVDLIGQGIRAGLDATLS 
Sery1824_pET-29a
6516 bps
1000
2000
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II.b) ω-transaminase Sery4673 
Cloning strategy  
The coding region of the transaminases Sace4673 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGACCACGCTCGACAACGCCACCGCACCGTCCACATCGCAAACCCCGGCCGCCGAGTCCGCCGCGCGCCACCTCTGGATGCACTTCGCCCGCA
TGGGCGGCCGAGGACCGGAGAACCCCGTCCCGGTCATCACCCGCGGCGAGGGCGTGCACCTCTGGGACGACCGCGGCCGACGCGTCCTCGACGG
CCTGGCCGGGCTGTTCGTGGTGCAGGCCGGCCACGGCCGCCGCGAGCTGGCCGAGGTGGCCGCCCGCCAGGCCTGCGAGCTCGCCTACTTCCCG
GTGTGGGGCTACGCCACTCCGCCGGCGGCCGAGCTCGCCGAGCGCCTGGCCCACCTCGCCCCGGGCGACCTCAACCGCGTCTTCTTCACCTCCG
GCGGAGGCGAAGCCGTCGAGTCGGCCTGGAAGGTCGCCAAGCAGTACTTCAAGCTCGTCGGAAAACCGCTGAAGCACAAGGTGATCAGCCGGTC
CGTGGCCTACCACGGCACACCGCACGGCGCGATGGCCATCACCGGGCTGCCGAAGATGAAGCAGGACTTCGAGCCGCTGGCCCCGGGCGGTTTC
CGGGTGCCCAACACCAACATCTACCGGAACCCCGAGTTCGCCGGCGACCCGGAGGCGTTCGGCCGCTGGGCCGCCGACCGCGTCGAGGAGGCCA
TCCTCTTCGAGGGTCCCGACACGGTGGCCGCCGTCGTGCTCGAGCCGGTGCAGAACTCCGGCGGATGCCTGACCGCGCCCCCGAGCTACTTCGC
GCGGGTCCGCGAGATCTGCGACCGCCACGACGTGCTGCTGGTCTCCGACGAGGTCATCTGCGCGTTCGGCAGGCACGGCCACACCTTCGCCTGC
GACAAGTTCGGCTACGTGCCCGACCTGATCACCTGCGCGAAGGGCATGACCTCCGGCTACGGCCCGCTCGGAGCGCTGATCGCCTCCGACCGCG
TGATGGAACCGTTCCTGCGGCCCGGCGTCACCTTCCCCCACGGCTACACCTGGGGCGGCCACCCCGTCTCGGCGGCCGTCGCGCTCGCCAATCT
CGAGCTGATGGCGGAGGAAGGACTGCACCAGCGGGTTCTGGACAACGAGCGGGCGTTCGGCGAGACGCTCGGCAAGCTGCTGGACCTGCCGATC
GTCGGCGACGTCCGCGGCGACGGGTACTTCTGGGCCGTCGAGCTGGTCAAGGACAAGGCCACCCGCGAGACCTTCGACGCCGACGAGCGGGAGC
GTCTGGTCCGCGGCTTCCTGCCCGGGGCCCTGTTCGACAACGGGCTGTACTGCCGCCCCGACGACCGCGGCGACGTCGTCGTCCAGCTCGCCCC
GCCGCTGATCGCCGGGCAGGCCGAGTTCGACGAGATCGAGGGCATCCTCCGGCACACGCTGCTCGAAGCCACGTCCGCCCTCTGA 
 
Protein sequence: 
 
MTTLDNATAPSTSQTPAAESAARHLWMHFARMGGRGPENPVPVITRGEGVHLWDDRGRRVLDGLAGLFVVQAGHGRRELAEVAARQACELAYFP
VWGYATPPAAELAERLAHLAPGDLNRVFFTSGGGEAVESAWKVAKQYFKLVGKPLKHKVISRSVAYHGTPHGAMAITGLPKMKQDFEPLAPGGF
RVPNTNIYRNPEFAGDPEAFGRWAADRVEEAILFEGPDTVAAVVLEPVQNSGGCLTAPPSYFARVREICDRHDVLLVSDEVICAFGRHGHTFAC
DKFGYVPDLITCAKGMTSGYGPLGALIASDRVMEPFLRPGVTFPHGYTWGGHPVSAAVALANLELMAEEGLHQRVLDNERAFGETLGKLLDLPI
VGDVRGDGYFWAVELVKDKATRETFDADERERLVRGFLPGALFDNGLYCRPDDRGDVVVQLAPPLIAGQAEFDEIEGILRHTLLEATSAL 
  
Sace4673 in pET-29a
6639 bps
1000
2000
3000
4000
5000
6000
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II.c) ω-transaminase Sery1902 
Cloning strategy  
The coding region of the transaminases Sery1902 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGACCGCGACGGAGAACCCCGCCGCCACCAGGACGCTCGGCGACCGAGCCCGCGACCACCTGTGGTTGCACTTCGCCCAGCACGCCGGCTACG
CCGACCGGGAGATCCCGGTGATCACCCGCGGCGAGGGCGCCTACGTCTACGACGAGCGCGGCAAGCGCTACCTCGACGGCCTGGCCGGGCTGTT
CGCGGTCCAGGTCGGCCACGGCCGCGAGGAGTTGGCGCTGGCCGCGGCCGAGCAGACCCGCAAGCTCGCCTACTTCCCGCTGTGGTCGCACGCG
CACCCCAGCGCCATCGAGCTCGCCGAGCGGATCGCCGCGCAGGCGCCGGGCGAGCTGAACCGGGTCTTCTTCACCGGAGGCGGCGGCGAGGCCG
TCGAAACCGCGTGGAAGCTGGCCAAGCAGTACTTCAAGAAGACCGGCAAGCCGACCAAGCACAAGGTGATCAGCCGCTCGCTGGCCTACCACGG
CACGTCGCAGGGTGCGCTGTCGATCACCGGCATCCCGGGCGCGAAGCAGGACTTCGAACCGCTGGTGCCCAGCGCCATCAAGGTGCCCAACACC
AACTTCTACCGCGCTCCCGAGCACGCCGGCGACTACGAGGCGTTCGGCCGGTGGGCCGCCGACCAGGTCGCGCTGGCCATCGAGATGGAGGGGC
CGGACACCGTGGCGGCGGTGTTCCTCGAACCGCTGCAGAACACCGGCGGCTGCTTCCCGCCGCCGCCCGGCTACTGGCAGCGGGTCCGCGAGAT
CTGCGACGCCTACGACGTCCTGCTGGTCTCCGACGAGGTGATCTGCGCATTCGGCCGCCTGGGGCACGACTTCGGCGCCAACCGCTACGGCTAC
CAGCCCGACATCATCACCACCGCCAAGGGCCTCACCTCCGGCTACGCGCCGCTGGGCGCGATGATCGCCGACGAACGGCTGATGCGGCCGTTCC
TGTCCGGCGGCAGCAGCTTCGCGCACGGCTCGACCTACGGCGGACATCCCGTCTCGTGCGCGGTGGCGATGGCCAACCTCGACGTCATGGAGTC
CGAGGACCTCTACGGCCGGGTGCTGTCCAACGAGGCGAACTTCCGCGCCACGCTGGAGAAGCTGCTCGACCTGCCGATCGTCGGCGACGTGCGC
GGGCAGGGCTACTTCTACGGCATCGAGCTGGTGAAGGACAAAGCGACCAAGGCGACCTTCACCCCGGACGACGCCGAGCGCGTGCTGCGCGGCT
ACGTCTCCGACGCACTGTTCGACGCCGGGCTCTACTGCCGCGCCGACGACCGCGCCGAACCGGTGATCCAGCTCGCGCCGCCGCTGATCTGCAC
CCAGGAGCACTTCGACGAGGTCGAGCAGATCCTGCGCTCGGTGCTGTCGGAGGCGTGGACGCGGCTGTGA 
 
Protein sequence: 
 
MTATENPAATRTLGDRARDHLWLHFAQHAGYADREIPVITRGEGAYVYDERGKRYLDGLAGLFAVQVGHGREELALAAAEQTRKLAYFPLWSHA
HPSAIELAERIAAQAPGELNRVFFTGGGGEAVETAWKLAKQYFKKTGKPTKHKVISRSLAYHGTSQGALSITGIPGAKQDFEPLVPSAIKVPNT
NFYRAPEHAGDYEAFGRWAADQVALAIEMEGPDTVAAVFLEPLQNTGGCFPPPPGYWQRVREICDAYDVLLVSDEVICAFGRLGHDFGANRYGY
QPDIITTAKGLTSGYAPLGAMIADERLMRPFLSGGSSFAHGSTYGGHPVSCAVAMANLDVMESEDLYGRVLSNEANFRATLEKLLDLPIVGDVR
GQGYFYGIELVKDKATKATFTPDDAERVLRGYVSDALFDAGLYCRADDRAEPVIQLAPPLICTQEHFDEVEQILRSVLSEAWTRL 
  
Sery1902 in pET-29a 
6647 bps
1000
2000
3000
4000
5000
6000
NdeI 
Xho
kan Res
Sery1902
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II.d) ω-transaminase Sav4551 
Cloning strategy  
The coding region of the transaminases Sav4551 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGACCCCTCAGCCGAATCCCCAGGTCGGTGCCGCCGTCAAGGCCGCGGACCGTGCGCATGTCTTCCACTCCTGGTCAGCGCAGGAGCTCATCG
ACCCGCTCGCCGTCGCCGGTGCGGAGGGGTCGTACTTCTGGGACTACGACGGCAGGCGGTACCTGGACTTCACCAGCGGACTCGTCTTCACCAA
CATCGGGTACCAGCACCCCAAGGTCGTCGCCGCCATTCAGGAGCAGGCCGCGAGCCTGACCACCTTCGCGCCCGCCTTCGCCGTCGAGGCGCGG
TCCGAGGCGGCCCGGCTCATCGCCGAGCGGACGCCCGGAGACCTCGACAAGATCTTCTTCACCAACGGCGGGGCCGACGCCATCGAGCACGCCG
TGCGCATGGCGCGGATACACACCGGGCGGCCCAAGGTGCTGTCCGCCTACCGCTCCTACCACGGTGGCACCCAGCAGGCCGTCAACATCACCGG
TGATCCGCGCCGCTGGGCCTCCGACAGCGCCTCGGCGGGCGTCGTGCACTTCTGGGCGCCGTACCTCTACCGGTCGCGCTTCTACGCGGAGACC
GAGCAGCAGGAGTGCGAGCGGGCGCTGGAGCACCTGGAGACGACCATCGCCTTCGAGGGGCCGGGCACGATCGCCGCGATCGTGCTGGAGACCG
TTCCGGGGACCGCGGGGATCATGGTTCCGCCGCCCGGATATCTCGCCGGGGTGCGTGAGCTGTGCGACAAGTACGGCATCGTCTTCGTCCTGGA
CGAGGTGATGGCCGGGTTCGGACGGACCGGTGAGTGGTTCGCCGCGGATCTCTTCGACGTCACACCCGACCTGATGACCTTCGCCAAGGGCGTG
AACTCCGGATATGTGCCGCTGGGCGGTGTCGCGATCTCCGGGAAGATCGCCGAGACCTTCGGGAAGCGGGCCTACCCGGGCGGTCTGACCTACT
CCGGGCATCCGCTCGCCTGCGCCGCCGCCGTCGCCACGATCAACGTCATGGCCGAGGAGGGGGTCGTCGAGAACGCGGCGAACCTCGGCGCCCG
GGTCATCGAGCCGGGGCTGCGCGAGCTGGCCGAGCGGCACCCGTCCGTGGGCGAGGTGCGCGGTGTCGGCATGTTCTGGGCGCTGGAGCTGGTC
AAGGACCGGGAGACGCGGGAGCCGCTGGTGCCGTACAACGCGGCGGGCGAGGCGAACGCGCCGATGGCCGCCTTCGGTGCCGCCGCCAAGGCGA
ACGGCCTGTGGCCGTTCATCAACATGAACCGCACGCACGTCGTGCCCCCGTGCAACGTCACGGAGGCCGAGGCCAAGGAAGGCCTGGCGGCCCT
CGACGCGGCCCTCTCGGTGGCGGACGAGTACACGGTTTAG 
 
Protein sequence: 
 
MTPQPNPQVGAAVKAADRAHVFHSWSAQELIDPLAVAGAEGSYFWDYDGRRYLDFTSGLVFTNIGYQHPKVVAAIQEQAASLTTFAPAFAVEAR
SEAARLIAERTPGDLDKIFFTNGGADAIEHAVRMARIHTGRPKVLSAYRSYHGGTQQAVNITGDPRRWASDSASAGVVHFWAPYLYRSRFYAET
EQQECERALEHLETTIAFEGPGTIAAIVLETVPGTAGIMVPPPGYLAGVRELCDKYGIVFVLDEVMAGFGRTGEWFAADLFDVTPDLMTFAKGV
NSGYVPLGGVAISGKIAETFGKRAYPGGLTYSGHPLACAAAVATINVMAEEGVVENAANLGARVIEPGLRELAERHPSVGEVRGVGMFWALELV
KDRETREPLVPYNAAGEANAPMAAFGAAAKANGLWPFINMNRTHVVPPCNVTEAEAKEGLAALDAALSVADEYTV 
  
Sav4551 in pET-29a
6594 bps
1000
2000
3000
400
5000
600
NdeI
Xho
kan Res
Sav4551
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II.e) ω-transaminase Sav2612 
Cloning strategy  
The coding region of the transaminases Sav2612 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGGGGAACCCGATAGCCGTGAGCAAGGACCTCAGCCGAACCGCGTACGACCACCTGTGGATGCACTTCACCCGCATGTCCTCGTACGAGAACG
CGCCCGTTCCCACCATCGTCCGTGGTGAGGGCACCTACATCTACGACGACAAGGGCAAGCGCTACCTCGACGGTCTCTCGGGTCTGTTCGTGGT
CCAGGCGGGCCACGGCCGCACGGAGCTGGCGGAGACCGCGTTCAAGCAGGCTCAGGAACTGGCCTTCTTCCCGGTGTGGTCCTACGCCCACCCG
AAGGCCGTGGAACTGGCCGAGCGCCTTGCGAACTACGCCCCGGGCGACCTCAACAAGGTCTTCTTCACCACCGGCGGCGGCGAGGCGGTCGAGA
CCGCCTGGAAGCTCGCCAAGCAGTACTTCAAGCTCCAGGGCAAGCCGACCAAGTACAAGGTCATCTCGCGCGCGGTCGCCTACCACGGCACCCC
GCAGGGCGCCCTGTCCATCACCGGCCTGCCGGCCCTGAAGGCCCCCTTCGAGCCGCTGGTCCCGGGCGCCCACAAGGTCCCGAACACCAACATC
TACCGCGCCCCGCTCTTCGGCGACGACCCCGAGGCCTTCGGCCGCTGGGCCGCCGACCAGATCGAGCAGCAGATCCTCTTCGAGGGCCCGGAGA
CGGTCGCGGCCGTCTTCCTGGAGCCGGTGCAGAACGCCGGCGGCTGCTTCCCGCCGCCGCCCGGCTACTTCCAGCGCGTGCGCGAGATCTGCGA
CCAGTACGACGTGCTGCTGGTGTCGGACGAGGTCATCTGTGCCTTCGGCCGCCTCGGCACGATGTTCGCCTGCGACAAGTTCGGCTACGTACCG
GACATGATCACCTGCGCCAAGGGCATGACCTCGGGCTACTCCCCGATCGGCGCGTGCATCGTCTCCGACCGCATCGCCGAGCCGTTCTACAAGG
GCGACAACACCTTCCTGCACGGCTACACGTTCGGCGGCCACCCGGTCTCCGCCGCCGTGGGTGTCGCCAACCTCGACCTGTTCGAGCGCGAGGG
CCTCAACCAGCACGTGCTGGACAACGAGTCCGCGTTCCTCACGACGCTCCAGAAGCTGCACGACCTGCCGATCGTCGGCGACGTCCGCGGCAAC
GGCTTCTTCTACGGCATCGAGCTGGTGAAGGACAAGGCCACCAAGGAGACGTTCACGGACGAGGAGTCGGAGCGCGTGCTCTACGGCTTCGTCT
CCAAGAAGCTCTTCGAGTACGGCCTCTACTGCCGCGCCGACGACCGCGGTGACCCGGTCATCCAGCTGTCGCCGCCGCTGATCTCCAACCAGTC
GACCTTCGACGAGATCGAATCGATCATCCGGCAGGTGCTGACGGAGGCGTGGACGAAGCTCTGA 
 
Protein sequence: 
 
MGNPIAVSKDLSRTAYDHLWMHFTRMSSYENAPVPTIVRGEGTYIYDDKGKRYLDGLSGLFVVQAGHGRTELAETAFKQAQELAFFPVWSYAHP
KAVELAERLANYAPGDLNKVFFTTGGGEAVETAWKLAKQYFKLQGKPTKYKVISRAVAYHGTPQGALSITGLPALKAPFEPLVPGAHKVPNTNI
YRAPLFGDDPEAFGRWAADQIEQQILFEGPETVAAVFLEPVQNAGGCFPPPPGYFQRVREICDQYDVLLVSDEVICAFGRLGTMFACDKFGYVP
DMITCAKGMTSGYSPIGACIVSDRIAEPFYKGDNTFLHGYTFGGHPVSAAVGVANLDLFEREGLNQHVLDNESAFLTTLQKLHDLPIVGDVRGN
GFFYGIELVKDKATKETFTDEESERVLYGFVSKKLFEYGLYCRADDRGDPVIQLSPPLISNQSTFDEIESIIRQVLTEAWTKL 
  
Sav2612 in pET-29a
6618 bps
1000
2000
3000
4000
5000
6000
Nde
XhoI
kan Res
Sav2612
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II.f) ω-transaminase Sco5655 
Cloning strategy  
The coding region of the transaminases Sco5655 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the XhoI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGAGCACCGACAGCCCCAAGGACCTCAGCCGGACCGCCTACGACCACCTGTGGATGCACTTCACCCGCATGTCGTCGTACGAGAACGCCCCCG
TCCCCACCATCGTCCGCGGTGAGGGCACCCACATCTACGACGACAAGGGCAGGCGCTACCTCGACGGTCTCGCCGGCCTGTTCGTGGTCCAGGC
CGGACACGGCCGCCAGGAGCTCGCGGAGACCGCCTCCAAGCAGGCGCAGGAGCTCGCCTTCTTCCCGGTGTGGTCCTACGCCCACCCCAAGGCC
GTCGAGCTGGCCGAGCGGCTGGCCAACGAGGCCCCCGGCGACCTCAACAAGGTCTTCTTCACCACCGGCGGCGGCGAGGCGGTGGAGACCGCCT
GGAAGCTCGCCAAGCAGTACTTCAAGCTGACCGGCAAGCCCACCAAGTACAAGGTGATCTCCCGCGCGGTGGCCTACCACGGCACCCCGCAGGG
CGCCCTGTCCATCACCGGCCTGCCCGCCCTGAAGGCTCCCTTCGAGCCGCTGGTCCCCGGCGCGCACAAGGTGCCGAACACCAACATCTACCGC
GCCCCGATCCACGGCGACGACCCCGAGGCCTACGGCCGCTGGGCCGCCGACCAGATCGAGCAGCAGATCCTGTTCGAGGGTCCGGAGACCGTCG
CGGCGGTCTTCCTTGAGCCGGTGCAGAACGCGGGCGGCTGCTTCCCGCCCCCGCCCGGCTACTTCCAGCGGGTGCGCGAGATCTGCGACCAGTA
CGACGTACTGCTCGTCTCGGACGAGGTCATCTGCGCCTTCGGCCGCCTGGGCACCACCTTCGCCTGCGACAAGTTCGGCTACGTCCCGGACATG
ATCACCTGCGCCAAGGGCATGACCTCGGGCTACTCCCCGATCGGCGCCTGCGTCATCTCCGACCGCCTGGCCGAGCCCTTCTACAAGGGCGACA
ACACCTTCCTGCACGGCTACACCTTCGGCGGCCACCCGGTCTCCGCCGCGGTCGGCATCGCCAACCTCGACCTCTTCGAGCGCGAGGGCCTCAA
CCAGCACGTGCTGGACAACGAGGGCGCCTTCCGCGCCACCCTGGAGAAGCTGCACGACCTGCCGATCGTCGGCGACGTCCGCGGCAACGGCTTC
TTCTACGGCATCGAGCTGGTGAAGGACAAGGCCACCAAGGAGTCCTTCGACGAGGAGGAGACCGAGCGCGTCCTGTACGGCTTCCTCTCCAAGA
AGCTCTTCGAGAACGGCCTGTACTGCCGTGCCGACGACCGCGGCGACCCGGTCATCCAGCTCGCCCCGCCGCTGATCTCCAACCAGGAGACCTT
CGACGAGATCGAGCAGATCCTGCGCGCCACGCTGACGGAGGCGTGGACGAAGCTCTGA 
 
Protein sequence: 
 
MSTDSPKDLSRTAYDHLWMHFTRMSSYENAPVPTIVRGEGTHIYDDKGRRYLDGLAGLFVVQAGHGRQELAETASKQAQELAFFPVWSYAHPKA
VELAERLANEAPGDLNKVFFTTGGGEAVETAWKLAKQYFKLTGKPTKYKVISRAVAYHGTPQGALSITGLPALKAPFEPLVPGAHKVPNTNIYR
APIHGDDPEAYGRWAADQIEQQILFEGPETVAAVFLEPVQNAGGCFPPPPGYFQRVREICDQYDVLLVSDEVICAFGRLGTTFACDKFGYVPDM
ITCAKGMTSGYSPIGACVISDRLAEPFYKGDNTFLHGYTFGGHPVSAAVGIANLDLFEREGLNQHVLDNEGAFRATLEKLHDLPIVGDVRGNGF
FYGIELVKDKATKESFDEEETERVLYGFLSKKLFENGLYCRADDRGDPVIQLAPPLISNQETFDEIEQILRATLTEAWTKL 
  
MP15.3 in pET-29a
6767 bps
1000
2000
3000
4000
5000
6000
NdeI
XhoI
XhoI
kan Res
MP15.3
Sco56 5
Sco5655 
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II.g) ω-transaminase PP5182 
Cloning strategy  
The coding region of the transaminases PP5182 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGAGCGTCAACAACCCGCAAACCCGTGAATGGCAAACCCTGAGCGGGGAGCATCACCTCGCACCTTTCAGTGACTACAAGCAGCTGAAGGAGA
AGGGGCCGCGCATCATCACCAAGGCCCAGGGTGTGCATTTGTGGGATAGCGAGGGGCACAAGATCCTCGACGGCATGGCCGGTCTATGGTGCGT
GGCGGTCGGCTACGGACGTGAAGAGCTGGTGCAGGCGGCGGAAAAACAGATGCGCGAGCTGCCGTACTACAACCTGTTCTTCCAGACCGCTCAC
CCGCCTGCGCTCGAGCTGGCCAAGGCGATCACCGACGTGGCGCCGAAAGGTATGACCCATGTGTTCTTCACCGGCTCCGGCTCCGAAGGCAACG
ACACTGTGCTGCGCATGGTGCGTCACTACTGGGCGCTGAAGGGCAAACCGCACAAGCAGACCATCATCGGCCGCATCAACGGTTACCACGGCTC
CACCTTCGCCGGTGCATGCCTGGGCGGTATGAGCGGCATGCACGAGCAGGGTGGCCTGCCGATCCCGGGCATCGTGCACATCCCTCAGCCGTAC
TGGTTCGGCGAGGGAGGCGACATGACCCCTGACGAATTCGGTGTCTGGGCCGCCGAGCAGTTGGAGAAGAAGATCCTCGAAGTCGGCGAAGACA
ACGTCGCGGCCTTCATCGCCGAGCCGATCCAGGGCGCTGGTGGCGTGATCATCCCGCCGGAAACCTACTGGCCGAAGGTGAAGGAGATCCTCGC
CAGGTACGACATCCTGTTCGTCGCCGACGAGGTGATCTGCGGCTTCGGCCGTACCGGCGAGTGGTTCGGCTCGGACTACTACGACCTCAAGCCC
GACCTGATGACCATCGCGAAAGGCCTGACCTCCGGTTACATCCCCATGGGCGGTGTGATCGTGCGTGACACCGTGGCCAAGGTGATCAGCGAAG
GCGGCGACTTCAACCACGGTTTCACCTACTCCGGCCACCCGGTGGCGGCCGCGGTGGGCCTGGAAAACCTGCGCATTCTGCGTGACGAGAAAAT
TGTCGAGAAGGCGCGCACGGAAGCGGCACCGTATTTGCAAAAGCGTTTGCGCGAGCTGCAAGACCATCCACTGGTGGGTGAAGTGCGCGGCCTG
GGCATGCTGGGAGCGATCGAGCTGGTCAAGGACAAGGCAACCCGCAGCCGTTACGAGGGCAAGGGCGTTGGCATGATCTGTCGCACCTTCTGCT
TCGAGAACGGCCTGATCATGCGTGCGGTGGGTGACACCATGATCATCGCGCCGCCGCTGGTAATCAGCCATGCGGAGATCGACGAACTGGTGGA
AAAGGCGCGCAAGTGCCTGGACCTGACCCTTGAGGCGATTCAATAA 
 
Protein sequence: 
 
MSVNNPQTREWQTLSGEHHLAPFSDYKQLKEKGPRIITKAQGVHLWDSEGHKILDGMAGLWCVAVGYGREELVQAAEKQMRELPYYNLFFQTAH
PPALELAKAITDVAPKGMTHVFFTGSGSEGNDTVLRMVRHYWALKGKPHKQTIIGRINGYHGSTFAGACLGGMSGMHEQGGLPIPGIVHIPQPY
WFGEGGDMTPDEFGVWAAEQLEKKILEVGEDNVAAFIAEPIQGAGGVIIPPETYWPKVKEILARYDILFVADEVICGFGRTGEWFGSDYYDLKP
DLMTIAKGLTSGYIPMGGVIVRDTVAKVISEGGDFNHGFTYSGHPVAAAVGLENLRILRDEKIVEKARTEAAPYLQKRLRELQDHPLVGEVRGL
GMLGAIELVKDKATRSRYEGKGVGMICRTFCFENGLIMRAVGDTMIIAPPLVISHAEIDELVEKARKCLDLTLEAIQ 
 
  
PP5182 in pET-29a
6600 bps
1000
2000
3000
4000
5000
6000
NdeI 
XhoI
XhoI
kan Res
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II.h) ω-transaminase PP2799 
Cloning strategy  
The coding region of the transaminases PP2799 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGAGCACCCACTCTTCAACCGTTCAGAACGATCTGGCGGCACTCATTCATCCCAACACCAACCTGGCCCAGCACCGAGAGGTCGGGCCACTCG
TGATCGCCAGAGGTGACGGCGTCCGGGTCTTTGACGAGCAAGGCAATGCCTACATCGAAGCCATGTCGGGCCTGTGGAGCGCGGCATTGGGCTT
CAGTGAACAGCGCCTGGTCGATGCTGCCGTCGAGCAGTTCAAGCAACTGCCCTACTACCACAGCTTCAGCCACAAGACCAATGCGCCTGCCGCA
GCGCTCGCCGCCAAGTTGGCAGCGCTGGCGCCGGGTGATCTGAACCATGTGTTCTTCACCAACTCAGGTTCCGAGGCCAATGATTCGGTGGTGA
AAATGGTGTGGTACGTGAACAACGCACTGGGCCGGCCCGCCAAAAAGAAATTCATCTCTCGACAACAGGCCTATCACGGCGCCACCGTCGCCGC
AGCAAGCCTGACCGGCATCCCATCGATGCACCGTGACTTCGATCTGCCGGCCATCCCGGTTCATCACCTGACCTGCCCGAACTTCTACCGATTT
GCTCGGCCAGGAGAATCGCAAGAGGCCTTTACGGTCCGTCTGGCGAACGAACTGGAACGCTATATCCTTGCCGAAGGGCCGGAAACCATCGCCG
CGTTCATCGGCGAGCCGGTAATCGCGGCAGGTGGCGTGATCCCTCCTCCCACAGGCTACTGGGCGGCGATCCAGGCGGTGTGCAAACGCTACGA
CATCCTCGTGGTGATCGACGAAATCATCACCGGCTTTGGCAGGCTTGGCACAATGTTCGGCTCTCAGTTGTACGGCATCCAGCCCGACATCATG
GTGCTCTCCAAGCAGCTCACCTCCTCATACCAGCCGCTGGCGGCCGTGGTGGTGTCCGATGCCATGAACGATGTACTGGTGAGCCAGAGCCAGC
GCCTGGGGGCATTCGCCCACGGCCTGACCTGCACGGGCCACCCCGTCGCCACGGCGGTTGCGCTGGAAAACATCCGCATCATCGAAGAGCGCGA
TCTGGTCGGCCATGTGCAGCACCTGGCCCCCGTGTTCCAGCGCCACCTGCGCGCGTTCGAAGACCACCCGTTGGTCGGCAACGTCAGAGGCGTC
GGGCTGATGGGCGGGATCGAACTGGTTGCCGACAAGGCCACCCGCCAACCGTTCGCCCAGCCAGGGACGTTGGGCGGCTACGTGTTCAAACAGG
CTCACAAGCATGGGCTGATCATTCGCGCCATCTACGACACGATCGCCTTCTGTCCTCCGTTGATTACCACCCAGGACGATATCGAGGCGATCTT
CAGCGCCTTCGAGCGGACGCTGGCTGACGCGACGGATTGGGCGCGCTCACAGCACCTGCTGTAA 
 
Protein sequence: 
 
MSTHSSTVQNDLAALIHPNTNLAQHREVGPLVIARGDGVRVFDEQGNAYIEAMSGLWSAALGFSEQRLVDAAVEQFKQLPYYHSFSHKTNAPAA
ALAAKLAALAPGDLNHVFFTNSGSEANDSVVKMVWYVNNALGRPAKKKFISRQQAYHGATVAAASLTGIPSMHRDFDLPAIPVHHLTCPNFYRF
ARPGESQEAFTVRLANELERYILAEGPETIAAFIGEPVIAAGGVIPPPTGYWAAIQAVCKRYDILVVIDEIITGFGRLGTMFGSQLYGIQPDIM
VLSKQLTSSYQPLAAVVVSDAMNDVLVSQSQRLGAFAHGLTCTGHPVATAVALENIRIIEERDLVGHVQHLAPVFQRHLRAFEDHPLVGNVRGV
GLMGGIELVADKATRQPFAQPGTLGGYVFKQAHKHGLIIRAIYDTIAFCPPLITTQDDIEAIFSAFERTLADATDWARSQHLL 
  
PP2799 in pET-29a
6618 bps
1000
2000
3000
4000
5000
6000
NdeI
XhoI
kan Res
PP2799
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II.i) ω-transaminase PP2588 
Cloning strategy  
The coding region of the transaminases PP2588 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGAACGCGCCTTTCGCCCCGCAACGCCAGACCCGTGACTACCAGGCAGCCGATGCCGCCCACCACATTCATGCCTTCCTCGACCAGAAGGCGC
TGAACGCCGAAGGGCCGCGGGTGATCGTCGGTGGCGAACGCCTGCACCTGTGGGACAGCGAGGGCAAGCGTTACCTGGATGGCATGTCCGGCCT
GTGGTGCACCCAGCTCGGTTATGGCCGTCGTGACCTGACGGCCGCCGCGGCCACGCAGATGGATCAGCTGGCCTACTACAACATGTTTTTCCAC
ACCACCCACCCGGCGGTGATCGAACTGTCCGAGTTGCTGTTCAGCCTGCTGCCGGGGCACTACAGCCACGCGATCTACACCAACTCCGGCTCCG
AGGCCAACGAGGTACTGATCCGCACCGTGCGCCGCTACTGGCAGGTGGTTGGCCAGCCAGGCAAGAAAATCATGATCGGCCGCTGGAACGGCTA
CCACGGCTCGACCCTGGCGGCCACGGCGCTGGGTGGGATGAAGTTCATGCACGACATGGGCGGGTTGATTCCGGATGTGGCACACATCGACGAA
CCCTACTGGTACGCCGAGGGCGGTGAACTGACTCCGGCCGAGTTCGGCCGCCGCTGCGCCCTGCAGCTGGAGGAAAAAATCCTCGAACTGGGTG
CCGAGAACGTTGCCGGCTTCATTGCCGAACCCTTCCAGGGGGCCGGCGGCATGATCTTCCCGCCGGAAAGCTACTGGCCGGAAATCCAGCGTAT
CTGCCGCCAGTACGACGTGCTGCTGTGCGCCGATGAGGTGATCGGTGGCTTTGGCCGCACCGGCGAATGGTTCGCCCATGAATACTTCGGCTTC
GAGCCCGACACCTTGTCGATTGCCAAGGGCCTGACCAGCGGCTATGTGCCCATGGGCGGCCTGGTGCTGAGCAAGCGCATTGCCGAGGCGTTGG
TGGAGCGCGGCGGGGTATTTGCCCACGGCCTGACCTATTCCGGCCACCCGGTGGCGGCGGCAGTGGCCATCGCCAACCTGAAGGCGCTGCGTGA
CGAAGGCATCGTGCGCCAGGTGAAGGACGACACGGGGCCGTACCTGCAGCGCATCCTGCGGGAAGTGTTTGCCGACCACCCATTGATCGGCCAG
GTGCAAGGGGCCGGGCTGGTGGCGGCGCTGCAGTTCGCCGAGCACAAGCCGACGCGCAAGCGCTTTGCCAACGAGAACGACCTGGCCTGGCAGT
GCCGCACCTTTGGTTTCGAGGAAGGGGTGATCATTCGCTCGACCCTGGGCCGGATGATCATGGCCCCGGCCTTGATCGCCAACCACAGCGAGCT
GGATGAGCTGGTGGAGAAGACCCGGATAGCCGTAGACCGCACGGCGCGGCTGGTCGGCAAGCTGTAA 
 
Protein sequence: 
 
MNAPFAPQRQTRDYQAADAAHHIHAFLDQKALNAEGPRVIVGGERLHLWDSEGKRYLDGM 
SGLWCTQLGYGRRDLTAAAATQMDQLAYYNMFFHTTHPAVIELSELLFSLLPGHYSHAIYTNSGSEANEVLIRTVRRYWQVVGQPGKKIMIGRW
NGYHGSTLAATALGGMKFMHDMGGLIPDVAHIDEPYWYAEGGELTPAEFGRRCALQLEEKILELGAENVAGFIAEPFQGAGGMIFPPESYWPEI
QRICRQYDVLLCADEVIGGFGRTGEWFAHEYFGFEPDTLSIAKGLTSGYVPMGGLVLSKRIAEALVERGGVFAHGLTYSGHPVAAAVAIANLKA
LRDEGIVRQVKDDTGPYLQRILREVFADHPLIGQVQGAGLVAALQFAEHKPTRKRFANENDLAWQCRTFGFEEGVIIRSTLGRMIMAPALIANH
SELDELVEKTRIAVDRTARLVGKL 
  
PP2588 in pET-29a
6621 bps
1000
2000
3000
4000
5000
6000
NdeI
XhoI
kan Res
PP2588
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II.j) ω-transaminase PP0596 
Cloning strategy  
The coding region of the transaminases PP0596 was cloned by our cooperation 
partner into the vector pET-24a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGAACATGCCCGAAACTGGTCCTGCCGGTATCGCCAGCCAGCTCAAGCTGGACGCCCACTGGATGCCCTACACCGCCAACCGCAACTTCCAGC
GCGACCCACGCCTGATCGTGGCGGCCGAAGGCAACTACCTGGTCGATGACCACGGGCGCAAGATCTTCGACGCCCTGTCCGGCCTGTGGACCTG
CGGCGCAGGGCACACTCGCAAGGAAATCGCTGACGCGGTGACCCGTCAACTGAGTACGCTGGACTACTCCCCAGCGTTCCAGTTCGGCCACCCG
CTGTCGTTCCAGCTGGCGGAAAAGATCGCCGAGCTGGTTCCGGGCAATCTGAATCACGTCTTCTATACCAACTCCGGTTCCGAGTGCGCCGATA
CCGCACTGAAGATGGTGCGTGCCTACTGGCGCCTGAAAGGCCAGGCAACCAAGACCAAGATCATCGGCCGTGCCCGTGGTTACCATGGCGTGAA
CATCGCCGGTACCAGCCTGGGTGGCGTCAACGGTAACCGCAAGATGTTTGGCCAGCTGCTGGACGTCGACCACCTGCCTCACACTGTATTGCCG
GTGAACGCCTTCTCGAAAGGCTTGCCGGAAGAGGGCGGTATCGCGCTGGCTGACGAAATGCTCAAGCTGATCGAGCTGCACGATGCCTCCAACA
TCGCAGCAGTCATCGTCGAGCCGCTGGCCGGTTCGGCCGGTGTGCTGCCGCCGCCAAAGGGTTACCTGAAGCGCCTGCGTGAAATCTGCACCCA
GCACAACATTCTGCTGATCTTCGACGAAGTGATCACAGGCTTCGGCCGCATGGGCGCGATGACCGGCTCGGAAGCCTTCGGCGTTACCCCGGAC
CTGATGTGCATCGCCAAGCAGGTGACCAACGGCGCCATCCCGATGGGCGCAGTGATTGCCAGCAGCGAGATCTACCAGACCTTCATGAACCAGC
CGACCCCGGAATACGCCGTGGAATTCCCACACGGCTACACCTATTCGGCGCACCCGGTAGCCTGTGCCGCCGGTCTCGCCGCGCTGGACCTGCT
GCAGAAGGAAAACCTGGTGCAGTCCGCGGCTGAACTGGCGCCGCATTTCGAGAAGCTGCTGCACGGCGTGAAGGGCACCAAGAATATCGTCGAT
ATCCGCAACTACGGCCTGGCCGGCGCCATCCAGATCGCCGCCCGTGACGGTGATGCCATCGTTCGCCCTTACGAAGCGGCCATGAAGCTGTGGA
AAGCGGGCTTCTATGTACGCTTTGGTGGCGACACCCTGCAGTTCGGCCCAACCTTCAATACCAAGCCGCAGGAACTGGACCGCTTGTTCGATGC
TGTTGGCGAAACCCTGAACCTGATCGACTGA 
 
Protein sequence: 
 
MNMPETGPAGIASQLKLDAHWMPYTANRNFQRDPRLIVAAEGNYLVDDHGRKIFDALSGLWTCGAGHTRKEIADAVTRQLSTLDYSPAFQFGHP
LSFQLAEKIAELVPGNLNHVFYTNSGSECADTALKMVRAYWRLKGQATKTKIIGRARGYHGVNIAGTSLGGVNGNRKMFGQLLDVDHLPHTVLP
VNAFSKGLPEEGGIALADEMLKLIELHDASNIAAVIVEPLAGSAGVLPPPKGYLKRLREICTQHNILLIFDEVITGFGRMGAMTGSEAFGVTPD
LMCIAKQVTNGAIPMGAVIASSEIYQTFMNQPTPEYAVEFPHGYTYSAHPVACAAGLAALDLLQKENLVQSAAELAPHFEKLLHGVKGTKNIVD
IRNYGLAGAIQIAARDGDAIVRPYEAAMKLWKAGFYVRFGGDTLQFGPTFNTKPQELDRLFDAVGETLNLID 
 
  
PP0596 in pET-24a
6581 bps
1000
2000
3000
4000
5000
6000
NdeI 
XhoI
Kan ResPP0596
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II.k) ω-transaminase PA0221 
Cloning strategy  
The coding region of the transaminases PA0221 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103]  
 
 
Gene sequence: 
 
ATGACCGCTCAGCTCAACCCGCAGCGCGACACCCGCGACTACCAGCAACTGGACGCCGCGCACCACATCCACGCCTTCCTCGACCAGAAGGCGC
TGAACCGCGAAGGCCCGCGGGTGATGGTCCGCGGCGATGGCCTGCAGCTCTGGGACAACGACGGCAAGCGCTACCTGGACGGCATGTCCGGCCT
CTGGTGCACCAACCTCGGCTACGGCCGCCAGGACCTCGCCGCCGCCGCCAGCCGCCAGCTGGAACAACTGCCGTACTACAACATGTTCTTCCAC
ACCACCCACCCGGCGGTGGTGGAGCTTTCCGAGATGCTCTTCAGCCTGCTGCCGGACCACTACAGCCACGCGATCTACACCAACTCCGGCTCCG
AGGCCAACGAGGTGCTGATCCGTACCGTGCGGCGCTACTGGCAGATCCTCGGCAAGCCGCAGAAGAAGATCATGATCGGCCGCTGGAACGGCTA
CCACGGCTCGACCCTGGGCAGCACCGCGCTCGGCGGGATGAAGTTCATGCACGAGATGGGCGGCATGCTGCCGGACTTCGCCCACATCGACGAA
CCCTACTGGTACGCCAACGGCGGCGAGCTGAGCCCGGCCGAGTTCGGTCGCCGCGCGGCGCTGCAACTGGAGGAGAAGATCCTCGAACTGGGCG
CGGAGAACGTCGCCGCCTTCGTCGCCGAGCCCTTCCAGGGCGCCGGCGGCATGATCTTCCCGCCGCAAAGCTATTGGCCGGAGATCCAGCGCAT
CTGCCGGCAGTACGACGTGCTGCTGTGCGCCGACGAAGTGATCGGCGGCTTCGGCCGCACCGGCGAATGGTTCGCCCACGAACACTTCGGCTTC
CAGCCGGACACCCTGTCCATCGCCAAGGGCCTGACGTCCGGCTACATCCCCATGGGCGGCCTGGTACTCGGCAAGCGCATCGCCGAGGTGCTGG
TGGAGCAGGGCGGGGTGTTCGCCCACGGCCTGACCTATTCCGGCCACCCGGTGGCGGCGGCGGTGGCCATCGCCAACCTCAAGGCGCTGCGCGA
CGAGGGCGTGGTCACGCGGGTCAGGGAGGAGACCGGCCCCTACCTGCAACGCTGCCTGCGCGAGGTCTTCGGCGACCATCCGCTGGTCGGCGAG
GTCCAGGGCGCCGGCTTCGTCGCCGCGCTGCAGTTCGCCGAGGACAAGGTGACCCGCAAGCGCTTCGCCAACGAGAACGATCTGGCCTGGCGCT
GCCGCACCATCGGCTTCGAGGAGGGCGTGATCATCCGCTCCACCCTCGGCCGCATGATCATGGCCCCGGCGCTGGTGGCCGGGCGTGCCGAGAT
CGACGAACTGATCGACAAGACCCGTATCGCGGTGGATCGCACCGCGCGCGAGATCGGCGTGCTCTGA 
 
Protein sequence: 
 
MTAQLNPQRDTRDYQQLDAAHHIHAFLDQKALNREGPRVMVRGDGLQLWDNDGKRYLDGMSGLWCTNLGYGRQDLAAAASRQLEQLPYYNMFFH
TTHPAVVELSEMLFSLLPDHYSHAIYTNSGSEANEVLIRTVRRYWQILGKPQKKIMIGRWNGYHGSTLGSTALGGMKFMHEMGGMLPDFAHIDE
PYWYANGGELSPAEFGRRAALQLEEKILELGAENVAAFVAEPFQGAGGMIFPPQSYWPEIQRICRQYDVLLCADEVIGGFGRTGEWFAHEHFGF
QPDTLSIAKGLTSGYIPMGGLVLGKRIAEVLVEQGGVFAHGLTYSGHPVAAAVAIANLKALRDEGVVTRVREETGPYLQRCLREVFGDHPLVGE
VQGAGFVAALQFAEDKVTRKRFANENDLAWRCRTIGFEEGVIIRSTLGRMIMAPALVAGRAEIDELIDKTRIAVDRTAREIGVL 
 
MP15.6.1 in pET-29a
6621 bps
1000
2000
3000
4000
5000
6000
NdeI
XhoI
kan Res
MP15.6.1
PA0221
A022  
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II.l) ω-transaminase PA4805 
Cloning strategy  
The coding region of the transaminases PA4805 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGAACGCAAGACTGCACGCCACGTCCCCCCTCGGCGACGCCGACCTGGTCCGTGCCGACCAGGCCCACTACATGCACGGCTACCACGTGTTCG
ACGACCACCGCGTCAACGGCTCGCTGAACATCGCCGCCGGCGACGGCGCCTATATCTACGACACCGCCGGCAACCGCTACCTCGACGCGGTGGG
CGGCATGTGGTGCACCAACATCGGCCTGGGGCGCGAGGAAATGGCTCGCACCGTGGCCGAGCAGACCCGCCTGCTGGCCTATTCCAATCCCTTC
TGCGACATGGCCAACCCGCGCGCCATCGAACTCTGCCGCAAGCTCGCCGAGCTGGCCCCCGGCGACCTCGACCACGTGTTCCTCACCACCGGCG
GTTCCACCGCCGTGGACACCGCGATCCGCCTCATGCACTACTACCAGAACTGCCGCGGCAAGCGCGCCAAGAAGCACGTCATCACGCGGATCAA
CGCCTACCACGGCTCGACCTTCCTCGGCATGTCGCTGGGCGGCAAGAGCGCCGACCGGCCGGCCGAGTTCGACTTCCTCGACGAGCGCATCCAC
CACCTCGCCTGTCCCTATTACTACCGCGCTCCGGAAGGGCTGGGCGAAGCCGAGTTCCTCGATGGCCTGGTGGACGAGTTCGAACGCAAGATCC
TCGAACTGGGCGCCGACCGGGTGGGGGCGTTCATCTCCGAGCCGGTGTTCGGCTCCGGCGGCGTGATCGTCCCGCCCGCGGGCTACCACAGGCG
GATGTGGGAGCTGTGCCAGCGCTACGACGTGCTGTACATCTCCGACGAAGTGGTGACCTCCTTCGGCCGCCTCGGCCACTTCTTCGCCAGCCAG
GCGGTGTTCGGCGTACAGCCGGACATCATCCTCACCGCCAAGGGCCTCACCTCCGGCTACCAGCCGCTGGGCGCGTGCATCTTCTCCCGGCGCA
TCTGGGAGGTGATCGCCGAGCCGGACAAGGGCCGCTGCTTCAGCCATGGTTTCACCTACTCCGGCCACCCGGTGGCCTGCGCGGCGGCGCTGAA
GAACATCGAGATCATCGAGCGCGAGGGCTTGCTCGCCCACGCCGACGAGGTCGGCCGCTACTTCGAGGAGCGCCTGCAAAGCCTCCGCGACCTG
CCCATCGTCGGCGACGTGCGCGGGATGCGCTTCATGGCCTGTGTCGAGTTCGTCGCCGACAAGGCGAGCAAGGCGCTGTTTCCGGAAAGCCTGA
ACATCGGCGAGTGGGTCCACCTGCGGGCGCAGAAGCGCGGCCTGCTGGTTCGTCCGATCGTCCACCTGAACGTGATGTCGCCGCCGCTGATCCT
CACCCGCGAACAGGTCGATACCGTGGTCCGGGTGCTGCGCGAGAGCATCGAGGAAACCGTGGAGGATCTTGTCCGCGCCGGTCACCGGTAA 
 
Protein sequence: 
 
MNARLHATSPLGDADLVRADQAHYMHGYHVFDDHRVNGSLNIAAGDGAYIYDTAGNRYLDAVGGMWCTNIGLGREEMARTVAEQTRLLAYSNPF
CDMANPRAIELCRKLAELAPGDLDHVFLTTGGSTAVDTAIRLMHYYQNCRGKRAKKHVITRINAYHGSTFLGMSLGGKSADRPAEFDFLDERIH
HLACPYYYRAPEGLGEAEFLDGLVDEFERKILELGADRVGAFISEPVFGSGGVIVPPAGYHRRMWELCQRYDVLYISDEVVTSFGRLGHFFASQ
AVFGVQPDIILTAKGLTSGYQPLGACIFSRRIWEVIAEPDKGRCFSHGFTYSGHPVACAAALKNIEIIEREGLLAHADEVGRYFEERLQSLRDL
PIVGDVRGMRFMACVEFVADKASKALFPESLNIGEWVHLRAQKRGLLVRPIVHLNVMSPPLILTREQVDTVVRVLRESIEETVEDLVRAGHR 
 
PA4805 in pET-29a
6645 bps
1000
2000
3000
4000
5000
6000
NdeI
XhoI
kan Res
PA408 
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II.m) ω-transaminase PA5313 
Cloning strategy  
The coding region of the transaminases PA5313 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGACAATGAATGACGAGCCGCAGTCGAGCAGCCTCGACAACTTCTGGATGCCCTTCACCGCCAACCGCCAGTTCAAGGCGCGGCCGCGCCTGC
TGGAAAGCGCCGAAGGCATCCACTATATCGCCCAGGGCGGGCGCCGCATCCTCGACGGCACCGCCGGCCTCTGGTGCTGCAATGCCGGCCACGG
CCGGCGCGAGATCAGCGAAGCGGTGGCCCGGCAGATCGCCACCCTCGACTACGCCCCGCCGTTCCAGATGGGTCACCCGCTGCCGTTCGAACTC
GCCGCGCGGCTGACGGAAATCGCCCCGCCGAGCCTGAACAAAGTATTCTTCACCAACTCCGGCTCGGAATCGGCGGACACCGCGCTGAAGATCG
CCCTTGCCTACCAGCGCGCCATCGGCCAGGGCACCCGCACCCGCCTGATCGGCCGCGAACTGGGCTACCACGGGGTCGGCTTCGGCGGCCTGTC
GGTAGGCGGTATGGTCAACAACCGCAAGGCCTTCTCCGCCAACCTGCTGCCGGGGGTCGACCACCTGCCGCACACCCTGGACGTCGCCCGCAAC
GCCTTCACCGTCGGCCTGCCCGAGCATGGCGTGGAAAAGGCCGAGGAGCTGGAACGCCTGGTGACCCTGCACGGCGCCGAGAATATCGCCGCGG
TGATCGTCGAGCCGATGTCCGGCTCGGCCGGCGTGGTGCTGCCGCCCAAGGGCTACCTTCAGCGGCTGCGCGAGATAACCCGCAAGCATGGCAT
CCTGCTGATCTTCGACGAAGTGATCACCGGTTTCGGCCGCGTCGGCGAAGCCTTCGCCGCGCAGCGCTGGGGCGTCGTCCCGGACCTGCTGACC
TGCGCCAAGGGGCTGACCAACGGCAGCATCCCGATGGGCGCCGTATTCGTCGACGAGAAGATCCATGCTGCCTTCATGCAAGGCCCGCAGGGCG
CCATCGAGTTCTTCCACGGCTATACCTATTCCGGCCATCCGGTAGCCTGCGCCGCCGCCCTGGCGACCCTGGACATCTACCGTCGCGACGACCT
GTTCCAGCGGGCCGTCGAACTGGAAGGCTACTGGCAGGACGCGCTGTTCAGCCTGCGCGACCTGCCCAACGTGGTCGACATCCGCGCCGTAGGC
CTGGTCGGCGGCGTGCAACTGGCGCCGCACGCGGACGGCCCCGGCAAGCGCGGCTACGACGTCTTCGAGCGCTGCTTCTGGGAGCACGACCTGA
TGGTCCGGGTGACCGGCGACATCATCGCCATGTCGCCGCCGCTGATCATCGACAAGCCCCACATCGACCAGATCGTCGAGCGCCTGGCCCAGGC
CATCCGCGCCAGCGTCTAA 
 
Protein sequence: 
 
MTMNDEPQSSSLDNFWMPFTANRQFKARPRLLESAEGIHYIAQGGRRILDGTAGLWCCNAGHGRREISEAVARQIATLDYAPPFQMGHPLPFEL
AARLTEIAPPSLNKVFFTNSGSESADTALKIALAYQRAIGQGTRTRLIGRELGYHGVGFGGLSVGGMVNNRKAFSANLLPGVDHLPHTLDVARN
AFTVGLPEHGVEKAEELERLVTLHGAENIAAVIVEPMSGSAGVVLPPKGYLQRLREITRKHGILLIFDEVITGFGRVGEAFAAQRWGVVPDLLT
CAKGLTNGSIPMGAVFVDEKIHAAFMQGPQGAIEFFHGYTYSGHPVACAAALATLDIYRRDDLFQRAVELEGYWQDALFSLRDLPNVVDIRAVG
LVGGVQLAPHADGPGKRGYDVFERCFWEHDLMVRVTGDIIAMSPPLIIDKPHIDQIVERLAQAIRASV 
 
  
PA5313 in pET-29a
6573 bps
1000
2000
3000
4000
5000
6000
NdeI
XhoI
kan Res
PA5313
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II.n) ω-transaminase CV2025 
Cloning strategy  
The coding region of the transaminases CV2025 was cloned by our cooperation 
partner into the vector pET-29a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described previously.[103] 
 
 
Gene sequence: 
 
ATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGCAGAAGCAACGTACGACCAGCCAATGGCGCGAACTGGATGCCGCCCATCACCTGCA
TCCGTTCACCGATACCGCATCGCTGAACCAGGCGGGCGCGCGCGTGATGACGCGCGGAGAGGGCGTCTACCTGTGGGATTCGGAAGGCAACAAG
ATCATCGACGGCATGGCCGGACTGTGGTGCGTGAACGTCGGCTACGGCCGCAAGGACTTTGCCGAAGCGGCGCGCCGGCAGATGGAAGAGCTGC
CGTTCTACAACACCTTCTTCAAGACCACCCATCCGGCGGTGGTCGAGCTGTCCAGCCTGCTGGCTGAAGTGACGCCGGCCGGTTTCGACCGCGT
GTTCTATACCAATTCCGGTTCCGAATCGGTGGACACCATGATCCGCATGGTGCGCCGCTACTGGGACGTGCAGGGCAAGCCGGAGAAGAAGACG
CTGATCGGCCGCTGGAACGGCTATCACGGCTCCACCATCGGCGGCGCCAGCCTGGGCGGCATGAAGTACATGCACGAGCAGGGCGACTTGCCGA
TTCCGGGCATGGCCCACATCGAGCAGCCTTGGTGGTACAAGCACGGCAAGGACATGACGCCGGACGAGTTCGGCGTGGTGGCCGCGCGCTGGCT
GGAAGAGAAGATTCTGGAAATCGGCGCCGACAAGGTGGCCGCCTTCGTCGGCGAACCCATCCAGGGCGCCGGCGGCGTGATCGTCCCGCCGGCC
ACCTACTGGCCGGAAATCGAGCGCATTTGCCGCAAGTACGACGTGCTGCTGGTGGCCGACGAAGTGATCTGCGGCTTCGGGCGTACCGGCGAAT
GGTTCGGCCATCAGCATTTCGGCTTCCAGCCCGACCTGTTCACCGCCGCCAAGGGCCTGTCCTCCGGCTATCTGCCGATAGGCGCGGTCTTTGT
CGGCAAGCGCGTGGCCGAAGGCCTGATCGCCGGCGGCGACTTCAACCACGGCTTCACCTACTCCGGCCACCCGGTCTGCGCCGCCGTCGCCCAC
GCCAACGTGGCGGCGCTGCGCGACGAGGGCATCGTCCAGCGCGTCAAGGACGACATCGGCCCGTACATGCAAAAGCGCTGGCGTGAAACCTTCA
GCCGTTTCGAGCATGTGGACGACGTGCGCGGCGTCGGCATGGTGCAGGCGTTCACCCTGGTGAAGAACAAGGCGAAGCGCGAGCTGTTCCCCGA
TTTCGGCGAGATCGGCACGCTGTGCCGCGACATCTTCTTCCGCAACAACCTGATCATGCGGGCATGCGGCGACCACATCGTGTCGGCGCCGCCG
CTGGTGATGACGCGGGCGGAAGTGGACGAGATGCTGGCGGTGGCGGAACGCTGTCTGGAGGAATTCGAGCAGACGCTGAAGGCGCGCGGGCTGG
CTTAGCTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAA 
 
Protein sequence: 
 
MQKQRTTSQWRELDAAHHLHPFTDTASLNQAGARVMTRGEGVYLWDSEGNKIIDGMAGLWCVNVGYGRKDFAEAARRQMEELPFYNTFFKTTHP
AVVELSSLLAEVTPAGFDRVFYTNSGSESVDTMIRMVRRYWDVQGKPEKKTLIGRWNGYHGSTIGGASLGGMKYMHEQGDLPIPGMAHIEQPWW
YKHGKDMTPDEFGVVAARWLEEKILEIGADKVAAFVGEPIQGAGGVIVPPATYWPEIERICRKYDVLLVADEVICGFGRTGEWFGHQHFGFQPD
LFTAAKGLSSGYLPIGAVFVGKRVAEGLIAGGDFNHGFTYSGHPVCAAVAHANVAALRDEGIVQRVKDDIGPYMQKRWRETFSRFEHVDDVRGV
GMVQAFTLVKNKAKRELFPDFGEIGTLCRDIFFRNNLIMRACGDHIVSAPPLVMTRAEVDEMLAVAERCLEEFEQTLKARGLA 
 
  
MP15.7_pET-29a
6618 bps
1000
2000
3000
4000
5000
6000
XhoI
NdeI
MP15.7
kan res
CV2025 in
CV2025
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II.o) ω-transaminase CV2025-His 
Cloning strategy  
The coding region of the transaminases CV2025-His (CV2025 with His-tag) was 
cloned by our cooperation partner into the vector pET-29a vector (Novagen) using 
the NdeI restriction sites at the N-terminus and XhoI sites at the C-terminus. The 
manual was performed like described for the construction of the expression vector for 
the enzyme CV2025 from Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGGGCCATCATCATCATCATCATATGCAGAAGCAACGTACGACCAGCCAATGGCGCGAACTGGATGCCGCCCATCACCTGCATCCGTTCACCG
ATACCGCATCGCTGAACCAGGCGGGCGCGCGCGTGATGACGCGCGGAGAGGGCGTCTACCTGTGGGATTCGGAAGGCAACAAGATCATCGACGG
CATGGCCGGACTGTGGTGCGTGAACGTCGGCTACGGCCGCAAGGACTTTGCCGAAGCGGCGCGCCGGCAGATGGAAGAGCTGCCGTTCTACAAC
ACCTTCTTCAAGACCACCCATCCGGCGGTGGTCGAGCTGTCCAGCCTGCTGGCTGAAGTGACGCCGGCCGGTTTCGACCGCGTGTTCTATACCA
ATTCCGGTTCCGAATCGGTGGACACCATGATCCGCATGGTGCGCCGCTACTGGGACGTGCAGGGCAAGCCGGAGAAGAAGACGCTGATCGGCCG
CTGGAACGGCTATCACGGCTCCACCATCGGCGGCGCCAGCCTGGGCGGCATGAAGTACATGCACGAGCAGGGCGACTTGCCGATTCCGGGCATG
GCCCACATCGAGCAGCCTTGGTGGTACAAGCACGGCAAGGACATGACGCCGGACGAGTTCGGCGTGGTGGCCGCGCGCTGGCTGGAAGAGAAGA
TTCTGGAAATCGGCGCCGACAAGGTGGCCGCCTTCGTCGGCGAACCCATCCAGGGCGCCGGCGGCGTGATCGTCCCGCCGGCCACCTACTGGCC
GGAAATCGAGCGCATTTGCCGCAAGTACGACGTGCTGCTGGTGGCCGACGAAGTGATCTGCGGCTTCGGGCGTACCGGCGAATGGTTCGGCCAT
CAGCATTTCGGCTTCCAGCCCGACCTGTTCACCGCCGCCAAGGGCCTGTCCTCCGGCTATCTGCCGATAGGCGCGGTCTTTGTCGGCAAGCGCG
TGGCCGAAGGCCTGATCGCCGGCGGCGACTTCAACCACGGCTTCACCTACTCCGGCCACCCGGTCTGCGCCGCCGTCGCCCACGCCAACGTGGC
GGCGCTGCGCGACGAGGGCATCGTCCAGCGCGTCAAGGACGACATCGGCCCGTACATGCAAAAGCGCTGGCGTGAAACCTTCAGCCGTTTCGAG
CATGTGGACGACGTGCGCGGCGTCGGCATGGTGCAGGCGTTCACCCTGGTGAAGAACAAGGCGAAGCGCGAGCTGTTCCCCGATTTCGGCGAGA
TCGGCACGCTGTGCCGCGACATCTTCTTCCGCAACAACCTGATCATGCGGGCATGCGGCGACCACATCGTGTCGGCGCCGCCGCTGGTGATGAC
GCGGGCGGAAGTGGACGAGATGCTGGCGGTGGCGGAACGCTGTCTGGAGGAATTCGAGCAGACGCTGAAGGCGCGCGGGCTGGCTTAG 
 
Protein sequence: 
 
MGHHHHHHMQKQRTTSQWRELDAAHHLHPFTDTASLNQAGARVMTRGEGVYLWDSEGNKIIDGMAGLWCVNVGYGRKDFAEAARRQMEELPFYN
TFFKTTHPAVVELSSLLAEVTPAGFDRVFYTNSGSESVDTMIRMVRRYWDVQGKPEKKTLIGRWNGYHGSTIGGASLGGMKYMHEQGDLPIPGM
AHIEQPWWYKHGKDMTPDEFGVVAARWLEEKILEIGADKVAAFVGEPIQGAGGVIVPPATYWPEIERICRKYDVLLVADEVICGFGRTGEWFGH
QHFGFQPDLFTAAKGLSSGYLPIGAVFVGKRVAEGLIAGGDFNHGFTYSGHPVCAAVAHANVAALRDEGIVQRVKDDIGPYMQKRWRETFSRFE
HVDDVRGVGMVQAFTLVKNKAKRELFPDFGEIGTLCRDIFFRNNLIMRACGDHIVSAPPLVMTRAEVDEMLAVAERCLEEFEQTLKARGLA 
  
MP15.7.b_in_PET-29a
6641 bps
1000
2000
3000
4000
5000
6000
XbaI
NdeI
XhoI
kan res
MP15.7.b
CV2025-His 
CV2025 
(with His-tag) 
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II.p) ω-transaminase KPN04441 
Cloning strategy  
The coding region of the transaminases KPN04441 was cloned by our cooperation 
partner into the vector pET-21a vector (Novagen) using the NdeI restriction sites at 
the N-terminus and XhoI sites at the C-terminus. The manual was performed like 
described for the construction of the expression vector for the enzyme CV2025 from 
Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGTTTCAAAAAGTTGACGCCTACGCCGGCGACCCTATTCTTTCTCTGATGGAACGCTTCAAAGAAGACCCGCGAAGCGACAAAGTCAACCTGA
GTATCGGGCTGTACTACAACGATGACGGCATTATCCCGCAGCTGCAGGCGGTGGCGGAAGCGGAAGCACGCCTGAACGCCGAGCCACATGGCGC
CTCGCTGTATCTGCCAATGGAAGGGTTGAGCGGCTACCGTCAGGCGATTGCGCCGCTGCTGTTTGGCGCAGAGCATACCGCGCTTAAGCAAAAT
CGCATTGCCTCTATTCAGACGGTCGGCGGTTCGGGCGCACTGAAGGTCGGGGCCGACTTCCTCAAACGTTACTTTCCTGAGTCTCATGTCTGGG
TCAGCGATCCGACCTGGGAAAACCACATCGCCATTTTTGAAGGGGCTGGCTTCGAAGTAAGTACTTACCCCTGGTTTGATAAAGCCACCAACGG
CGTGCGCTTTGAGGACCTGCTGGCGACGCTGCAAACGCTGCCGGCGCGCGATATTGTGCTGCTGCACCCTTGCTGCCACAACCCGACCGGCGCC
GACCTTACGCCAGCCCAGTGGGACCGCGTGGTTGAGGTATTAAAAGCGCGTCAGCTGATCCCCTTCCTCGACATCGCCTACCAGGGCTTTGGCG
GGGGGCTGGAAGAGGATGCCTACGCTATTCGCGCCATCGCCAGCGCCGGGATGCCGATGCTGGTCAGCAACTCGTTCTCCAAAATTTTCTCGCT
GTACGGGGAGCGCGTCGGCGGTCTGTCCGTGGTCTGTGAAGACAGCGAAACCGCGGGCCGCGTGCTGGGGCAGCTGAAGGCCACCGTGCGCCGC
AACTACTCCAGCCCGCCGAGCTTTGGCGCGCAGTGGTGGCGACGGTGCTGA 
 
Protein sequence: 
 
MFQKVDAYAGDPILSLMERFKEDPRSDKVNLSIGLYYNDDGIIPQLQAVAEAEARLNAEPHGASLYLPMEGLSGYRQAIAPLLFGAEHTALKQN
RIASIQTVGGSGALKVGADFLKRYFPESHVWVSDPTWENHIAIFEGAGFEVSTYPWFDKATNGVRFEDLLATLQTLPARDIVLLHPCCHNPTGA
DLTPAQWDRVVEVLKARQLIPFLDIAYQGFGGGLEEDAYAIRAIASAGMPMLVSNSFSKIFSLYGERVGGLSVVCEDSETAGRVLGQLKATVRR
NYSSPPSFGAQWWRRC 
  
KPN04441 in pET-21a
6560 bps
1000
2000
3000
4000
5000
6000NdeI 
XhoI
Amp ResKPN04441
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II.q) ω-transaminase POAB80-1 
Cloning strategy  
The coding region of the transaminases POAB80-1 (pQR902) was cloned by our 
cooperation partner into the vector pET-21a vector (Novagen) using the NdeI 
restriction sites at the N-terminus and XhoI sites at the C-terminus. The manual was 
performed like described for the construction of the expression vector for the enzyme 
CV2025 from Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGGCTAGCATGACCACGAAGAAAGCTGATTACATTTGGTTCAATGGGGAGATGGTTCGCTGGGAAGACGCGAAGGTGCATGTGATGTCGCACG
CGCTGCACTATGGCACTTCGGTTTTTGAAGGCATCCGTTGCTACGACTCGCACAAAGGACCGGTTGTATTCCGCCATCGTGAGCATATGCAGCG
TCTGCATGACTCCGCCAAAATCTATCGCTTCCCGGTTTCGCAGAGCATTGATGAGCTGATGGAAGCTTGTCGTGACGTGATCCGCAAAAACAAT
CTCACCAGCGCCTATATCCGTCCGCTGATCTTCGTCGGTGATGTTGGCATGGGAGTAAACCCGCCAGCGGGATACTCAACCGACGTGATTATCG
CTGCTTTCCCGTGGGGAGCGTATCTGGGCGCAGAAGCGCTGGAGCAGGGGATCGATGCGATGGTTTCCTCCTGGAACCGCGCAGCACCAAACAC
CATCCCGACGGCGGCAAAAGCCGGTGGTAACTACCTCTCTTCCCTGCTGGTGGGTAGCGAAGCGCGCCGCCACGGTTATCAGGAAGGTATCGCG
CTGGATGTGAACGGTTATATCTCTGAAGGCGCAGGCGAAAACCTGTTTGAAGTGAAAGATGGTGTGCTGTTCACCCCACCGTTCACCTCCTCCG
CGCTGCCGGGTATTACCCGTGATGCCATCATCAAACTGGCGAAAGAGCTGGGAATTGAAGTACGTGAGCAGGTGCTGTCGCGCGAATCCCTGTA
CCTGGCGGATGAAGTGTTTATGTCCGGTACGGCGGCAGAAATCACGCCAGTGCGCAGCGTAGACGGTATTCAGGTTGGCGAAGGCCGTTGTGGC
CCGGTTACCAAACGCATTCAGCAAGCCTTCTTCGGCCTCTTCACTGGCGAAACCGAAGATAAATGGGGCTGGTTAGATCAAGTTAATCAACTCG
AGCACCACCACCACCACCACTGA 
 
Protein sequence: 
 
MASMTTKKADYIWFNGEMVRWEDAKVHVMSHALHYGTSVFEGIRCYDSHKGPVVFRHREHMQRLHDSAKIYRFPVSQSIDELMEACRDVIRKNN
LTSAYIRPLIFVGDVGMGVNPPAGYSTDVIIAAFPWGAYLGAEALEQGIDAMVSSWNRAAPNTIPTAAKAGGNYLSSLLVGSEARRHGYQEGIA
LDVNGYISEGAGENLFEVKDGVLFTPPFTSSALPGITRDAIIKLAKELGIEVREQVLSRESLYLADEVFMSGTAAEITPVRSVDGIQVGEGRCG
PVTKRIQQAFFGLFTGETEDKWGWLDQVNQLEHHHHHH 
 
  
POAB80-1 (pQR902)
in pET-21a 
6303 bps
1000
2000
3000
4000
5000
6000
NdeI 
XhoI
Amp Res
POAB80 (pQR902)
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II.r) ω-transaminase POAB80-2 
Cloning strategy  
The coding region of the transaminases POAB80-2 (pQR907) was cloned by our 
cooperation partner into the vector pET-21a vector (Novagen) using the NdeI 
restriction sites at the N-terminus and XhoI sites at the C-terminus. The manual was 
performed like described for the construction of the expression vector for the enzyme 
CV2025 from Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGGCTAGCATGACCACGAAGAAAGCTGATTACATTTGGTTCAATGGGGAGATGGTTCGCTGGGAAGACGCGAAGGTGCATGTGATGTCGCACG
CGCTGCACTATGGCACTTCGGTTTTTGAAGGCATCCGTTGCTACGACTCGCACAAAGGACCGGTTGTATTCCGCCATCGTGAGCATATGCAGCG
TCTGCATGACTCCGCCAAAATCTATCGCTTCCCGGTTTCGCAGAGCATTGATGAGCTGATGGAAGCTTGTCGTGACGTGATCCGCAAAAACAAT
CTCACCAGCGCCTATATCCGTCCGCTGATCTTCGTCGGTGATGTTGGCATGGGAGTAAACCCGCCAGCGGGATACTCAACCGACGTGATTATCG
CTGCTTTCCCGTGGGGAGCGTATCTGGGCGCAGAAGCGCTGGAGCAGGGGATCGATGCGATGGTTTCCTCCTGGAACCGCGCAGCACCAAACAC
CATCCCGACGGCGGCAAAAGCCGGTGGTAACTACCTCTCTTCCCTGCTGGTGGGTAGCGAAGCGCGCCGCCACGGTTATCAGGAAGGTATCGCG
CTGGATGTGAACGGTTATATCTCTGAAGGCGCAGGCGAAAACCTGTTTGAAGTGAAAGATGGTGTGCTGTTCACCCCACCGTTCACCTCCTCCG
CGCTGCCGGGTATTACCCGTGATGCCATCATCAAACTGGCGAAAGAGCTGGGAATTGAAGTACGTGAGCAGGTGCTGTCGCGCGAATCCCTGTA
CCTGGCGGATGAAGTGTTTATGTCCGGTACGGCGGCAGAAATCACGCCAGTGCGCAGCGTAGACGGTATTCAGGTTGGCGAAGGCCGTTGTGGC
CCGGTTACCAAACGCATTCAGCAAGCCTTCTTCGGCCTCTTCACTGGCGAAACCGAAGATAAATGGGGCTGGTTAGATCAAGTTAATCAACTCG
AGCACCACCACCACCACCACTGA 
 
Protein sequence: 
 
MASMTTKKADYIWFNGEMVRWEDAKVHVMSHALHYGTSVFEGIRCYDSHKGPVVFRHREHMQRLHDSAKIYRFPVSQSIDELMEACRDVIRKNN
LTSAYIRPLIFVGDVGMGVNPPAGYSTDVIIAAFPWGAYLGAEALEQGIDAMVSSWNRAAPNTIPTAAKAGGNYLSSLLVGSEARRHGYQEGIA
LDVNGYISEGAGENLFEVKDGVLFTPPFTSSALPGITRDAIIKLAKELGIEVREQVLSRESLYLADEVFMSGTAAEITPVRSVDGIQVGEGRCG
PVTKRIQQAFFGLFTGETEDKWGWLDQVNQLEHHHHHH 
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 Appendix
II.s) ω-transaminase POAB80-3 
Cloning strategy  
The coding region of the transaminases POAB80-3 (pQR908) was cloned by our 
cooperation partner into the vector pET-21a vector (Novagen) using the NdeI 
restriction sites at the N-terminus and XhoI sites at the C-terminus. The manual was 
performed like described for the construction of the expression vector for the enzyme 
CV2025 from Chromobacterium violaceum previously.[103] 
 
 
Gene sequence: 
 
ATGGCTAGCATGACCACGAAGAAAGCTGATTACATTTGGTTCAATGGGGAGATGGTTCGCTGGGAAGACGCGAAGGTGCATGTGATGTCGCACG
CGCTGCACTATGGCACTTCGGTTTTTGAAGGCATCCGTTGCTACGACTCGCACAAAGGACCGGTTGTATTCCGCCATCGTGAGCATATGCAGCG
TCTGCATGACTCCGCCAAAATCTATCGCTTCCCGGTTTCGCAGAGCATTGATGAGCTGATGGAAGCTTGTCGTGACGTGATCCGCAAAAACAAT
CTCACCAGCGCCTATATCCGTCCGCTGATCTTCGTCGGTGATGTTGGCATGGGAGTAAACCCGCCAGCGGGATACTCAACCGACGTGATTATCG
CTGCTTTCCCGTGGGGAGCGTTACTGGGCGCAGAAGCGCTGGAGCAGGGGATCGATGCGATGGTTTCCTCCTGGAACCGCGCAGCACCAAACAC
CATCCCGACGGCGGCAAAAGCCGGTGGTAACTACCTCTCTTCCCTGCTGGTGGGTAGCGAAGCGCGCCGCCACGGTTATCAGGAAGGTATCGCG
CTGGATGTGAACGGTTATATCTCTGAAGGCGCAGGCGAAAACCTGTTTGAAGTGAAAGATGGTGTGCTGTTCACCCCACCGTTCACCTCCTCCG
CGCTGCCGGGTATTACCCGTGATGCCATCATCAAACTGGCGAAAGAGCTGGGAATTGAAGTACGTGAGCAGGTGCTGTCGCGCGAATCCCTGTA
CCTGGCGGATGAAGTGTTTATGTCCGGTACGGCGGCAGAAATCACGCCAGTGCGCAGCGTAGACGGTATTCAGGTTGGCGAAGGCCGTTGTGGC
CCGGTTACCAAACGCATTCAGCAAGCCTTCTTCGGCCTCTTCACTGGCGAAACTGAAGATAAATGGGGCTGGTTAGATCAAGTTAATCAACTCG
AGCACCACCACCACCACCACTGA 
 
Protein sequence: 
 
MASMTTKKADYIWFNGEMVRWEDAKVHVMSHALHYGTSVFEGIRCYDSHKGPVVFRHREHMQRLHDSAKIYRFPVSQSIDELMEACRDVIRKNN
LTSAYIRPLIFVGDVGMGVNPPAGYSTDVIIAAFPWGALLGAEALEQGIDAMVSSWNRAAPNTIPTAAKAGGNYLSSLLVGSEARRHGYQEGIA
LDVNGYISEGAGENLFEVKDGVLFTPPFTSSALPGITRDAIIKLAKELGIEVREQVLSRESLYLADEVFMSGTAAEITPVRSVDGIQVGEGRCG
PVTKRIQQAFFGLFTGETEDKWGWLDQVNQLEHHHHHH 
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